Home › Filings & Releases

Filings & Releases

SEC filings and press releases from the companies Biotech Distilled covers, in one place, newest first. Each row links the document itself — the exhibit for an 8-K that carries a release, the release on the company's own site — and, where a Biotech Distilled update has read it, one line on what it announced. Filings come from EDGAR; releases are captured from company investor-relations sites, so a release a site does not list (or lists late) can be missing or appear a day or two after its date.

Last 30 days · 1,169 documents from 245 companies (670 releases) · updated Nov 7, 2026

Company

All filings (+144)

Friday, November 647

ZBIOZenas BioPharma8-KCurrent report: other eventsWith SunStone weeks away, Zenas quietly reloaded its ATM program after-hours on Friday — resetting to a fresh $200M capacity after drawing ~$153M from the prior tranche, a move that lands before the binary and not reflected in today's +9% session close.
ZBIOZenas BioPharma424B5Prospectus supplement (offering)Summary on the 8-K
XNCRXencorSCHEDULE 13G/A13G amendment
XENEXenon PharmaceuticalsSCHEDULE 13G/A13G amendment
XENEXenon PharmaceuticalsSCHEDULE 13GPassive >5% holder (13G)
VRDNViridian TherapeuticsReleaseViridian Therapeutics to Host Conference Call to Present VRDN-008 Phase 1 Data and FcRn Portfolio Plans on November 9, 2026
VIRVir BiotechnologySCHEDULE 13D/A13D amendment
TNGXTango TherapeuticsSCHEDULE 13G/A13G amendment
TARAProtara TherapeuticsReleaseProtara Therapeutics Announces Third Quarter 2026 Financial Results and Provides a Business Update → BD updateSummary on the 8-K
TARAProtara Therapeutics8-KCurrent report: results of operations · EX-99.1 PRESS RELEASE DATED NOVEMBER 6, 2026, ISSUED BY THE REGISTRANT → BD updateProtara just bought its own manufacturing facility for $8.75M, completed THRIVE-3 Phase 2b enrollment with interim data due by year-end, and confirmed ADVANCED-2 BCG-Unresponsive enrollment wraps Q4 — a dense catalyst stack into a name trading at ~41% below the post-ASCO close.
TARAProtara Therapeutics10-QQuarterly report → BD updateSummary on the 8-K
SLDBSolid BiosciencesSCHEDULE 13D/A13D amendment
RNACCartesian TherapeuticsSCHEDULE 13G/A13G amendment
REPLReplimune Group10-Q/AQuarterly report (amended)
RAREUltragenyx PharmaceuticalReleaseUltragenyx Announces the Marketing Authorisation Application (MAA) for its Investigational Gene Therapy for MPS IIIA (Sanfilippo syndrome Type A) is Under Review with the UK Medicines and Healthcare Pvia aggregator
QTTBQ32 BioSCHEDULE 13G/A13G amendment
QTTBQ32 BioSCHEDULE 13G/A13G amendment
QNRXQuoin PharmaceuticalsReleaseQuoin Pharmaceuticals’ Latest NETHERTON NOW Video Details the Life of a Family Living with Netherton Syndrome
QNRXQuoin Pharmaceuticals8-KCurrent report: results of operations · EX-99.1 EXHIBIT 99.1
PTGXProtagonist Therapeutics10-QQuarterly report → BD updateThe Q3 10-Q confirms the buyback is real ($5.8M executed, $294.2M remaining), drops ICONIC-ASCEND data for the first time (70% IGA 0/1 vs placebo, non-inferior to ustekinumab), and adds an NCCN Category 1 guideline win for MIMRYLO — while the ICOTYDE royalty line goes dark for a third straight quarter.
PHIOPhio PharmaceuticalsReleasePhio Pharmaceuticals Announces Invitation for Oral Presentation at 41st Annual SITC Meeting (Society for Immunotherapy of Cancer)
PCVXVaxcyteSCHEDULE 13G/A13G amendment
PCVXVaxcyteSCHEDULE 13G/A13G amendment
OCGNOcugenDEFA14AProxy soliciting material
OCGNOcugenDEFA14AProxy soliciting material
NKTXNkartaReleaseNkarta to Host Webcast to Discuss Initial Clinical Data for NKX019 in Autoimmune Diseases at ACR Convergence 2026
NKTXNkarta8-KCurrent report: Reg FD disclosure · EX-99.1
KTTAPasithea TherapeuticsSCHEDULE 13G/A13G amendment
INKTMiNK TherapeuticsReleaseMiNK Therapeutics New Data Highlights Its Off-the-Shelf iNKT Cell Therapy Targets Two Key Mechanisms of Tumor Resistance Presented at the Society of Immunotherapy of Cancer (SITC 2026)
IMRXImmuneeringReleaseAtebimetinib Combinations with Anti-PD1 Cured 50% of Mice in a RAS-Mutant Colorectal Cancer Model and Nearly Doubled Survival in a RAS-Mutant Lung Cancer Model; New Data Presented at SITC 2026The Q4 2026 preclinical SITC catalyst just landed with more force than expected: atebimetinib + anti-PD-1 cured 50% of mice in a RAS-mutant colorectal model with no regrowth after stopping, and nearly doubled survival in a PD-1-cold lung model — with an immune mechanism story that explains why DCI and checkpoint blockade may be natural partners.
IMCRImmunocoreReleaseImmunocore presents promising data from Phase 1/2 trial cohort evaluating brenetafusp plus KIMMTRAK® (tebentafusp-tebn) in metastatic uveal melanoma → BD updateSummary on the 8-K
IMCRImmunocoreReleaseImmunocore reports third quarter financial results and provides a business update → BD updateSummary on the 8-K
IMCRImmunocore8-KCurrent report: results of operations · EX-99.1 → BD updateTEBE-AM's OS readout just slipped to Q2 2027 — the fourth milestone re-date on the most important catalyst in the company — while fresh SITC data show the KIMMTRAK + brenetafusp combination produced a 70% two-year OS rate in 17 first-line mUM patients, and Q3 revenue printed its first nominal year-over-year decline.
IMCRImmunocore10-QQuarterly report → BD updateSummary on the 8-K
HURATuHURA Biosciences8-KCurrent report: debt / obligation
HROWHarrowSCHEDULE 13G/A13G amendment
HELPHelus Pharma6-KForeign issuer report · EX-99.1
GUTSFractyl HealthReleaseFractyl Health to Report Third Quarter 2026 Financial Results and Provide Business Updates on November 12, 2026
GUTSFractyl Health8-KCurrent report: officer / director change
GOSSGossamer BioSCHEDULE 13G/A13G amendment
GOSSGossamer BioSCHEDULE 13GPassive >5% holder (13G)
EYPTEyePointReleaseEyePoint Announces Participation at Upcoming Investor Conferences and Scientific Meetings
ETONEton PharmaceuticalsSCHEDULE 13G/A13G amendment
ENTXEntera BioReleaseEntera Announces Third Quarter 2026 Financial Results and Business Updates
ENTXEntera Bio8-KCurrent report: results of operations, Reg FD disclosure · EX-99.1 EXHIBIT 99.1
ENTXEntera Bio10-QQuarterly report
DTILPrecision Biosciences8-KCurrent report: other events · EX-99.1
DTILPrecision Biosciences424B5Prospectus supplement (offering)
CTNMContineum TherapeuticsSCHEDULE 13G/A13G amendment
CRVOCervoMed10-QQuarterly report → BD update
CMPXCompass TherapeuticsReleaseCompass Therapeutics Presents Novel Mechanism of Action Data for CTX-10726 (PD-1 x VEGF-A Bispecific Antibody) at the SITC 2026 Annual Meeting
CGONCG OncologyReleaseCG Oncology Reports Third Quarter 2026 Financial Results and Provides Business Updates → BD updateSummary on the 8-K
CGONCG Oncology8-KCurrent report: results of operations · EX-99.1 → BD updatePIVOT-006 Phase 3 topline is now "November 2026" — the Market Expander readout is weeks, not quarters, away — while ANI has escalated to the Delaware Supreme Court, introducing a wrinkle I called "mostly resolved." The stock surged 17.3% on today's Q3 print.
CGONCG Oncology10-QQuarterly report → BD updateSummary on the 8-K
CATXPerspective TherapeuticsReleasePerspective Therapeutics Presents Promising [212Pb]Lapemelanotide Zapixetar (VMT01) Monotherapy Data from a Phase 1/2a Study in Heavily Pretreated Advanced Melanoma Patients at SITC 2026 → BD updateSummary on the 8-K
CATXPerspective Therapeutics8-KCurrent report: other events · EX-99.1 → BD updateNANETS data reveals a sharper enrichment strategy for bamzireotide's Phase 3: SSTR2+ GEP-NET patients show 37–47% ORR and 75% PFS at 18 months, well above Lutathera's labeled benchmarks, with an End-of-Phase 2 FDA meeting now targeted for Q1 2027 — a meaningful step forward on the registration path I've been tracking all year.
CATXPerspective Therapeutics8-KCurrent report: other events · EX-99.1 → BD updateSummary on the 8-K
CADLCandel TherapeuticsReleaseCandel Therapeutics Presents SITC 2026 Data Highlighting Systemic Immune Activation and Survival Outcomes Across Clinical-Stage Portfolio
CABACabaletta BioSCHEDULE 13G/A13G amendment
CABACabaletta BioSCHEDULE 13G/A13G amendment
BCTXBriaCell TherapeuticsReleaseBriaCell and BriaPro Present Positive Preclinical Immunotherapy Data Across Four Posters at SITC 2026via aggregator
ALLOAllogene Therapeutics10-QQuarterly report → BD updateThe Q3 10-Q lands with three things subscribers need to know before Sunday: Cellectis just announced it's pivoting away from ex vivo CAR-T — the company that makes the TALEN scissors Allogene rents for cema-cel is now openly de-emphasizing the business — and Allogene is already hunting for alternative supply. Meanwhile, the ALLO-329 autoimmune data drops at ACR on November 9, the "autoimmune call option" I've been tracking all year. And Q3 burn on cema-cel alone jumped to $14M external, signaling manufacturing reactivation is real — and expensive.
ALDXAldeyra TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
ACRVAcrivon TherapeuticsReleaseAcrivon Expands into Immunology and Inflammation with Acquisition of Phase 2-Ready Differentiated, Oral JAK1 Inhibitor ACR-525, and PKCθ Inhibitor Preclinical Program from Aqilion AB → BD updateSummary on the 8-K
ACRVAcrivon Therapeutics8-KCurrent report: other events · EX-99.1 → BD updateAcrivon just bought a Phase 2-ready JAK1 inhibitor from Sweden's Aqilion AB, paying undisclosed cash with no future milestone or royalty obligations — and in the process formally declared immunology & inflammation a second strategic pillar alongside oncology. The AP3 platform's ability to characterize pathway activity without relying on genetic mutations may be even better suited to autoimmune disease than cancer.

Thursday, November 5191

ZBIOZenas BioPharmaSCHEDULE 13G/A13G amendment
ZBIOZenas BioPharmaReleaseZenas BioPharma Reports Third Quarter 2026 Financial Results and Provides Corporate Update → BD updateSummary on the 8-K
ZBIOZenas BioPharma8-KCurrent report: results of operations · EX-99.1 EXHIBIT 99.1 → BD updateNew OLE data shows 93% of patients remain flare-free at 12 months and obexelimab's B-cell brake can be released for vaccination — directly answering the reversibility and infection-risk questions — while the Q3 burn rate accelerates to ~$108M/quarter, SunStone inches closer, and the EMA clock starts ticking.
ZBIOZenas BioPharma10-QQuarterly report → BD updateSummary on the 8-K
XERSXeris BiopharmaReleaseXeris Biopharma Reports Third Quarter 2026 Financial Results and Business Highlights → BD updateSummary on the 8-K
XERSXeris Biopharma8-KCurrent report: results of operations · EX-99.1 → BD updateRecorlev just printed $71.5M in Q3 (+93% YoY), Xeris raised 2030 revenue guidance to >$1B, and the stock surged 25% on the earnings release — the cash engine is compounding faster than anyone (including me) modeled.
XERSXeris Biopharma10-QQuarterly report → BD updateSummary on the 8-K
XENEXenon PharmaceuticalsSCHEDULE 13G/A13G amendment
VYGRVoyager TherapeuticsReleaseVoyager Reports Third Quarter 2026 Financial and Operating ResultsSummary on the 8-K
VYGRVoyager Therapeutics8-KCurrent report: acquisition / disposition · EX-99.1Voyager's Q3 print lands with $132.1M cash, a fully confirmed Q4 VY7523 PET readout, and VY1706 dosing on a "pending enrollment" clock — while the ATM is being worked below $3.50 and the stock now trades at a ~19% discount to cash.
VYGRVoyager Therapeutics10-QQuarterly reportSummary on the 8-K
VTVTvTv TherapeuticsReleasevTv Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate UpdateSummary on the 8-K
VTVTvTv Therapeutics8-KCurrent report: results of operations · EX-99.1vTv's Q3 print arrives with VTVT down ~28% from early October — the stock's slide predates tonight's release, and three of the most watched variables (ATM, cash runway, timeline) are mostly holding, though a CFO 10b5-1 plan and a quiet G42 timeline slip deserve attention.
VTVTvTv Therapeutics10-QQuarterly reportSummary on the 8-K
VSTMVerastemS-8Employee plan registration
VSTMVerastemS-3ASRAutomatic shelf registration
VSTMVerastemReleaseVerastem Oncology Reports Third Quarter 2026 Financial Results and Highlights Recent Business Updates
VSTMVerastem8-KCurrent report: Reg FD disclosure · EX-99.1 EXHIBIT 99.1
VSTMVerastem10-QQuarterly report
VRCAVerrica PharmaceuticalsReleaseVerrica Pharmaceuticals to Report Third Quarter 2026 Financial Results and Provide a Corporate Update on November 12, 2026
VORVor BiopharmaSCHEDULE 13G/A13G amendment
VKTXViking TherapeuticsSCHEDULE 13G/A13G amendment
VIRVir BiotechnologyReleaseVir Biotechnology to Present Topline Phase 3 ECLIPSE 1 Data for Elebsiran and Tobevibart in Chronic Hepatitis Delta at AASLD’s The Liver Meeting® 2026 and Host Investor Conference CallTHE BIG ONE is here: ECLIPSE 1 topline data hits the AASLD late-breaking session tomorrow (November 8), with an investor call Monday morning — seven months of buildup lands in the next 72 hours.
VERAVera TherapeuticsReleaseVera Therapeutics Provides Business Update and Reports Third Quarter 2026 Financial ResultsSummary on the 8-K
VERAVera Therapeutics8-KCurrent report: results of operations · EX-99.1TRUTAKNA's first revenue quarter clears $10M on ~700 patient start forms, the ORIGIN 3 data lands in the NEJM, the sBLA is filed, and PIONEER flashes its first signal — yet VERA trades 29% below the December offering price.
VERAVera Therapeutics10-QQuarterly reportSummary on the 8-K
TYRATyra BiosciencesReleaseTyra Biosciences to Participate in Upcoming Investor Conferences
TVTXTravere TherapeuticsSCHEDULE 13G/A13G amendment
TTRXTurn TherapeuticsReleaseTurn Therapeutics’ GX-03 Earns “Developmental Immunology Solution of the Year” in 2026 BioTech Breakthrough Awards Program
TSHATaysha Gene TherapiesReleaseTaysha Gene Therapies to Release Third Quarter 2026 Financial Results and Host Conference Call and Webcast on November 12
TLSATiziana Life SciencesReleaseTiziana to Host Investor Call with Key Opinion Leaders to Discuss Positive Phase 2a INFORM-MS Topline Results
TLSATiziana Life Sciences6-KForeign issuer report · EX-99.1 TIZIANA LIFE SCIENCES LTD PRESS RELEASE, DATED NOVEMBER 5, 2026
TENXTenax TherapeuticsReleaseTenax Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update → BD updateSummary on the 8-K
TENXTenax Therapeutics8-KCurrent report: results of operations · EX-99.1 → BD updateThe Q3 10-Q revealed a tighter LEVEL-2 enrichment design (+34 m in qualifying patients, 95% CI 15–53), confirmed the Type C meeting is granted, disclosed a securities class-action lawsuit, and showed the August 2024 warrant tranche expired worthless — four developments that collectively update the post-LEVEL bear and watch-list picture.
TENXTenax Therapeutics10-QQuarterly report → BD updateSummary on the 8-K
TECXTectonic TherapeuticReleaseReported favorable safety, tolerability and pharmacokinetic (“PK”) results from the single ascending-dose portion of the TX2100 Phase 1a clinical trial in healthy adult volunteers; FDA granted TX2100 → BD updateSummary on the 8-K
TECXTectonic Therapeutic8-KCurrent report: acquisition / disposition · EX-99.1 → BD updateAPEX is now inside an 8-week window (end of January 2027), ALPINE dosed its first patient, the ATM accelerated to $22.3M in Q3 alone, and — buried in the 10-Q risk factors — Tectonic itself flags that AZD5462's LUMINARA data "may have affected investor perception of relaxin product candidates," which may help explain the stock's -16.8% slide since the September update.
TECXTectonic Therapeutic10-QQuarterly report → BD updateSummary on the 8-K
STOKStoke TherapeuticsSCHEDULE 13G/A13G amendment
SRPTSarepta TherapeuticsReleaseSarepta Therapeutics Announces Third Quarter 2026 Financial Results and Recent Corporate DevelopmentsSummary on the 8-K
SRPTSarepta Therapeutics8-KCurrent report: results of operations · EX-99.1Q3 2026 earnings land with the PMO sNDA PDUFA date finally disclosed (February 28, 2027), MAD data for SRP-1003 and SRP-1001 locked in for Q4 2026 with Phase 3 prep already underway, and the balance sheet growing to ~$999M — but a new $62M Catalent take-or-pay charge and a 7.5% session drop heading into the print keep the tension alive.
SRPTSarepta Therapeutics10-QQuarterly reportSummary on the 8-K
SLDBSolid BiosciencesReleaseSolid Biosciences to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conferencevia aggregator
SCYXScynexisS-3Shelf registration → BD updateSummary on the 10-Q
SCYXScynexisReleaseSCYNEXIS Reports Third Quarter 2026 Financial Results and Provides Corporate Update → BD updateSummary on the 10-Q
SCYXScynexis10-QQuarterly report → BD updateThe Phase 1 SCY-770 gating study is done, the Phase 2 clock is ticking, and SCYX just hired a nephrologist to run R&D — but the stock is down 14% on the day, and the market is reading the S-3 shelf renewal as a capital-raise signal.
SANASana BiotechnologySCHEDULE 13G/A13G amendmentSummary on the 8-K
SANASana BiotechnologyReleaseSana Biotechnology Reports Third Quarter 2026 Financial Results and Business UpdatesSummary on the 8-K
SANASana Biotechnology8-KCurrent report: results of operations · EX-99.1Q3 delivered a GAAP profit (a $63M non-cash accounting gain, not a business transformation), but underneath the headlines: SG293 first-in-human data slipped to 1Q 2027, Mayo passed on its $25M second tranche, and the going-concern flag persists on $121.7M cash — the thesis is tracking but the runway is tighter and the binary catalyst window just moved.
SANASana Biotechnology10-QQuarterly reportSummary on the 8-K
SABSSAB BiotherapeuticsReleaseSAB BIO Reports Q3 2026 Financial Results and Provides Business Highlights → BD updateSummary on the 10-Q
SABSSAB Biotherapeutics10-QQuarterly report → BD updateSAFEGUARD's adult and adolescent cohorts just closed for screening — the enrollment milestone I told you to watch for. The 10-Q also surfaces a quiet internal signal: management's "probability of survival" assumption jumped from 57.5% to 70.0% in a single quarter.
RVMDRevolution MedicinesSCHEDULE 13G/A13G amendment
RNACCartesian TherapeuticsReleaseCartesian Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update → BD updateSummary on the 8-K
RNACCartesian Therapeutics8-KCurrent report: results of operations · EX-99.1 → BD updateQ3 earnings confirm the AURORA 1Q27 readout and mid-2027 BLA are on track, but quarterly burn has accelerated to ~$98M annualized and the WestGene in vivo trial hasn't launched yet — with the K2HV covenant clock now five months away, the execution margin is tighter than it looked in August.
RNACCartesian Therapeutics10-QQuarterly report → BD updateSummary on the 8-K
QNRXQuoin PharmaceuticalsReleaseQuoin Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2026 Financial ResultsSummary on the 10-Q
QNRXQuoin Pharmaceuticals10-QQuarterly reportThe going-concern flag that I quoted verbatim in every QNRX post is gone from the Q3 10-Q — replaced by an affirmative one-year liquidity statement — while $33.2M in cash and investments sits on the balance sheet and a peer-reviewed case report extends the durability data to 21 months.
PTGXProtagonist TherapeuticsReleaseProtagonist Reports Third Quarter 2026 Financial Results and Provides Corporate Updatevia aggregator→ BD updateSummary on the 8-K
PTGXProtagonist Therapeutics8-KCurrent report: results of operations · EX-99.1 EXHIBIT 99.1 → BD updateQ3 2026 earnings land after the close: ICOTYDE royalties go undisclosed for a second consecutive full commercial quarter, PN-477sc delivers positive Phase 1 SAD data prompting a strategic pivot to the oral program, and cash prints at $834.6M — confirming the Q4 timing gap I flagged in September.
PMNProMIS NeurosciencesReleaseProMIS Neurosciences to Participate in Upcoming Conferences in November
PHIOPhio PharmaceuticalsReleasePhio Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Update as It Advances PH-762 Toward Phase 2b Study InitiationSummary on the 8-K
PHIOPhio Pharmaceuticals8-KCurrent report: results of operations · EX-99.1 EXHIBIT 99.1The Q3 10-Q lands a going-concern flag and a Nasdaq minimum-bid-price warning (21 of 30 consecutive days already below $1.00) while cash falls to $10.6M — the death-by-a-thousand-warrants thesis just got a formal auditor co-sign, with an FDA response due by end of November as the only potential escape valve.
PHIOPhio Pharmaceuticals10-QQuarterly reportSummary on the 8-K
PCSAProcessa PharmaceuticalsDEFA14AProxy soliciting material
PCSAProcessa PharmaceuticalsDEFA14AProxy soliciting material
PCSAProcessa Pharmaceuticals8-KCurrent report: other events · EX-99.1 EXHIBIT 99.1
NTLAIntellia TherapeuticsReleaseIntellia Therapeutics Announces Third Quarter 2026 Financial Results and Business UpdatesSummary on the 8-K
NTLAIntellia Therapeutics8-KCurrent report: results of operations · EX-99.1Q3 earnings landed this morning with MAGNITUDE-2 enrollment complete (exceeding its target), a new CMO aboard, and a $127.5M net loss that includes a $10.4M non-cash investment writedown — the market sold the print −9.8%, likely misreading the headline; here's what actually changed and what didn't.
NTLAIntellia Therapeutics10-QQuarterly reportSummary on the 8-K
NRXPNRX PharmaceuticalsDEFA14AProxy soliciting material
NRXPNRX PharmaceuticalsDEF 14AProxy statement
NRIXNurix TherapeuticsSCHEDULE 13G/A13G amendment
NRIXNurix TherapeuticsReleaseNurix Therapeutics to Present New and Updated Data from Ongoing Phase 1a/1b Trial of Bexobrutideg (NX-5948) in Relapsed/Refractory CLL/SLL at the 68th ASH Annual Meeting and Exposition
NKTXNkartaReleaseNkarta Reports Third Quarter 2026 Financial Results and Provides Business UpdateSummary on the 8-K
NKTXNkarta8-KCurrent report: results of operations · EX-99.1Three days before Nkarta's first NKX019 efficacy readout at ACR, the Q3 10-Q reveals burn accelerating to $33.3M/quarter, cash down to $216M, and a board member resigning — while the stock's -9.2% session move on the filing day suggests the market may already be reading the abstract tea leaves.
NKTXNkarta10-QQuarterly reportSummary on the 8-K
NBPNovaBridge BiosciencesSCHEDULE 13D/A13D amendment
NAMSNewAmsterdam PharmaSCHEDULE 13G/A13G amendment
MESOMesoblastReleaseUse Of Ryoncil First Line After Steroids For Pediatric Acute Graft Versus Host Disease Highlighted In Key Opinion Leader Webinarvia aggregator
LRMRLarimar TherapeuticsReleaseLarimar Therapeutics Announces Three Poster Presentations for the Nomlabofusp Program at the Upcoming International Congress for Ataxia Research
LGVNLongeveronSCHEDULE 13G/A13G amendment
LGVNLongeveron8-KCurrent report: officer / director change
LENZLENZ TherapeuticsSCHEDULE 13G/A13G amendment
LEGNLegend BiotechSCHEDULE 13G/A13G amendment
LCTXLineage Cell TherapeuticsReleaseLineage Cell Therapeutics to Report Third Quarter 2026 Financial Results and Provide Business Update on November 12, 2026
LBRXLB PharmaceuticalsReleaseLB Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Corporate Update → BD updateSummary on the 8-K
LBRXLB Pharmaceuticals8-KCurrent report: results of operations · EX-99.1 → BD updateLBRX's Q3 10-Q checks every box on my watch list: $403.8M in cash (at the top of my estimate), NOVA-2 enrollment "progressing strongly" with 1H 2027 readout intact, and two new senior hires filling the leadership gaps that were the clearest near-term bear flags.
LBRXLB Pharmaceuticals10-QQuarterly report → BD updateSummary on the 8-K
KZIAKazia TherapeuticsReleaseKazia Therapeutics Recognized as "Drug Discovery Company of the Year" in 2026 BioTech Breakthrough Awards
KYTXKyverna TherapeuticsReleaseKyverna Therapeutics to Present at the Jefferies London Healthcare Conference
KROSKeros TherapeuticsReleaseKeros Therapeutics Reports Recent Business Highlights and Third Quarter 2026 Financial Results → BD update
KROSKeros Therapeutics8-KCurrent report: Reg FD disclosure · EX-99.1 → BD update
KROSKeros Therapeutics8-KCurrent report: results of operations · EX-99.1 → BD update
KROSKeros Therapeutics10-QQuarterly report → BD update
KAPAKairos PharmaReleaseKairos Pharma Recognized by Biotech Breakthrough Awards in Oncology
KAPAKairos Pharma8-KCurrent report: other events · EX-99.1
JANXJanux TherapeuticsReleaseJanux Therapeutics Reports Third Quarter 2026 Financial Results and Business HighlightsSummary on the 8-K
JANXJanux Therapeutics8-KCurrent report: results of operations · EX-99.1Four days before Janux presents the first clinical data from the ARM platform (JANX011), the Q3 release drops a new mechanism disclosure: the drug selectively engages a specific T cell subset (TRBV6-expressing) rather than broad CD3+ activation — a detail that completely reframes what readers should be watching for on November 9.
JANXJanux Therapeutics10-QQuarterly reportSummary on the 8-K
IRONDisc MedicineReleasePivotal Phase 3 APOLLO trial of bitopertin in erythropoietic protoporphyria (EPP) successfully met all primary and secondary endpoints Bitopertin NDA resubmission planned by end of 2026, with an FDA dSummary on the 8-K
IRONDisc Medicine8-KCurrent report: results of operations · EX-99.1Disc's Q3 10-Q is out and the numbers have changed: 45.5M shares outstanding post-offering, ~$1.17B pro forma cash, runway into 2030, and a new ATM replacing Cantor. The balance sheet is the strongest it's ever been—but dilution math and the December 17 patent clock are both worth updating before the FDA resubmission.
IRONDisc Medicine424B5Prospectus supplement (offering)Summary on the 8-K
IRONDisc Medicine10-QQuarterly reportSummary on the 8-K
IRDOpus GeneticsReleaseOpus Genetics Completes Dosing in Cohort 2 of Phase 1/2 Clinical Trial of OPGx-BEST1 Gene Therapy for Inherited Retinal DiseasesOpus dosed all 11 Cohort 2 participants at the 3x higher BEST1 dose, putting topline data in Q1 2027 and a potential pivotal Phase 3 start in H2 2027 — the "other open question" from September is now closed on the input side.
INMBInmune BioReleaseINmune Bio Inc. Announces Third Quarter 2026 Results and Provides Business Update → BD updateSummary on the 10-Q
INMBInmune Bio10-QQuarterly report → BD updateQ3 reveals $16.3M cash and a drained Australian rebate well — the non-dilutive buffer that bought time all year is gone — while management guides runway through Q3 2027 and quietly pivots XPro toward a quantum-computing-assisted rare-disease search.
INABIN8bioReleaseIN8bio Reports Third Quarter 2026 Financial Results and Recent Business HighlightsSummary on the 8-K
INABIN8bio8-KCurrent report: results of operations · EX-99.1Q3 puts $14.0M cash against an April 2027 wall, but the hire of a gamma-delta TCE pioneer as SVP of R&D and INB-619's debut in Nature Reviews Drug Discovery signal a company accelerating toward the year-end animal data that could unlock the $20.1M PIPE second tranche — if the listing holds.
INABIN8bio10-QQuarterly reportSummary on the 8-K
IMUXImmunic8-KCurrent report: Reg FD disclosure · EX-99.1
GRCEGrace TherapeuticsReleaseGrace Therapeutics Announces Participation in Upcoming Industry and Investor Events in November 2026
GPCRStructure TherapeuticsSCHEDULE 13G/A13G amendment
GLUEMonte Rosa TherapeuticsReleaseMonte Rosa Therapeutics Announces Third Quarter 2026 Financial Results and Business UpdatesSummary on the 8-K
GLUEMonte Rosa Therapeutics8-KCurrent report: results of operations · EX-99.1Q3 delivered GLUE's first GAAP-profit quarter on the $50M Novartis milestone, cash is effectively ~$620M when the PsA payment lands, and GEMINI-1 in gout is on the doorstep — but the next-gen NEK7 IND slipped again and the stock fell 5% on the print.
GLUEMonte Rosa Therapeutics10-QQuarterly reportSummary on the 8-K
GHRSGH ResearchSCHEDULE 13G/A13G amendment
GANXGain TherapeuticsReleaseGain Therapeutics Announces Late-Breakers and Poster Presentations at Upcoming Scientific Conferences
FBIOFortress BiotechReleaseJourney Medical Corporation to Announce Third Quarter 2026 Financial Results on November 12, 2026
FATEFate TherapeuticsS-3Shelf registration → BD updateSummary on the 8-K
FATEFate TherapeuticsReleaseFate Therapeutics Reports Third Quarter 2026 Financial Results And Business Updates → BD updateSummary on the 8-K
FATEFate Therapeutics8-KCurrent report: material agreement, agreement terminated → BD updateFate's Q3 print confirms the raise I said was inevitable has begun — a fresh $100M ATM with Leerink is live, cash sits at $139.1M (plus a $15M CIRM grant), and the runway guidance nudges to mid-2028; now we know exactly what the dilution trap looks like.
FATEFate Therapeutics8-KCurrent report: results of operations · EX-99.1 → BD updateSummary on the 8-K
FATEFate Therapeutics424B5Prospectus supplement (offering)→ BD updateSummary on the 8-K
FATEFate Therapeutics10-QQuarterly report → BD updateSummary on the 8-K
EYPTEyePointReleaseEyePoint to Report Third Quarter 2026 Financial Results on November 12, 2026
EWTXEdgewise TherapeuticsSCHEDULE 13G/A13G amendment → BD update
EWTXEdgewise TherapeuticsReleaseEdgewise Therapeutics Announces Productive End-of-Phase 2 Meeting with FDA for EDG-7500 in HCM; Phase 3 Protocol Features Tolerability-Based Dose Escalation Without Safety Echo Monitoring → BD update
EVMNEvommuneReleaseEvommune Announces Webcast Discussing EVO570 and Its Expanding Immunology Portfolio Today at 8:30 a.m. ET
EVMNEvommune8-KCurrent report: Reg FD disclosure · EX-99.1
ETONEton PharmaceuticalsReleaseEton Pharmaceuticals Reports Third Quarter 2026 Financial ResultsSummary on the 8-K
ETONEton PharmaceuticalsReleaseEton Pharmaceuticals Announces Preliminary ET-700 Pilot Study Results Evaluating Copper Absorption Inhibition and Gastrointestinal TolerabilitySummary on the 8-K
ETONEton Pharmaceuticals8-KCurrent report: results of operations · EX-99.1Eton printed a blowout Q3 — $57.9M revenue, 49% Adjusted EBITDA margin, guidance raised to >$175M — but the ET-700 pilot data delivered a split verdict: excellent tolerability (1/12 AEs vs. 8/12 for GALZIN), underwhelming copper blockade (12% reduction vs. 46%), pushing the program back into reformulation and delaying the >$100M peak-sales catalyst into 2027 or beyond.
ETONEton Pharmaceuticals8-KCurrent report: other events · EX-99.1 EXHIBIT 99.1 PRESS RELEASE RELATING TO ET-700Summary on the 8-K
ETONEton Pharmaceuticals10-QQuarterly reportSummary on the 8-K
ELVNEnliven TherapeuticsReleaseEnliven Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Business UpdateSummary on the 8-K
ELVNEnliven Therapeutics8-KCurrent report: results of operations · EX-99.1Enliven has locked in FDA alignment on the final ENABLE-2 Phase 3 design and is on track to dose the first patient before year-end — clearing the last major setup hurdle the thesis was waiting on, while Q3 spend signals the burn rate is accelerating materially as pivotal infrastructure spins up.
ELVNEnliven Therapeutics10-QQuarterly reportSummary on the 8-K
ELTXElicio TherapeuticsReleaseElicio Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update → BD updateSummary on the 8-K
ELTXElicio Therapeutics8-KCurrent report: results of operations · EX-99.1 → BD updateElicio's Q3 print extends the cash runway to Q2 2027 — removing the imminent extinction risk flagged in October — while the Q4 2026 Phase 1 combination trial with daraxonrasib remains on track, but going-concern language persists and no partner has materialized.
ELTXElicio Therapeutics10-QQuarterly report → BD updateSummary on the 8-K
DYNDyne TherapeuticsReleaseDyne Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business HighlightsSummary on the 8-K
DYNDyne Therapeutics8-KCurrent report: results of operations · EX-99.1Q3 burn hit $193.6M as launch prep spending surges 65% YoY; cash sits at $1.134B into Q2 2028, but the BIOSECURE CDMO injunction and new pharma tariff risk add nuance to the supply chain picture heading into the January 21 PDUFA.
DYNDyne Therapeutics10-QQuarterly reportSummary on the 8-K
DTILPrecision BiosciencesReleasePrecision BioSciences Announces Positive DSMB Safety Review Supporting Additional PBGENE-DMD Dosing in Phase 1/2 FUNCTION-DMD Study → BD updateSummary on the 8-K
DTILPrecision BiosciencesReleasePrecision BioSciences Announces Pricing of $125 Million Underwritten Offering of Common Stock and Pre-Funded Warrants → BD updateSummary on the 8-K
DTILPrecision BiosciencesReleasePrecision BioSciences Announces Late-Breaking PBGENE-HBV Data at AASLD The Liver Meeting® 2026 Further Demonstrating cccDNA Elimination and Potential to Drive Viral Cure → BD updateSummary on the 8-K
DTILPrecision BiosciencesFWPFree writing prospectus (offering terms)→ BD updateSummary on the 8-K
DTILPrecision Biosciences8-KCurrent report: Reg FD disclosure, other events · EX-99.1 → BD updateToday was the day I said to wait for: PBGENE-HBV's AASLD data beat the bar I set, the first DMD patient cleared the 8-week safety window the field was watching, and a $125M offering at $7.75 — backed by named institutional buyers — just retired the dilution trap I called the most dangerous item in the bear case.
DFTXDefinium TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
CTNMContineum TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
CTMXCytomX TherapeuticsReleaseCytomX Therapeutics Announces Q3 2026 Financial Results and Provides Business UpdateSummary on the 8-K
CTMXCytomX Therapeutics8-KCurrent report: results of operations · EX-99.1 CYTOMX Q3 2026 EARNINGS RELEASE_DRAFT_POST_AC_FOR APPROVALQ3 earnings confirm the dose-selection data readout slips to January 2027, BMS's termination is now on the books, and the stock has cratered 37% since the August Fast Track update — but $348M in cash and an expanding indication footprint say the thesis isn't broken, just delayed.
CTMXCytomX Therapeutics10-QQuarterly reportSummary on the 8-K
CRVSCorvus PharmaceuticalsReleaseCorvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2026 Financial Results → BD updateSummary on the 8-K
CRVSCorvus Pharmaceuticals8-KCurrent report: results of operations · EX-99.1 PRESS RELEASE → BD updateCorvus's Q3 2026 update delivered the first real clinical data since my original deep dive — ALPS Phase 2 initial results show soquelitinib's immune-rebalancing mechanism working in a genetically-confirmed rare disease, while the 2027 catalyst calendar is now tighter and better-defined than ever.
CRVSCorvus Pharmaceuticals10-QQuarterly report → BD updateSummary on the 8-K
CRBUCaribou BiosciencesReleaseCaribou Biosciences Reports Third Quarter 2026 Financial Results
CRBUCaribou Biosciences8-KCurrent report: results of operations · EX-99.1
CRBUCaribou Biosciences10-QQuarterly report
COGTCogent BiosciencesReleaseCogent Biosciences Reports Recent Business Highlights and Third Quarter 2026 Financial ResultsSummary on the 8-K
COGTCogent Biosciences8-KCurrent report: results of operations · EX-99.1With the GIST PDUFA 25 days out, Cogent's Q3 print shows a commercial build burning fast — G&A tripled to $42.1M in a single quarter — but $791M in cash, $108.5M in locked-in CMO commitments, and a first clinical look at the avapritinib-switch data at ASH keep the thesis intact heading into the most consequential month in the company's history.
COGTCogent Biosciences10-QQuarterly reportSummary on the 8-K
CLYMClimb BioSCHEDULE 13G/A13G amendmentSummary on the 8-K
CLYMClimb BioS-3ASRAutomatic shelf registrationSummary on the 8-K
CLYMClimb BioReleaseClimb Bio Reports Third Quarter 2026 Financial Results and Provides Business UpdatesSummary on the 8-K
CLYMClimb Bio8-KCurrent report: results of operations, Reg FD disclosure · EX-99.1Q3 earnings surface three under-the-radar thesis updates: Fidelity emerges at 15% ownership, the ATM drew its first $10.1M at $10.00/share in October, and the Delaware summary-judgment hearing on the $157.5M Acelyrin milestone fight has now been held — with a ruling pending.
CLYMClimb Bio10-QQuarterly reportSummary on the 8-K
CLDXCelldex TherapeuticsS-3ASRAutomatic shelf registrationSummary on the 8-K
CLDXCelldex TherapeuticsReleaseCelldex Reports Third Quarter Financial Results and Provides Corporate UpdateSummary on the 8-K
CLDXCelldex Therapeutics8-KCurrent report: results of operations · EX-99.1 PRESS RELEASEQ3 earnings confirm the fortress balance sheet is intact at $650.3M through 2028, but the old ATM shelf expired and Celldex immediately refiled a new S-3ASR — and management just teased new barzolvolimab indications by year-end, with the stock sitting below the April offering print.
CLDXCelldex Therapeutics10-QQuarterly reportSummary on the 8-K
CGTXCognition TherapeuticsReleaseCognition Therapeutics Reports Financial Results for the Third Quarter 2026 and Provides Business UpdateSummary on the 8-K
CGTXCognition Therapeutics8-KCurrent report: results of operations, listing notice · EX-99.1 EXHIBIT 99.1Nasdaq sent the deficiency letter — CGTX officially has until May 3, 2027 to get back above $1.00. The Q3 print shows the balance sheet is holding up better than feared, but the listing clock is now ticking in writing.
CGTXCognition Therapeutics10-QQuarterly reportSummary on the 8-K
CCCCC4 TherapeuticsReleaseC4 Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights
CCCCC4 Therapeutics8-KCurrent report: results of operations · EX-99.1
CCCCC4 Therapeutics10-QQuarterly report
CATXPerspective TherapeuticsReleasePerspective Therapeutics Presents Encouraging Incremental Data and Analyses from Phase 1/2a Trial of [212Pb]Bamzireotide Navoxetan (VMT-α-NET) in Advanced SSTR2 Expressing NETs
CABACabaletta BioReleaseCabaletta Bio Reports Third Quarter 2026 Financial Results and Provides Business UpdateSummary on the 8-K
CABACabaletta Bio8-KCurrent report: results of operations · EX-99.1Cabaletta's Q3 earnings reveal a 3Q enrollment slowdown in the myositis registrational cohort — blamed on Novartis/BMS competitor safety events — pushing the BLA submission to 1Q28, while $299.4M in cash buys runway to that date and ACR drops one-year DM durability data this Sunday.
CABACabaletta Bio10-QQuarterly reportSummary on the 8-K
BLTEBelite BioReleaseBelite Bio to Host Webcast on November 12, 2026, to Discuss Third Quarter 2026 Financial Results
BIOABioAge LabsReleaseBioAge Labs Reports Third Quarter 2026 Financial Results and Provides Business UpdatesSummary on the 8-K
BIOABioAge Labs8-KCurrent report: results of operations · EX-99.1QUELL-CV topline is now locked to Q4 2026 — the binary is weeks away — but a new manufacturing risk just appeared in the fine print: BioAge's CDMO WuXi AppTec was placed on the Pentagon's Chinese Military Company list in June 2026, adding supply-chain uncertainty to a thesis that was otherwise tracking cleanly into the readout.
BIOABioAge Labs10-QQuarterly reportSummary on the 8-K
BBOTBridgeBio Oncology Therapeutics8-KCurrent report: officer / director change
APVOAptevo TherapeuticsReleaseAptevo Achieves Key Clinical Development Objective, Significantly Reducing Infusion-Related Reactions with Mipletamig in Frontline AML
APVOAptevo Therapeutics8-KCurrent report: other events · EX-99.1
ANNXAnnexonSCHEDULE 13G/A13G amendment
AMLXAmylyx PharmaceuticalsReleaseAmylyx Pharmaceuticals Reports Third Quarter 2026 Financial ResultsSummary on the 8-K
AMLXAmylyx Pharmaceuticals8-KCurrent report: results of operations · EX-99.1Q3 earnings bring the two things the thesis needed most: Amylyx has signed a definitive manufacturing deal with Bachem Americas and a binding term sheet with Polypeptide Group AG (with a $30M upfront capacity reservation), closing the CMC risk I'd been flagging as the last major overhang — and the stock has quietly given back 30% of its post-LUCIDITY gains, setting up an interesting entry point ahead of the ObesityWeek data presentation on November 15.
AMLXAmylyx Pharmaceuticals10-QQuarterly reportSummary on the 8-K
ALTAltimmuneReleaseAltimmune to Report Third Quarter 2026 Financial Results and Provide Business Update on November 12, 2026Summary on the release
ALTAltimmuneReleaseAltimmune Announces Data from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder Selected as Late-Breaking Oral Presentation at AASLD The Liver Meeting® 2026The full RECLAIM dataset lands at AASLD on November 9 as a late-breaking oral — the highest-visibility slot the conference offers — and an FDA End-of-Phase 2 meeting for the AUD registrational program is now confirmed for December, making the next six weeks the most catalyst-dense stretch in Altimmune's story since the January BTD print.
ALLOAllogene TherapeuticsReleaseAllogene Therapeutics Reports Third Quarter 2026 Financial Results and Business UpdateSummary on the 8-K
ALLOAllogene Therapeutics8-KCurrent report: results of operations · EX-99.1ALLO-329's first real-world test in autoimmune disease drops in four days at ACR — the "autoimmune call option" I've been tracking all year is finally cashing out, one way or another. Here's what to watch for in the data, what the Q3 numbers tell us about the runway, and why the stock sitting at $1.09 going into the read is either an opportunity or a warning.
ALDXAldeyra Therapeutics10-QQuarterly report
AKBAAkebia TherapeuticsReleaseAkebia Therapeutics Reports Third Quarter 2026 Financial Results and Business HighlightsSummary on the 8-K
AKBAAkebia TherapeuticsReleaseAkebia Therapeutics Reports Positive Topline Data from VOCAL Trial Showing Vadadustat Dosed TIW Met Primary Endpoint of Non-Inferiority to ESA in Maintaining HemoglobinSummary on the 8-K
AKBAAkebia Therapeutics8-KCurrent report: results of operations · EX-99.1VOCAL hit its non-inferiority endpoint against ESA, completing the clinical evidence arc — but Vafseo's Q3 revenues collapsed to $14.8M on TDAPA inventory destocking even as patients grew to 11,500, exposing the full brutality of the post-TDAPA price reset that starts January 1.
AKBAAkebia Therapeutics10-QQuarterly reportSummary on the 8-K
AGIOAgios PharmaceuticalsReleaseAgios Reports Third Quarter 2026 Financial Results and Provides Business Update → BD updateSummary on the 8-K
AGIOAgios Pharmaceuticals8-KCurrent report: results of operations · EX-99.1 → BD updateAGIO dropped ~10% on Q3 results that actually showed record revenue of $55.4M — the thalassemia launch is accelerating faster than the bear case allowed, with 75% six-month retention, but the market appears to be pricing the REMS/February-label uncertainty and a new R&D headcount cut that acknowledges the cost base problem.
AGIOAgios Pharmaceuticals10-QQuarterly report → BD updateSummary on the 8-K
ACRSAclaris TherapeuticsReleaseAclaris Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate and Clinical UpdateSummary on the 8-K
ACRSAclaris Therapeutics8-KCurrent report: results of operations · EX-99.1Q3 earnings reveal a third, undisclosed ATM tap in September at ~$5.56/share, pushing the dilution toll to ~30M new shares year-to-date, while runway gets extended to 1H 2029 and the bosakitug ADMIRATION readout is now weeks away.
ACRSAclaris Therapeutics10-QQuarterly reportSummary on the 8-K
ACETAdicet BioReleaseAdicet Bio Reports Third Quarter 2026 Financial Results and Provides Business Updates → BD updateSummary on the 8-K
ACETAdicet Bio8-KCurrent report: results of operations · EX-99.1 → BD updateAdicet's Q3 10-Q — filed after the close — contains a formal going-concern disclosure and a $100.9M cash balance against ~$79M annualized burn, with the pivotal readout not until 2029. The raise is no longer a risk; it's a schedule.
ACETAdicet Bio10-QQuarterly report → BD updateSummary on the 8-K
ABOSAcumen Pharmaceuticals8-KCurrent report: agreement terminated, exit / restructuring costs

Wednesday, November 4144

XNCRXencorReleaseXencor Reports Third Quarter 2026 Financial ResultsSummary on the 8-K
XNCRXencor8-KCurrent report: results of operations · EX-99.1Q3 delivers net income of $39.4M, year-end cash guidance rises to $480–500M (third consecutive raise), and Xencor cashes out $66.9M of Zenas stock — the balance sheet is stronger than ever as XmAb819 heads toward an FDA accelerated-approval meeting in 1H 2027.
XNCRXencor10-QQuarterly reportSummary on the 8-K
XFORX4 PharmaceuticalsReleaseX4 Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Corporate Update → BD updateSummary on the 10-Q
XFORX4 Pharmaceuticals10-QQuarterly report → BD updateThe Q3 10-Q finally discloses the K2 covenant structure — a 75%-of-debt cash lock starting Oct 1, 2027 that compresses usable runway ahead of the H1 2028 4WARD readout — while 4STEPS emerges as a new clinical program and WHIM sales tick up for the first time in three quarters.
VRDNViridian TherapeuticsReleaseViridian Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Recent Business Progress → BD updateSummary on the 8-K
VRDNViridian Therapeutics8-KCurrent report: results of operations · EX-99.1 → BD updateLumvoa's first real revenue quarter prints $24.7M — ahead of what a mid-quarter launch should deliver — and the stock surged 15.5% on the day; the J-code, the Q4 pipeline catalysts, and the royalty math all need a fresh read.
VRDNViridian Therapeutics10-QQuarterly report → BD updateSummary on the 8-K
VIRVir BiotechnologyReleaseVir Biotechnology Provides Corporate Update and Reports Third Quarter 2026 Financial Results → BD updateSummary on the 8-K
VIRVir Biotechnology8-KCurrent report: results of operations · EX-99.1 → BD updateQ3 earnings land with ECLIPSE 1 now explicitly "this quarter," VIR-5500 earns FDA Fast Track and proof-of-concept status, and the VIR-5818 HER2 data timeline quietly slips on FDA Project Optimus feedback — the platform-generalization test just got delayed.
VIRVir Biotechnology10-QQuarterly report → BD updateSummary on the 8-K
UNCYUnicycive TherapeuticsReleaseUnicycive Therapeutics to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference
TNGXTango TherapeuticsReleaseTango and Erasca Initiate Phase 1/2 Study of Oral PRMT5 Inhibitor Vopimetostat in Combination with Pan-RAS Molecular Glue ERAS-0015
STROSutro BiopharmaReleaseSutro Biopharma to Participate in Upcoming Investor Conferencesvia aggregator
SNDXSyndax PharmaceuticalsReleaseSyndax Highlights Acceptance of 19 Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr) Abstracts, Including 7 for Oral Presentation, at ASH 2026via aggregatorSummary on the release
SNDXSyndax PharmaceuticalsReleaseSyndax to Host ASH Investor Event in Person and via Webcast on December 14, 2026via aggregatorSNDX dropped ~27% today with no company-disclosed catalyst, while Syndax simultaneously announced 19 ASH abstracts including seven oral presentations — first post-transplant maintenance trial data, updated BEAT AML/SAVE frontline combinations, and two menin-resistance mechanism readouts arriving December 12-14.
SMMTSummit TherapeuticsReleaseSummit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2026Summary on the 8-K
SMMTSummit Therapeutics8-KCurrent report: results of operations, charter / bylaws / fiscal year, shareholder vote · EX-99.1Summary on the 8-K
SMMTSummit Therapeutics8-KCurrent report: other eventsWith the authorized-share vote cleared today and the PDUFA 10 days out, Summit enters its most consequential window yet — a fortified balance sheet, imminent HARMONi-3 squamous data, and a binary FDA decision all stacking into the same fortnight.
SMMTSummit Therapeutics424B7Prospectus supplementSummary on the 8-K
SMMTSummit Therapeutics10-QQuarterly reportSummary on the 8-K
SLSSELLAS Life Sciences GroupReleaseSELLAS Life Sciences to Present Positive Phase 2 Data Demonstrating Encouraging Response and Survival Outcomes with SLS009 Combination in High-Risk AML at ASH 2026With the REGAL binary imminent, SELLAS's Plan B just got a lot more real: SLS009 Phase 2 data headed to ASH shows 54–57% ORR in venetoclax-failed, high-risk AML subgroups where historical survival is ~2.5 months — and the safety profile is clean.
SLDBSolid BiosciencesReleaseSolid Biosciences Reports Third Quarter 2026 Financial Results and Provides Business UpdatesSummary on the 10-Q
SLDBSolid Biosciences10-QQuarterly reportThe Q3 10-Q lands weeks before the Type C FDA meeting that decides SGT-003's accelerated approval fate — the binary I've been tracking all year is now imminent, the safety database is holding, and the balance sheet is intact at $348.9M.
SEPNSepterna8-KCurrent report: Reg FD disclosure · EX-99.1
RYTMRhythm PharmaceuticalsReleaseRhythm Pharmaceuticals Announces NICE Guidance for IMCIVREE® (Setmelanotide) Updated to Include Adults Living with Bardet-Biedl SyndromeRYTM ripped 28% today — from the Q3 selloff low of $86.44 back to $110 — on NICE expanding adult BBS reimbursement in England, Wales and Northern Ireland. The move likely reflects more than one day's headline: it's a catch-up to the strong Q3 commercial print combined with a fresh UK payer win that adds real-world coverage to an already-approved indication.
RVMDRevolution MedicinesReleaseRevolution Medicines Reports Third Quarter 2026 Financial Results and Update on Corporate Progress → BD updateSummary on the 8-K
RVMDRevolution Medicines8-KCurrent report: results of operations · EX-99.1 → BD update$197.6M in RASONQUE net revenue on five weeks of sales, >5,000 patients, >90% covered lives reimbursed — the first commercial print just answered the question the whole Watch List thesis was waiting on.
RVMDRevolution Medicines10-QQuarterly report → BD updateSummary on the 8-K
RLMDRelmada TherapeuticsReleaseRelmada Therapeutics to Participate at the Jefferies Global Healthcare Conference in Londonvia aggregator
RLAYRelay TherapeuticsReleaseRelay Therapeutics Reports Third Quarter 2026 Financial Results and Corporate Updates → BD updateSummary on the 8-K
RLAYRelay Therapeutics8-KCurrent report: results of operations · EX-99.1 → BD updateRelay's Q3 print — released after the close — brings three thesis-movers: ReDiscover-2 enrollment tracking ~1 year ahead of benchmark (mid-2027 completion), updated ReInspire vascular anomaly data locked in for an ASH oral on December 14 with a same-day regulatory call, and a commercial hire (Shannon Campbell, ex-Merus CCO) signaling Relay is treating launch as a planning reality. The December 14 ASH readout is now the clearest near-term de-risking event in the story.
RLAYRelay Therapeutics10-QQuarterly report → BD updateSummary on the 8-K
RCUSArcus BiosciencesReleaseArcus Biosciences Reports Third-Quarter 2026 Financial Results and Provides a Pi...Summary on the 8-K
RCUSArcus Biosciences8-KCurrent report: results of operations · EX-99.1Q3 earnings confirm the fortress balance sheet now reaches into 2029 post-offering, Arcus named a fifth bispecific partner (Pfizer's tivunatamig), and the PRISM-1 interim analysis in pancreatic cancer is now expected this quarter — a binary catalyst I flagged as a "synthetic-control-arm coin flip" that has been quietly approaching.
RCUSArcus Biosciences10-QQuarterly reportSummary on the 8-K
RAREUltragenyx Pharmaceutical10-QQuarterly reportThe Q3 10-Q puts real numbers on the post-Aspire thesis for the first time: a $43M operating cash draw, ~$750M of pro-forma liquidity once both PRV sales close, and zero gene therapy revenue yet — the launch ramp that determines whether the 2027 profitability target is real is now the only story left to watch.
RAPPRapport Therapeutics8-KCurrent report: results of operations · EX-99.1
RAPPRapport Therapeutics10-QQuarterly report
QUREuniQureReleaseuniQure Announces Third Quarter 2026 Financial Results and Provides Company Updatevia aggregatorSummary on the 8-K
QUREuniQure8-KCurrent report: results of operations · EX-99.1 EXHIBIT 99.1The Q3 10-Q lands with a quietly important reversal: AMT-191 (Fabry) dosing has resumed after the DLT pause, the Genezen CDMO note got restructured at a higher cost, confirmatory-study screening kicks off by year-end, and the motion-to-dismiss deadline in the Scocco class action is today — all while the fortress balance sheet holds at $768.4M.
QUREuniQure10-QQuarterly reportSummary on the 8-K
QTTBQ32 BioReleaseQ32 Bio Reports Third Quarter 2026 Financial Results and Provides Corporate UpdateSummary on the 8-K
QTTBQ32 Bio8-KCurrent report: results of operations · EX-99.1Q32 Bio's Q3 10-Q confirms $289.6M in cash, zero ATM usage, and two senior leadership hires that close the organizational gap I flagged — with the FDA end-of-Phase 2 meeting now imminent this quarter and the stock still trading near or slightly below cash value.
QTTBQ32 Bio10-QQuarterly reportSummary on the 8-K
QNRXQuoin PharmaceuticalsEFFECTRegistration effective → BD updateSummary on the 8-K
QNRXQuoin Pharmaceuticals8-KCurrent report: material agreement → BD updateQuoin filed a new $11M at-the-market equity facility with Leerink after the close — just 10 weeks after closing a $30.8M PIPE — adding a continuous dilution spigot to a stock already down 44% from its September high and raising the question of why fresh capital is needed this soon.
QNRXQuoin Pharmaceuticals424B5Prospectus supplement (offering)→ BD updateSummary on the 8-K
QNRXQuoin Pharmaceuticals424B5Prospectus supplement (offering)→ BD updateSummary on the 8-K
PMVPPMV PharmaceuticalsReleasePivotal Phase 2 Rezatapopt PYNNACLE Data to Be Featured in Late-Breaking Oral Presentation at ENA 2026
PCVXVaxcyteReleaseVaxcyte Reports Third Quarter 2026 Financial Results and Provides Business Update → BD updateSummary on the 8-K
PCVXVaxcyte8-KCurrent report: results of operations · EX-99.1 → BD updateAfter the October OPUS-1 win and $1.1B raise, the Q3 10-Q restores the fortress balance sheet to ~$3.4B pro forma, cuts near-term manufacturing commitments, and quietly escalates the ACIP risk I've been flagging since day one — now acknowledged in Vaxcyte's own risk factors for the first time.
PCVXVaxcyte10-QQuarterly report → BD updateSummary on the 8-K
PCSAProcessa PharmaceuticalsReleaseProcessa Pharmaceuticals Announces Key Leadership AppointmentsSummary on the 8-K
PCSAProcessa Pharmaceuticals8-KCurrent report: officer / director change, other events · EX-99.1 EXHIBIT 99.1PCSA just hired a full C-suite: a COO with 25+ years of biotech ops experience, the scientist who helped *invent* VT-7208 as Head of Research, a seasoned regulatory/development lead, and a business operations chief — completing the institutional-grade team the $200M PIPE demanded to see.
ONCYOncolytics BiotechReleaseTranslational Data from Anal Cancer Patients Show Pelareorep Drives HPV-Specific Immune Responses, Supporting its Potential Across HPV-Driven Cancers
ONCYOncolytics Biotech8-KCurrent report: other events · EX-99.1
OLMAOlema PharmaceuticalsReleaseOlema Oncology to Present Combination Data from the Palazestrant and OP-3136 Programs at the 2026 San Antonio Breast Cancer Symposium
OKUROnKure TherapeuticsReleaseOnKure Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Highlights → BD updateSummary on the 8-K
OKUROnKure Therapeutics8-KCurrent report: results of operations · EX-99.1 → BD updateThe Q3 10-Q answers the three questions I told you to track: the ATM is still clean (zero shares sold), cash is $163.3M (~$3.27/share, still above the stock price), and PIKture-01 is still missing from every filing with SABCS seven weeks away. Two China-based CMOs are named for the first time, adding a supply-chain risk I could only flag as theoretical before.
OKUROnKure Therapeutics10-QQuarterly report → BD updateSummary on the 8-K
OCGNOcugenReleaseOcugen Provides Business Update with Third Quarter 2026 Financial ResultsSummary on the 8-K
OCGNOcugen8-KCurrent report: results of operations · EX-99.1 EXHIBIT 99.1Ocugen's Q3 2026 earnings landed with a nearly flat net loss of $3.6M — dramatically better than the year-ago $20M — driven by a $16.6M derivative liability mark-down as the stock slid from convertible pricing levels; the December 22 authorized-share vote is confirmed; and the investor deck breaks out new OCU400 Phase 1/2 data showing 71.4% of the 7-patient ITT cohort projected to clear the Phase 3 response bar.
OCGNOcugen10-QQuarterly reportSummary on the 8-K
NVCTNuvectis PharmaReleaseNuvectis Pharma Reports Third Quarter 2026 Financial Results and Business Highlightsvia aggregator→ BD updateSummary on the 8-K
NVCTNuvectis Pharma8-KCurrent report: results of operations · EX-99.1 EXHIBIT 99.1 → BD updateThe Q3 report brings the first confirmation that FDA discussions on a U.S. ciprocopan path are "well underway," but the NXP900 Phase 1b combination update has quietly slipped to 1H 2027 — and the ATM's $37M single-fund placement finally starts to answer the institutional-sponsorship question.
NVCTNuvectis Pharma10-QQuarterly report → BD updateSummary on the 8-K
NTLAIntellia TherapeuticsReleaseIntellia Therapeutics Completes Enrollment in Phase 3 MAGNITUDE-2 Trial of Nexiguran Ziclumeran (Nex-z) for Patients with Hereditary Transthyretin Amyloidosis with Polyneuropathy (ATTRv-PN)MAGNITUDE-2 is fully enrolled — the ATTRv-PN Phase 3 clock is now running, adding a second near-term readout to a catalyst stack already anchored by the March 10, 2027 lonvo-z PDUFA date.
NAMSNewAmsterdam PharmaReleaseNewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results → BD updateSummary on the 8-K
NAMSNewAmsterdam Pharma8-KCurrent report · EX-99.1 → BD updateWith the PREVAIL interim event count on track for Q4 2026 and a DSMB recommendation landing in Q1 2027, the binary I've been tracking is now weeks away — and today's Q3 update confirms $643.1M in cash, a new Phase 2b Alzheimer's trial (SPINOZA), and a RUBENS readout before year-end.
NAMSNewAmsterdam Pharma10-QQuarterly report → BD updateSummary on the 8-K
MLYSMineralys TherapeuticsReleaseMineralys Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update → BD updateSummary on the 8-K
MLYSMineralys Therapeutics8-KCurrent report: results of operations, officer / director change · EX-99.1 → BD updateQ3 earnings confirm the launch-cost ramp is steeper than prior quarters ($37.4M G&A vs. $9.7M a year ago), the Tanabe IP transfer is finally closed, RA Capital's board representative just resigned, and a 100%-tariff risk on drug imports is disclosed for the first time—all with 7 weeks to the PDUFA.
MLYSMineralys Therapeutics10-QQuarterly report → BD updateSummary on the 8-K
MLTXMoonLake ImmunotherapeuticsReleaseMoonLake Reports Third Quarter 2026 Financial Results and Provides a Business Update → BD updateSummary on the 8-K
MLTXMoonLake Immunotherapeutics8-KCurrent report: results of operations · EX-99.1 → BD updateMoonLake submitted the HS BLA on September 30 and will hear on acceptance by end of November — the thesis-defining unlock — but the Q3 10-Q reveals the Tranche 4 $50M quietly lapsed into the discretionary Tranche 6 and a $17M MHKDG milestone is already accrued, tightening the balance sheet further than the "$498.5M / mid-2028 runway" headline implies.
MLTXMoonLake Immunotherapeutics10-QQuarterly report → BD updateSummary on the 8-K
MDNAFMedicenna TherapeuticsReleaseMedicenna Completes Phase 1/2 ABILITY-1 Enrollment and Announces Webinar to Discuss Updated MDNA11 Results with Key Opinion LeadersABILITY-1 enrollment is complete at n=152, the oral at SITC lands November 7 with updated ORR data already in the release (36% mono / 43% combo in key cohorts), and a KOL webinar follows November 10 — the Q4 data catalyst I've been tracking all year is now days away.
MBRXMoleculin BiotechReleaseMoleculin Announces Acceptance of Annamycin Data for Presentation at the 2026 American Society of Hematology (ASH) Annual MeetingSummary on the 8-K
MBRXMoleculin Biotech8-KCurrent report: Reg FD disclosure · EX-99.1 EXHIBIT 99.1An ASH abstract acceptance just sent MBRX up 51% from the last-update close — the same n=45 interim data I've already dissected, now on a December poster, with the equity capital structure still a ratchet trap and cash cliff unchanged.
LXEOLexeo TherapeuticsEFFECTRegistration effective
LRMRLarimar TherapeuticsReleaseLarimar Therapeutics to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference
LENZLENZ TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
LEGNLegend BiotechReleaseLegend Biotech to Showcase CARVYKTI® Leadership and Next-Generation Cell Therapy Innovation at ASH 2026
LEGNLegend Biotech6-KForeign issuer report · EX-99.1 PRESS RELEASE
KURAKura OncologyReleaseKura Oncology and Kyowa Kirin to Present First Ziftomenib-FLT3 Inhibitor Clinical Data at ASH 2026
IRONDisc MedicineReleaseTwo oral presentations featuring additional data from RALLY-MF Phase 2 trial of selcodebart (DISC-0974) in anemia of myelofibrosis (MF) and RESTORE-PV Phase 2 trial of DISC-3405 in polycythemia vera (
INSMInsmedReleaseInsmed to Present at November and December 2026 Investor Conferences
IMRXImmuneeringReleaseImmuneering to Highlight Atebimetinib’s Broad Potential for Combinations in Pancreatic and Anaplastic Thyroid Cancers at the 2026 EORTC-NCI-AACR Symposium
IMRXImmuneeringReleaseImmuneering to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference
IMNMImmunomeReleaseImmunome to Present Initial First-in-Human Clinical Data for IM-1021 in Advanced B-Cell Lymphomas at ASH 2026via aggregator→ BD updateIM-1021 delivers a 53% ORR (64% in DLBCL) across all dose levels in heavily pretreated B-NHL patients — the first human proof that the HC74 TOP1i payload engine works, the exact catalyst I said could convert optionality into an asset.
IMMXImmix BiopharmaReleaseImmix Biopharma’s NXC-201 NEXICART-2 Interim Clinical Trial Results Selected for Oral Presentation at ASH 2026
IDYAIDEAYA BiosciencesReleaseIDEAYA Biosciences to Participate in Upcoming November 2026 Investor Relations Events
IBRXImmunityBioReleaseImmunityBio Announces First Patients in Europe Treated with ANKTIVA® Plus BCG for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in Situ
HURATuHURA BiosciencesReleaseTuHURA Biosciences Announces Three Presentations at the 68th American Society of Hematology Annual Meeting and Exposition
HRMYHarmony BiosciencesReleaseHarmony Biosciences Reports Q3 Financial Results on Track to Achieve More Than $1 Billion WAKIX Net Revenue and Announces Strong Multiple-Ascending Dose Data for Its Orexin Agonist BP-205, Supporting → BD updateSummary on the 8-K
HRMYHarmony Biosciences8-KCurrent report: results of operations, Reg FD disclosure · EX-99.1 → BD updateHarmony's Q3 earnings and BP-205 MAD data land on the same day — the first repeated-dose safety look at its orexin agonist clears the critical liver/cardiac bar, while WAKIX hits $269M (+12%) and a new legal calendar accelerates the patent-cliff timeline into early 2027.
HRMYHarmony Biosciences10-QQuarterly report → BD updateSummary on the 8-K
GPCRStructure TherapeuticsReleaseStructure Therapeutics to Participate in the Jefferies Global Healthcare Conference
GNLXGeneluxSCHEDULE 13G/A13G amendment
GERNGeronReleaseGeron Corporation Reports Third Quarter 2026 Financial Results and Recent Business Highlights → BD updateSummary on the 8-K
GERNGeronReleaseGeron Corporation to Present Data Highlighting Clinical and Biological Activity of RYTELO® (imetelstat) at ASH 2026 → BD updateSummary on the 8-K
GERNGeron8-KCurrent report: results of operations · EX-99.1 → BD updateQ3 2026 delivered GERN's first clean operating profit ($5.8M) post-IMpactMF collapse, cash grew sequentially to $339M, and demand accelerated 10% QoQ to 1,700 accounts — but the securities class action survived a motion to dismiss and is now in discovery, adding a new and unpriced tail risk to the already-levered balance sheet.
GERNGeron10-QQuarterly report → BD updateSummary on the 8-K
FBRXForte BiosciencesSCHEDULE 13G/A13G amendment
EYPTEyePointSCHEDULE 13G/A13G amendment
EWTXEdgewise TherapeuticsReleaseEdgewise Therapeutics Reports Third Quarter 2026 Financial Results → BD updateSummary on the 8-K
EWTXEdgewise Therapeutics8-KCurrent report: results of operations · EX-99.1 EXHIBIT 99.1 → BD updateEdgewise's Q3 print confirmed a better-than-estimated tax bill ($155M vs. ~$226M feared), leaving $1.74B in cash — but GRAND CANYON failed on November 3, wiping the $100–200M Becker milestone off the table, while EDG-15400 quietly dosed its first HFpEF patient, closing the Phase 1 disclosure gap I flagged in the original writeup.
EWTXEdgewise Therapeutics10-QQuarterly report → BD updateSummary on the 8-K
EVMNEvommuneReleaseEvommune Enters into Agreement to In-License EVO570, a Potential Best-in-Class Oral VAV1 Molecular Glue Degrader, from Hinova Pharmaceuticals → BD updateSummary on the 8-K
EVMNEvommuneReleaseEvommune Announces $30 Million Private Placement → BD updateSummary on the 8-K
EVMNEvommune8-KCurrent report: material agreement, unregistered sale of equity, Reg FD disclosure · EX-99.1 → BD updateEvommune just reloaded the pipeline with a licensed VAV1 molecular glue degrader (EVO570) showing ~20× greater preclinical potency than Novartis's MRT-6160, backed by a $30M PIPE at current prices from OrbiMed, Adage, and Balyasny — a meaningful signal that institutional money is re-engaging the story after two EVO756 failures.
EVMNEvommune424B3Prospectus (resale / update)→ BD updateSummary on the 8-K
ETONEton PharmaceuticalsReleaseEton Pharmaceuticals to Present at 2026 Jefferies Global Healthcare Conference in London
ERASErascaReleaseTango and Erasca Initiate Phase 1/2 Study of Oral PRMT5 Inhibitor Vopimetostat in Combination with Pan-RAS Molecular Glue ERAS-0015
ENTAEnanta PharmaceuticalsReleaseEnanta Pharmaceuticals to Participate in Upcoming Investor Conferences
ELTXElicio TherapeuticsReleaseElicio Therapeutics to Host Virtual KOL Event on November 11, 2026: ELI-002 7P for Metastatic and Neoadjuvant PDAC
DFTXDefinium TherapeuticsReleaseDefinium Therapeutics Presents Topline Phase 3 Data for DT120 ODT in Generalized Anxiety Disorder and Major Depressive Disorder at 2026 NEI Fall Congress
CRVSCorvus PharmaceuticalsReleaseCorvus Pharmaceuticals Announces Initial Data from Soquelitinib Clinical Trial in Patients with Autoimmune Lymphoproliferative Syndrome (ALPS) will be Presented at the 68ᵗʰ American Society for HematoThe ALPS catalyst I flagged for late 2026 just landed: soquelitinib's NIH-led Phase 2 delivered one-year safety and efficacy data in a genetically confirmed immune disorder — zero severe adverse events, all three patients off background steroids — providing the kind of mechanism validation the thesis called for ahead of the pivotal 1H 2027 AD readout.
CRBUCaribou BiosciencesReleaseCaribou Biosciences Announces Presentations at the 2026 American Society of Hematology (ASH) Annual Meeting
CMPSCOMPASS PathwaysReleaseCompass Pathways to Participate in Stifel 2026 Healthcare Conference on November 11th
CLYMClimb BioReleaseClimb Bio to Present New Data for Budoprutug in Immune Thrombocytopenia at the 68th American Society of Hematology Annual Meeting and Exposition
CLRBCellectar BiosciencesReleaseCellectar Biosciences to Present Three Posters Highlighting Durable Clinical Activity of Iopofosine I 131 in Waldenström Macroglobulinemia at the American Society of Hematology Annual Meeting and Expo
CLNNCleneReleaseClene Reports Third Quarter 2026 Financial Results and Recent Operating HighlightsSummary on the 8-K
CLNNClene8-KCurrent report: results of operations · EX-99.1 EXHIBIT 99.1The Q3 10-Q reveals $9.9M cash, a ~$13M current debt wall, a fresh $7.2M NIH subaward, and management's first explicit disclosure that NDA acceptance could trigger $6.7M–$7.8M in warrant cash — all landing the same morning the stock jumped +8.8%.
CLNNClene10-QQuarterly reportSummary on the 8-K
CLDXCelldex TherapeuticsReleaseCelldex to Present at Upcoming Investor Conferences
CGEMCullinan TherapeuticsReleaseCullinan Therapeutics Announces Presentations for CLN-049, a FLT3 T Cell Engager, and Velinotamig, a BCMA T Cell Engager, at the 68th ASH Annual MeetingSummary on the 8-K
CGEMCullinan Therapeutics8-KCurrent report: Reg FD disclosure, other events · EX-99.1The CLN-049 Phase 1 dataset — 87 patients, optimized dosing at 6 and 12 µg/kg — landed this morning and the stock dropped 20.7%, but the headline CRc compression vs. earlier data may be less damning than the tape suggests when you read the regimen change that drove it.
BEAMBeam TherapeuticsReleaseBeam Therapeutics to Present Updated Clinical Data from BEACON Phase 1/2 Trial of Risto-cel in Sickle Cell Disease in an Oral Presentation at American Society of Hematology (ASH) Annual MeetingThe BEACON risto-cel data earns an oral slot at ASH and lands in the press program — with patient-reported outcomes data showing real-world functional improvements now added to the efficacy story, and the BLA timeline locked to year-end 2026.
BCRXBiocryst PharmaceuticalsReleaseBioCryst Reports Third Quarter 2026 Financial Results → BD updateSummary on the 8-K
BCRXBiocryst PharmaceuticalsReleaseBioCryst to Present at Upcoming Investor Conferences → BD updateSummary on the 8-K
BCRXBiocryst Pharmaceuticals8-KCurrent report: results of operations, Reg FD disclosure · EX-99.1 PRESS RELEASE → BD updateBioCryst's Q3 print cleared the CareMed transition risk and accelerated the OMERS royalty-cap timeline, but investors should understand that headline ORLADEYO revenue was flattered by a mid-teens inventory build — the underlying business is tracking, not accelerating.
BCRXBiocryst Pharmaceuticals10-QQuarterly report → BD updateSummary on the 8-K
AUTLAutolus TherapeuticsReleaseAUTOLUS THERAPEUTICS TO PRESENT CLINICAL DATA UPDATES AT THE AMERICAN SOCIETY OF HEMATOLOGY (ASH) ANNUAL MEETING 2026
ARVNArvinasReleaseArvinas to Present Preliminary Clinical Data from Early Monotherapy Dose Escalation Cohorts in the Phase 1 Trial for ARV-393 (Zaloblideg), a PROTAC BCL6 Degrader, at the 2026 American Society of Hemat
ANTXAN2 TherapeuticsReleaseAN2 Therapeutics to Present at Jefferies Global Healthcare Conference in LondonAN2 Therapeutics has nominated AN2-504661 — a novel oral ENPP1 inhibitor — as a development candidate for hypophosphatasia (HPP), delivering on the catalyst the prior writeup flagged as a guided end-2026 milestone and adding a fourth rare-disease leg to the platform.
ANTXAN2 TherapeuticsReleaseAN2 Therapeutics Advances Pipeline With Development Candidate Nomination for Hypophosphatasia (HPP)Summary on the release
ANIXAnixa BiosciencesReleaseNOV 04, 2026 8:35 AM EST Anixa Biosciences Announces Presentation of Ovarian Cancer CAR-T Clinical Trial at ESMO Immuno-Oncology & Advanced Therapies Congress 2026↗ Robert Wenham, M.D., Chair of the G
AMLXAmylyx PharmaceuticalsReleaseAmylyx Pharmaceuticals to Host Investor Event at ObesityWeek® 2026 Featuring Leading PBH Experts
AGIOAgios PharmaceuticalsReleaseAgios to Highlight Strength and Differentiation of Rare Hematology Portfolio with New Clinical Data for Mitapivat in Sickle Cell Disease and AG-236 in Polycythemia Vera at ASH 2026
ADMAAdma BiologicsReleaseADMA Biologics Reports Third Quarter 2026 Financial Results and Provides Business Update → BD updateSummary on the 8-K
ADMAAdma Biologics8-KCurrent report: results of operations · EX-99.1 EXHIBIT 99.1 → BD updateADMA's Q3 2026 print shows ASCENIV at $124.7M (+31% YoY, +21% sequentially), gross margin of 71%, and $105M of nine-month operating cash flow — clearing another gate on the path from Watch List toward conviction, while FDA pre-IND feedback on SG-001 adds a first pipeline milestone.
ADMAAdma Biologics10-QQuarterly report → BD updateSummary on the 8-K
ADCTADC TherapeuticsReleaseADC Therapeutics Announces Abstracts at the 68th ASH Annual Meeting Highlighting Breadth of ZYNLONTA® Clinical Program → BD updateSummary on the 8-K
ADCTADC Therapeutics8-KCurrent report: results of operations, Reg FD disclosure, other events · EX-99.1 EXHIBIT 99.1 → BD updateThe LOTIS-7 abstract data the entire thesis has been waiting for arrived after the close: 88.7% ORR and 75.3% CR across 97 evaluable r/r DLBCL patients, with responses deepening over time and median PFS not reached — and critically, a safety profile that looks far cleaner than LOTIS-5's fatal-infection disaster.
ACTUActuate TherapeuticsReleaseACTUATE THERAPEUTICS TO PRESENT PROMISING PRECLINICAL DATA DEMONSTRATING ANTITUMOR AND IMMUNE ACTIVATION ACTIVITY OF ELRAGLUSIB ORAL TABLET IN ADVANCED MELANOMA MODELS AT ENA 2026
ACRVAcrivon TherapeuticsReleaseAcrivon to Present Late-Breaking Oral Plenary Presentation and Posters at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
ACIUAC ImmuneReleaseAC Immune Third Quarter 2026 Financial and Corporate Update → BD updateSummary on the 6-K
ACIUAC Immune6-KForeign issuer report · EX-99.1 → BD updateAC Immune's Q3 update quietly extends cash runway to Q1 2028, pushes the hsCRP readout to H1 2027, and declares a Morphomer a-syn lead candidate — the balance sheet got better, the near-term catalyst calendar shifted, and the stock moved +9.6% on the news.

Tuesday, November 380

ZURAZura BioEFFECTRegistration effective
XFORX4 PharmaceuticalsReleaseX4 Pharmaceuticals to Participate in Guggenheim, Stifel, and Jefferies Conferences in November 2026
XENEXenon PharmaceuticalsReleaseXenon to Present at Upcoming Investor Conferences
VNDAVanda PharmaceuticalsReleaseVanda Pharmaceuticals Announces Participation at November 2026 Investor Conferences
TNGXTango TherapeuticsReleaseTango Therapeutics to Participate in Guggenheim’s 3rd Annual Healthcare Innovation Conference
SYRESpyre TherapeuticsReleaseSpyre Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update → BD updateSummary on the 8-K
SYRESpyre Therapeutics8-KCurrent report: results of operations · EX-99.1 → BD updateSKYWAY's final two sub-studies (PsA and axSpA) missed their primary endpoints, closing the door on rheumatic diseases for SPY072 entirely — while SKYLINE Part B accelerates toward a Q3 2027 combination readout and the fortress balance sheet grows to $1.47B pro forma.
SYRESpyre Therapeutics10-QQuarterly report → BD updateSummary on the 8-K
STOKStoke TherapeuticsReleaseStoke Therapeutics to Present at Upcoming Investor Conferences in November
STOKStoke Therapeutics10-QQuarterly report
RYTMRhythm PharmaceuticalsReleaseRhythm Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Update → BD updateSummary on the 8-K
RYTMRhythm Pharmaceuticals8-KCurrent report: results of operations · EX-99.1 → BD updateQ3 delivered another strong commercial beat ($92.1M, +29% QoQ, >700 PSFs) — but the market is selling the news because Rhythm simultaneously agreed to pay LG Chem $350M over four years to slash its bivamelagon royalty, financed by a new $750M term loan that adds meaningful leverage to a company still burning cash.
RYTMRhythm Pharmaceuticals10-QQuarterly report → BD updateSummary on the 8-K
RLMDRelmada TherapeuticsReleaseRelmada Therapeutics to Report Third Quarter 2026 Financial Results on Thursday, November 12, 2026via aggregator
RAREUltragenyx PharmaceuticalReleaseUltragenyx Reports Third Quarter 2026 Financial Results, Announces Substantial Expense Reductions, and Reaffirms Profitability in 2027 → BD updateSummary on the 8-K
RAREUltragenyx Pharmaceutical8-KCurrent report: acquisition / disposition, results of operations, exit / restructuring costs · EX-99.1 → BD updateQ3 2026 earnings confirm the transformation is real: operating cash burn collapsed to $43M for the quarter, a second 20% workforce reduction is underway, UX701 is terminated, Angelman is officially wound down, and R&D spending is being cut in half — but 2027 GAAP profitability is reaffirmed and the balance sheet now has ~$750M+ of cash plus PRV proceeds incoming.
PMNProMIS NeurosciencesReleaseProMIS Neurosciences to Report Third Quarter 2026 Financial Results and Business Update on November 12, 2026
ORKAOruka TherapeuticsReleaseOruka Therapeutics to Participate in Multiple Upcoming Conferences
ORICOric PharmaceuticalsReleaseORIC® Pharmaceuticals to Participate in Upcoming Investor Conferencesvia aggregator
OCSOculis HoldingReleaseOculis Reports Q3 2026 Financial Results and Builds Momentum Toward Multiple Upcoming Pipeline Catalysts → BD updateSummary on the 6-K
OCSOculis Holding6-KForeign issuer report · EX-99.1 → BD updatePREDICT-1 enrollment is complete at 176 patients with topline data due around year-end, while new ACUITY biomarker data, two senior neurology hires, and an expanded $125M ATM arrive as OCS trades at $7.63 — a 40% slide since the August update — compressing the EV to a level where the speculative math looks different.
OCSOculis Holding424B5Prospectus supplement (offering)→ BD updateSummary on the 6-K
NTLAIntellia TherapeuticsReleaseIntellia Therapeutics Announces Upcoming Nexiguran Ziclumeran (nex-z) Medical Congress Presentations
NRIXNurix TherapeuticsReleaseNurix Therapeutics Announces Sanofi’s Decision to Discontinue Development of STAT6 Degrader SAR448272 → BD updateSummary on the 8-K
NRIXNurix Therapeutics8-KCurrent report: other events → BD updateSanofi has terminated the Phase 1 trial of SAR448272, its STAT6 degrader developed under the Nurix collaboration — permanently wiping ~$455M in future milestones from the "free carry" partnered pipeline I've been tracking since April. The reaction hasn't hit the tape yet, but the thesis needs a recalibration.
NGNENeurogeneReleaseNeurogene to Participate in Upcoming Investor Conferences
NAMSNewAmsterdam PharmaReleaseNewAmsterdam Pharma to Participate at Upcoming Investor Conferences in November
MLYSMineralys TherapeuticsReleaseMineralys Therapeutics to Participate in Upcoming Investor Conferences
MISTMilestone PharmaceuticalsReleaseMilestone Pharmaceuticals to Announce Third Quarter 2026 Financial Results on November 13, 2026
MESOMesoblast6-KForeign issuer report · EX-99.1
MAZEMaze TherapeuticsReleaseMaze Therapeutics to Participate in Upcoming Investor Conferences
LQDALiquidiaReleaseLiquidia Corporation to Report Third Quarter 2026 Financial Results on November 10, 2026
LENZLENZ Therapeutics10-QQuarterly report
KURAKura OncologyReleaseKura Oncology to Report Third Quarter Financial Results on November 10
KTTAPasithea TherapeuticsReleasePasithea Therapeutics Announces FDA Clearance of IND for PAS-004 in Neurofibromatosis Type 1 (NF1)-Associated Cutaneous Neurofibromas (cNF)→ BD updateThe FDA has cleared an IND for a randomized, placebo-controlled Phase 2 trial of PAS-004 in NF1-associated cutaneous neurofibromas — a 80,000-patient indication with zero approved systemic therapies, and the exact "label-expansion seed" I flagged in June.
KAPAKairos PharmaReleaseKairos Pharma Presents at United Scientific Group’s 11th International Conference on Cancer Research & Drug Development
KAPAKairos Pharma8-KCurrent report: material agreement, other events · EX-99.1
JBIOJade BiosciencesReleaseJade Biosciences to Participate in Upcoming Conferences
IRDOpus GeneticsReleaseOpus Genetics to Present at the Guggenheim Annual Healthcare Innovation Conference
IDYAIDEAYA BiosciencesS-8Employee plan registration → BD updateSummary on the 8-K
IDYAIDEAYA BiosciencesReleaseIDEAYA Biosciences Reports Financial Results for the Third Quarter 2026 and Provides a Business Update → BD updateSummary on the 8-K
IDYAIDEAYA Biosciences8-KCurrent report: results of operations · EX-99.1 → BD updateOptimUM-010 is formally dead — IDEAYA just canceled the neoadjuvant Phase 3, banking $100-125M in savings to fund two IDE849 registrational trials (SCLC and NEC). The Q3 10-Q confirms the burn is accelerating and the SCLC bet is scaling fast.
IDYAIDEAYA Biosciences10-QQuarterly report → BD updateSummary on the 8-K
HELPHelus PharmaReleaseHelus Pharma to Participate in the Guggenheim Healthcare Innovation Conference
HELPHelus Pharma6-KForeign issuer report · EX-99.1 EXHIBIT 99.1
GERNGeronReleaseGeron Corporation to Participate in the Stifel 2026 Healthcare Conference
FHTXFoghorn TherapeuticsReleaseFoghorn Therapeutics to Participate in Three Upcoming Investor Conferences in November
EXELExelixisReleaseExelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in November
ERASErascaReleaseErasca to Present at Upcoming Conferences in November
DTILPrecision BiosciencesSCHEDULE 13G/A13G amendment → BD updateSummary on the 8-K
DTILPrecision BiosciencesReleasePrecision BioSciences Reports Third Quarter 2026 Financial Results and Provides Business Update → BD updateSummary on the 8-K
DTILPrecision Biosciences8-KCurrent report: results of operations · EX-99.1 → BD updateQ3 numbers confirm the ATM is open again and cash is burning faster than the Q2 "discipline" signal suggested — but the bigger story is that new ELIMINATE-B data drops publicly on November 5 and hits the podium at AASLD on November 8, making this the most time-sensitive update since the August first-dosing post.
DTILPrecision Biosciences10-QQuarterly report → BD updateSummary on the 8-K
DFTXDefinium TherapeuticsReleaseDefinium Therapeutics to Participate at Upcoming Investor Conferences
CTNMContineum Therapeutics8-KCurrent report: results of operations · EX-99.1
CTNMContineum Therapeutics10-QQuarterly report
CRDLCardiol TherapeuticsSUPPLSUPPL → BD updateSummary on the 6-K
CRDLCardiol TherapeuticsReleaseCardiol Therapeutics Announces At-The-Market Equity Offering Program With Jefferies LLC → BD updateSummary on the 6-K
CRDLCardiol Therapeutics6-KForeign issuer report · EX-99.1 NEWS RELEASE DATED NOVEMBER 3, 2026 → BD updateSummary on the 6-K
CRDLCardiol Therapeutics6-KForeign issuer report · EX-99.1 EXHIBIT 99.1 → BD updateThe ATM dilution machine I warned about in September is now live: Cardiol activated a US$75M at-the-market offering through Jefferies, the exact scenario I flagged as a downside trigger — and the stock has already shed ~41% since the last update.
CNTBConnect BiopharmaSCHEDULE 13G/A13G amendment
CMPSCOMPASS PathwaysReleaseCompass Pathways Announces Third Quarter 2026 Financial Results and Business Highlights → BD updateSummary on the 8-K
CMPSCOMPASS Pathways8-KCurrent report: results of operations · EX-99.1 → BD updateThe NDA is days away and $444M in cash funds the company into 2028 — so why is CMPS down 43% since September? The Q3 report answers the question, and the thesis is intact.
CMPSCOMPASS Pathways10-QQuarterly report → BD updateSummary on the 8-K
CMMBChemomab Therapeutics6-KForeign issuer report
CGENCompugenReleaseCompugen to Participate in November Investor Conferences
CCCCC4 TherapeuticsReleaseC4 Therapeutics to Participate in Upcoming November Investor Conferences
CAPRCapricor TherapeuticsReleaseCapricor Therapeutics to Report Third Quarter 2026 Financial Results and Provide Recent Corporate Update on November 10
BEAMBeam TherapeuticsReleaseBeam Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Clinical Progress Across Base Editing PortfolioSummary on the 8-K
BEAMBeam Therapeutics8-KCurrent report: results of operations · EX-99.1Q3 earnings arrive as BEAM enters its most critical execution quarter: risto-cel BLA filing expected by year-end, BEAM-302 pivotal cohort dosing set to complete 1H 2027, and $1.0B on hand — but the runway math is now explicitly milestone-gated, and the Apellis collaboration has quietly unraveled.
BEAMBeam Therapeutics10-QQuarterly reportSummary on the 8-K
BCTXBriaCell TherapeuticsReleaseBriaCell and BriaPro to Present Preclinical Anti-Cancer Activity and Immunotherapy Findings at SITC 2026via aggregator
AXSMAxsome TherapeuticsReleaseAxsome Therapeutics to Participate in Upcoming Investor Conferences
ARVNArvinasS-3Shelf registration → BD updateSummary on the 8-K
ARVNArvinasReleaseArvinas Reports Third Quarter 2026 Financial Results and Provides Corporate Update → BD updateSummary on the 8-K
ARVNArvinas8-KCurrent report: results of operations, Reg FD disclosure · EX-99.1 → BD updateQ3 earnings confirm ARV-6723 is now dosing patients, ARV-393 data lands at ASH in December, and $558.9M cash holds the fort — but the stock is at $7.09, the CMO seat is still empty, and a fresh $400M shelf registration raises dilution awareness heading into the catalyst window.
ARVNArvinas10-QQuarterly report → BD updateSummary on the 8-K
ARDXArdelyxReleaseArdelyx Reports Third Quarter 2026 Financial Results and Provides Business Update → BD update
ARDXArdelyxReleaseArdelyx Completes Enrollment in Phase 3 ACCEL Clinical Trial of IBSRELA® (tenapanor) in Adults with Chronic Idiopathic Constipation → BD update
ARDXArdelyx8-KCurrent report: results of operations, Reg FD disclosure · EX-99.1 → BD update
ARDXArdelyx10-QQuarterly report → BD update
AMLXAmylyx PharmaceuticalsReleaseAmylyx Pharmaceuticals to Participate in Upcoming November Investor Conferences
ALLOAllogene TherapeuticsReleaseAllogene Highlights Clinical Progress and Next-Generation Innovation Across Its Off-the-Shelf CAR T Platform at SITC Annual Meeting
ADCTADC TherapeuticsS-4Merger registration
ADCTADC TherapeuticsReleaseADC Therapeutics to Present at November Investor Conferences

Monday, November 270

XERSXeris BiopharmaReleaseXeris Biopharma Welcomes Menassie M. Taddese to Board of Directors
XERSXeris Biopharma8-KCurrent report: officer / director change, Reg FD disclosure · EX-99.1
XENEXenon PharmaceuticalsReleaseXenon to Report Q3 2026 Financial Results on November 9, 2026
VSTMVerastemReleaseVerastem Oncology to Participate in Upcoming November Investor Conferences
VIRVir BiotechnologyReleaseVir Biotechnology to Participate in the Jefferies 2026 London Healthcare Conference
VERAVera TherapeuticsReleaseVera Therapeutics to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference
TVTXTravere TherapeuticsReleaseTravere Therapeutics Reports Third Quarter 2026 Financial Results → BD updateSummary on the 8-K
TVTXTravere Therapeutics8-KCurrent report: results of operations · EX-99.1 → BD updateFILSPARI hit $200M in a single quarter (+120% YoY) — another record print — while the IgAN patent finally issued and hit the Orange Book, the BIOSECURE injunction gave the API supplier a temporary reprieve, and ASN data reinforced the dual-blockade thesis one more time.
TVTXTravere Therapeutics10-QQuarterly report → BD updateSummary on the 8-K
TLSATiziana Life SciencesReleaseTiziana Announces Positive Topline Results from Phase 2a INFORM-MS Trial of Intranasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis → BD updateSummary on the 6-K
TLSATiziana Life Sciences6-K/AForeign issuer report (amended)→ BD updateSummary on the 6-K
TLSATiziana Life Sciences6-KForeign issuer report · EX-99.1 TIZIANA LIFE SCIENCES LTD PRESS RELEASE, DATED NOVEMBER 2, 2026 → BD updateINFORM-MS hit its primary PET endpoint (p=0.0168) and safety primary — the first randomized, placebo-controlled evidence that a nasal anti-CD3 antibody reduces microglial activation in the brain. The science score just moved, but the stock is down 16% on the day, likely pricing in the near-certain dilutive raise that was always going to follow this result.
TGTXTg TherapeuticsReleaseTG Therapeutics to Host Conference Call on Third Quarter 2026 Financial Results and Business Update
SPRBSpruce BiosciencesReleaseSpruce Biosciences to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference
SNDXSyndax PharmaceuticalsRelease11.02.26 Syndax Announces CFO Transition – Aaron A. Ondrey Appointed Chief Financial Officer - Keith A. Goldan to retire as CFO and remain with the Company through year-end to support the transition -→ BD updateSummary on the 8-K
SNDXSyndax PharmaceuticalsRelease11.02.26 Syndax Reports Third Quarter 2026 Financial Results and Provides Business Update – Total revenue of $83.3 million in 3Q26, an 82% year-over-year increase – – Revuforj ® (revumenib) net revenu → BD updateSummary on the 8-K
SNDXSyndax Pharmaceuticals8-KCurrent report: results of operations, officer / director change · EX-99.1 → BD updateRevuforj's Q3 print directly tests the NPM1m share-erosion tripwire I flagged in the writeup — and it holds: new patients accelerated 20% quarter-over-quarter with management claiming dominant share across all age groups, while the CFO transition adds a new strategic signal to decode.
SNDXSyndax Pharmaceuticals10-QQuarterly report → BD updateSummary on the 8-K
SIONSionna TherapeuticsReleaseSionna Therapeutics to Participate in Upcoming November 2026 Investor Conferences
RYTMRhythm PharmaceuticalsReleaseRhythm Pharmaceuticals and LG Chem Enter into Amendment to Bivamelagon Exclusive License Agreement
RXRXRecursion PharmaceuticalsReleaseRecursion Appoints Fred Hassan as Chair of the Board → BD updateSummary on the 8-K
RXRXRecursion PharmaceuticalsReleaseNew Phase 2 REC-4881 Data Presented at CGA-IGC Show Deep, Durable Polyp Burden Reductions in FAP, with Activity Across the GI Tract and in Larger, Higher-Risk Polyps → BD updateSummary on the 8-K
RXRXRecursion PharmaceuticalsReleaseRecursion Reports Third Quarter 2026 Financial Results and Extends Cash Runway; Highlights Positive Clinical Data in REC-4881 and REC-1245, Sanofi Development Candidate Option and Appointment of Fred → BD updateSummary on the 8-K
RXRXRecursion Pharmaceuticals8-KCurrent report: results of operations, officer / director change, Reg FD disclosure · EX-99.1 → BD updateThe CGA-IGC plenary I called a must-watch catalyst has landed — REC-4881's expanded TUPELO data strengthened across every GI compartment, and REC-1245 produced the first confirmed efficacy from a Recursion-designed molecule. The one watch-list trigger still outstanding: the FDA endpoint decision.
RXRXRecursion Pharmaceuticals10-QQuarterly report → BD updateSummary on the 8-K
RNTXRein TherapeuticsReleaseRein Therapeutics to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference
RLAYRelay TherapeuticsReleaseRelay Therapeutics to Participate in Three Upcoming Investor Conferences in November
RCUSArcus BiosciencesReleaseArcus Biosciences to Participate in the Jefferies Global Healthcare Conference 2...
QUREuniQureReleaseuniQure Announces FDA Acceptance and Priority Review of the Biologics License Application for ifezuntirgene inilparvovec for the Treatment of Huntington’s Diseasevia aggregator→ BD updateSummary on the 8-K
QUREuniQure8-KCurrent report: Reg FD disclosure, other events · EX-99.1 EXHIBIT 99.1 → BD updateThe FDA accepted the AMT-130 BLA under Priority Review with a May 1, 2027 PDUFA date — the exact binary I told readers to wait for in September — and the stock is inexplicably down 7.5% on the news, creating one of the more interesting re-entry setups this story has thrown off.
OLMAOlema PharmaceuticalsReleaseOlema Oncology to Participate in Upcoming Investor Conferences
OCSOculis HoldingReleaseOculis Appoints Experienced Life Sciences Leader Björn Tackenberg, M.D., Ph.D., as Chief Scientific Officer to Advance Neurology InnovationOculis hired Roche's former Head of Integrative Neuroscience as CSO — the most credible organizational signal yet that the Privosegtor neuro-axonal franchise is a real program, not a slide deck, arriving as the stock hits new post-DIAMOND lows.
NVCTNuvectis PharmaReleaseNuvectis Pharma to Report Third Quarter 2026 Financial Results on November 4, 2026via aggregator
NRXPNRX Pharmaceuticals8-KCurrent report: Reg FD disclosure · EX-99.1 EXHIBIT 99.1
NRSNNeuroSense TherapeuticsReleaseNeuroSense to Strengthen PrimeC Canadian ALS Submission With New NfL Data → BD updateSummary on the 6-K
NRSNNeuroSense Therapeutics6-KForeign issuer report · EX-99.1 PRESS RELEASE DATED NOVEMBER 2, 2026 → BD updateThe Canadian NDS deadline slipped three months to March 2027 — extending the one near-term catalyst into the Nasdaq Panel's maximum window — while new NfL biomarker data from PARADIGM provides a genuine, if incremental, scientific positive. The stock is down 38.6% week-over-week and now trading well below the $5M immediate-delisting floor.
MISTMilestone PharmaceuticalsReleaseNew Data Presented at AHA Scientific Sessions 2026 Demonstrate That CARDAMYST® (etripamil) Nasal Spray Converted Recurrent PSVT to Normal Heart Rhythm in Patients with Prior Catheter Ablation
LXEOLexeo TherapeuticsReleaseLexeo Therapeutics to Present Multiple Oral and Poster Presentations at Key Scientific Conferences in NovemberLX2006's 36-month follow-up data — being presented at ICAR this week — show sustained and *deepening* neurological benefit over time, directly answering the durability question I've called the thesis's most stubborn unknown since the December deep dive.company site may be offline after the acquisition
LENZLENZ TherapeuticsSCHEDULE 13D/A13D amendment → BD updateRA Capital — the "elite, science-literate" anchor I cited as a core conviction signal — sold its entire LENZ equity stake across three days this week, dropping from ~15.5% to 0.2% (warrants only). That changes the bull case in a way subscribers need to hear.
KZIAKazia TherapeuticsReleaseKazia Therapeutics Announces Two Abstracts on Paxalisib Tumor and Immune Reprogramming Research Accepted for Poster Presentation at 2026 San Antonio Breast Cancer Symposium
KZIAKazia TherapeuticsNT 20-FNT 20-F
JANXJanux TherapeuticsReleaseJanux Therapeutics to Host Virtual Event Presenting Initial Phase 1 Clinical Data for JANX011 in Healthy VolunteersThe JANX011 autoimmune lottery ticket is about to pay out — or not. Janux just announced a November 9 virtual event presenting the initial Phase 1 healthy-volunteer data, including safety, PK, and B-cell pharmacodynamics: the exact readout the thesis has been building toward.
IRONDisc MedicineReleaseWATERTOWN, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel
IONSIonis PharmaceuticalsReleaseIonis to hold third quarter 2026 financial results webcast
INKTMiNK TherapeuticsReleaseMiNK Therapeutics to Report Third Quarter 2026 Results and Outline Progress in Randomized Clinical Development and Scalable iNKT Cell Therapy
IMUXImmunicSCHEDULE 13G/A13G amendment
IMUXImmunicReleaseImmunic to Participate in Investor Conferences in November
IMNMImmunomeReleaseImmunome to Present at Guggenheim 3rd Annual Healthcare Innovation Conferencevia aggregator
HROWHarrowReleaseHarrow Launches HarrowRx Platform
ETONEton PharmaceuticalsReleaseEton Pharmaceuticals Announces Licensing and Initiation of ET-900 Program Evaluating Mecasermin/IGF-1 for Treatment of Infantile and Epileptic SpasmsSummary on the 8-K
ETONEton Pharmaceuticals8-KCurrent report: other events · EX-99.1 EXHIBIT 99.1 PRESS RELEASE RELATING TO INFANTILE SPASMSEton has licensed Baylor College of Medicine patent rights and submitted an IND to evaluate INCRELEX (mecasermin/IGF-1) as ET-900 in refractory pediatric epileptic spasms — repurposing a commercial asset into a new rare neurological indication and extending the pediatric neurology pivot begun with LIBERVANT.
ELOXEloxx PharmaceuticalsReleaseEloxx Pharmaceuticals to Present at the 3rd Annual Guggenheim Healthcare Innovation Conference
EIKNEikon TherapeuticsReleaseEikon Therapeutics to Participate in Multiple Investor Conferences in November
DBVTDBV TechnologiesReleaseDBV Technologies to Participate in Upcoming November Investor Conferences
CTMXCytomX TherapeuticsReleaseCytomX Therapeutics to Present at Upcoming November Investor Conferences
CMPXCompass TherapeuticsReleaseCompass Therapeutics to Participate in Upcoming November Investor Events
CMPSCOMPASS PathwaysReleaseNew Joint Survey from Compass Pathways and the Depression and Bipolar Support Alliance Reveals the Lived Burden of Treatment-Resistant Depression on Patients and CaregiversCMPS has cratered -44.6% from the September highs and -27.3% in today's session alone, with no new clinical data or FDA action in this window — the author needs to address whether the thesis is intact or broken, and why the stock is in freefall.
CMMBChemomab TherapeuticsReleaseChemomab Therapeutics and Scipher Medicine Announce SEC Registration Statement on Form S-4 Is EffectiveThe S-4 is effective and the shareholder vote is set for December 4 — the merger clock is now running, and existing holders face a hard deadline on the CVR record-date decision with the stock down another 45% since my last update.company site may be offline after the acquisition
CLYMClimb BioReleaseClimb Bio to Present at Guggenheim 3rd Annual Healthcare Innovation Conference
CLRBCellectar BiosciencesReleaseCellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Tuesday, November 10, 2026 LEARN MORE
CGTXCognition TherapeuticsReleaseCognition Therapeutics to Host Third Quarter 2026 Financial Results and Business Update Call on November 5, 2026
CBIOCrescent BiopharmaReleaseCrescent Biopharma to Present at November Investor Conferences
BCAXBicara TherapeuticsReleaseBicara Therapeutics to Report Third Quarter 2026 Financial Results and Business Updates on November 9, 2026, at 8:30 AM ET
AXSMAxsome TherapeuticsReleaseAxsome Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update → BD update
AXSMAxsome Therapeutics8-KCurrent report: results of operations, other events · EX-99.1 → BD update
AXSMAxsome Therapeutics10-QQuarterly report → BD update
APVOAptevo Therapeutics8-KCurrent report: other events
ANTXAN2 TherapeuticsReleaseAN2 Therapeutics Receives U.S. FDA IND Clearance to Proceed with Planned Phase 2 Global Study of Oral Epetraborole in Polycythemia VeraThe FDA has cleared AN2's IND for epetraborole in polycythemia vera, completing regulatory authorization across all three planned jurisdictions and setting the clock for a 4Q 2026 first patient — the last scheduled milestone before the 2027 data that carry the entire thesis.
AMLXAmylyx PharmaceuticalsReleaseAmylyx Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 5, 2026
ADCTADC TherapeuticsReleaseADC Therapeutics to Announce Third Quarter 2026 Financial Results on November 9, 2026
ACTUActuate TherapeuticsReleaseACTUATE THERAPEUTICS RECEIVES U.S. NOTICE OF ALLOWANCE FOR PATENT COVERING ELRAGLUSIB ORAL TABLETS
ABVXAbivaxReleaseAbivax to Participate in Upcoming Fall Investor Conferences

Sunday, November 11

MESOMesoblastReleaseMesoblast Board Changesvia aggregator→ BD updateTwo directors retire ahead of Mesoblast's November 10 AGM — including Philip Krause, whose son's firm was hired to publish the LVAD BLA. The board changes partially address governance concerns I flagged, but the key question — whether George's nominee Voigtman still stands — remains unanswered.

Friday, October 3026

XNCRXencorSCHEDULE 13G/A13G amendment
XERSXeris BiopharmaSCHEDULE 13G/A13G amendment
VSTMVerastemSCHEDULE 13G/A13G amendment
VORVor BiopharmaReleaseVor Bio Reports Third Quarter 2026 Financial Results and Provides Corporate Update → BD updateSummary on the 10-QBD extracted 1 program update from this document → VOR pipeline
VORVor Biopharma424B5Prospectus supplement (offering)→ BD updateSummary on the 10-Q
VORVor Biopharma10-QQuarterly report → BD updateVor Bio's Q3 print confirms enrollment is locked, the 48-week Chinese gMG data adds an MSE durability layer (42.1%, ~83% of follow-up in remission), and management wasted no time refreshing the ATM with a new $150M facility — exactly the watch item flagged in the August update.
SNDXSyndax PharmaceuticalsReleaseSyndax Announces Participation in November Investor Conferencesvia aggregator
SNDXSyndax PharmaceuticalsReleaseSyndax’s Revuforj® (revumenib) Wins Prestigious 2026 Prix Galien USA Award for Best Product for Rare/Orphan Diseasesvia aggregator
SNDXSyndax PharmaceuticalsRelease10.30.26 Syndax’s Revuforj® (revumenib) Wins Prestigious 2026 Prix Galien USA Award for Best Product for Rare/Orphan Diseases - Revuforj is the first and only menin inhibitor that is approved for adul
SNDXSyndax PharmaceuticalsRelease10.30.26 Syndax Announces Participation in November Investor Conferences NEW YORK, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company
RVMDRevolution MedicinesSCHEDULE 13GPassive >5% holder (13G)
RCKTRocket PharmaceuticalsSCHEDULE 13G/A13G amendment
RAREUltragenyx PharmaceuticalSCHEDULE 13G/A13G amendment
RAPPRapport Therapeutics8-KCurrent report: material agreement, results of operations, debt / obligation
RAPPRapport Therapeutics424B5Prospectus supplement (offering)
RAPPRapport Therapeutics424B5Prospectus supplement (offering)
PRQRProQR Therapeutics6-K/AForeign issuer report (amended)
PALIPalisade BioSCHEDULE 13GPassive >5% holder (13G)
OMEROmeros8-KCurrent report: officer / director change
NRXPNRX PharmaceuticalsReleaseNRx Pharmaceuticals (Nasdaq:NRXP) Receives FDA Approval of Preservative-Free Ketamine Ahead of November 10 FDA Goal Date → BD updateFDA approved KETAFREE (preservative-free ketamine) ahead of the November 10 GDUFA goal date — the exact binary the series has been circling since January. The approval landed; now the question is whether the stock's sharp pre-announcement drop reflects the market selling the news, ATM supply, or something else entirely.
MBRXMoleculin BiotechReleaseMoleculin Completes Dosing Patients in Part A of Pivotal MIRACLE Trial; Comprehensive Data Readout on Track for Q1 2027
MBRXMoleculin Biotech8-KCurrent report: Reg FD disclosure · EX-99.1 EXHIBIT 99.1BD extracted 1 program update from this document → MBRX pipeline
IMNMImmunomeSCHEDULE 13GPassive >5% holder (13G)Summary on the release
IMNMImmunomeReleaseImmunome Announces EMA Validation of Marketing Authorization Application for Varegacestat for the Treatment of Adults with Desmoid Tumorsvia aggregatorThe EMA has validated Immunome's Marketing Authorization Application for varegacestat — the EU dossier is now formally under centralized review, checking off the "EU MAA by end of 2026" catalyst I flagged, and bringing the European orphan-designation question I warned about into live play.BD extracted 1 program update from this document → IMNM pipeline
HRMYHarmony Biosciences8-K/ACurrent report (amended): officer / director change
GUTSFractyl HealthReleaseFractyl Health Strengthens Revita Patent Portfolio as It Advances Toward FDA Submission and Potential Commercialization
EYPTEyePointSCHEDULE 13G/A13G amendment
ENTXEntera BioSCHEDULE 13GPassive >5% holder (13G)
ELDNEledon PharmaceuticalsSCHEDULE 13G/A13G amendment
CMMBChemomab TherapeuticsEFFECTRegistration effectiveSummary on the DEFM14A
CMMBChemomab TherapeuticsDEFM14AMerger proxyThe definitive proxy arrived after the close tonight, setting the shareholder vote for December 4 and locking the conversion ratio at 0.187 SCIP shares per CMMB ADS — the clock is now running on whether holders can salvage the CVRs.
CABACabaletta BioSCHEDULE 13G/A13G amendment
ATHEAlterity TherapeuticsReleaseAlterity Therapeutics Releases Appendix 4C – Q1 FY27 Quarterly Cash Flow Report & Corporate Updatevia aggregator→ BD update
ATHEAlterity Therapeutics6-KForeign issuer report · EX-99.1 EXHIBIT 99.1 → BD updateBD extracted 1 program update from this document → ATHE pipeline
APVOAptevo Therapeutics424B5Prospectus supplement (offering)
AGIOAgios PharmaceuticalsReleaseAgios Announces New PDUFA Goal Date of February 1, 2027, for Mitapivat Sickle Cell Disease sNDA; Company Is Launch-Ready and in Labeling Discussions with FDA → BD updateThe FDA's REMS information request just triggered a three-month review extension — the exact scenario the prior writeup assigned a ~10% probability — and the stock shed 17.9% in a single session, landing squarely in the $27–29 range the writeup mapped to that outcome.
ACTUActuate TherapeuticsSCHEDULE 13GPassive >5% holder (13G)Summary on the 8-K
ACTUActuate Therapeutics8-KCurrent report: listing noticeActuate just received its second Nasdaq deficiency notice — this time for the $1.00 minimum bid price — adding a new April 2027 compliance deadline on top of the January 2027 MVLS clock, while the stock sits at $0.34 after a -16% week following the distressed offering close.
ABOSAcumen PharmaceuticalsReleaseAcumen Pharmaceuticals Announces Topline Results from Phase 2 ALTITUDE-AD Clinical Trial of Sabirnetug (ACU193) for the Treatment of Early Alzheimer’s Disease; Trial Did Not Meet Primary Endpoint → BD updateSummary on the 8-K
ABOSAcumen Pharmaceuticals8-KCurrent report: Reg FD disclosure, other events · EX-99.1 → BD updateALTITUDE-AD failed at both doses on iADRS and CDR-SB, Acumen is ceasing sabirnetug development and exploring strategic options — the stock cratered ~91% today, and the thesis I've tracked since February is over.BD extracted 1 program update from this document → ABOS pipeline

Thursday, October 2971

XFORX4 PharmaceuticalsReleaseX4 Pharmaceuticals Highlights Clinical Progress and Market Opportunity for Mavorixafor in Primary Chronic Neutropenia During Virtual Investor Day
XFORX4 Pharmaceuticals8-KCurrent report: other events · EX-99.1
XENEXenon PharmaceuticalsReleaseXenon Announces Positive Phase 1 and New Preclinical Data at IASP 2026 Supporting Advancement of XEN1701 and XEN1120 to Phase 2 Proof-of-Concept Studies in Acute Pain → BD updateXEN1701's Phase 1 data show >75% Nav1.7 receptor occupancy with no cardiovascular signal — the exact selectivity benchmark Big Pharma couldn't crack — while the stock sits -34.5% from its September high on psychiatry fears, making the pain pipeline's first real validation a potentially underappreciated signal.BD extracted 2 program updates from this document → XENE pipeline
VNDAVanda Pharmaceuticals10-QQuarterly report
VKTXViking Therapeutics10-QQuarterly report
TLXTelix Pharmaceuticals6-KForeign issuer report · EX-99.1
TECXTectonic TherapeuticSCHEDULE 13G/A13G amendment
STOKStoke TherapeuticsReleaseStoke Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business Updates → BD updateSummary on the 8-K
STOKStoke Therapeutics8-KCurrent report: results of operations · EX-99.1 → BD updateSTOK's Q3 print lands after the close: $358.8M cash, burn tracking ~$61M/quarter, ~5.9M new shares issued since year-end, and zero EMPEROR discontinuations through Week 52 — the scorecard the prior writeup told readers to watch for.
SCYXScynexisReleaseSCYNEXIS to Participate in the 3rd Annual Guggenheim Healthcare Innovation Conference
SABSSAB BiotherapeuticsReleaseSAB BIO to Host Third Quarter 2026 Financial Results Conference Call and Webcast on November 5, 2026, 08:30 AM ET
RVPHReviva PharmaceuticalsPRE 14APRE 14A
RAPPRapport Therapeutics305B2305B2
QNRXQuoin PharmaceuticalsReleaseQuoin Pharmaceuticals to Announce Corporate Update and Third Quarter 2026 Financial Results on Thursday, November 5, 2026
PYPDPolyPidReleasePolyPid to Report Third Quarter 2026 Financial Results and Operational Highlights on November 11, 2026
PCSAProcessa PharmaceuticalsReleaseProcessa Pharmaceuticals Announces Corporate and Pipeline Progress Following Acquisition of Vidya Therapeutics → BD updateSummary on the 8-K
PCSAProcessa Pharmaceuticals8-KCurrent report: other events · EX-99.1 EXHIBIT 99.1 → BD updateThe FDA just cleared the IND for VT-7208's Phase 2 CSU trial — the first hard regulatory milestone since the Vidya reverse merger — and Sheila Gujrathi steps up to Executive Chair while a new oral FcRn antagonist collaboration quietly expands the pipeline.
OCSOculis HoldingReleaseOculis to Feature Privosegtor’s Neuroprotective Potential and Ongoing PIONEER Program at APOIS Congress and CNS SummitBD extracted 1 program update from this document → OCS pipeline
OCGNOcugenReleaseOcugen to Participate in Upcoming November Investor and Industry Conferences
NTLAIntellia TherapeuticsReleaseIntellia Therapeutics Announces Upcoming Lonvoguran Ziclumeran (Lonvo-z) Investor Event and Seven Presentations at ACAAI 2026
NRXPNRX PharmaceuticalsReleaseNRx Pharmaceuticals (Nasdaq: NRXP) to Host Conference Call on October 30, 2026 to Discuss Regulatory Milestone for Preservative-Free KetamineNRx's "About" boilerplate now reads "has been awarded an Abbreviated New Drug Approval (ANDA) for Preservative-Free Ketamine" — language that wasn't there before — with a pre-market press release and 8:30am call scheduled for tomorrow. The November 10 GDUFA binary appears to have resolved early.
NRSNNeuroSense TherapeuticsReleaseNeuroSense to Present Integrated Clinical and Biomarker Evidence Shaping PrimeC's Phase 3 Development at NEALS 2026BD extracted 1 program update from this document → NRSN pipeline
MLYSMineralys Therapeutics8-KCurrent report: material agreement, agreement terminatedMineralys just closed the final chapter on its Tanabe IP deal — the License Agreement is terminated and the lorundrostat patents are now legally Mineralys's own, removing the co-ownership risk that was one of the key open questions in the writeup. With the PDUFA 54 days out, owning the keys to the kingdom matters.
MESOMesoblastReleaseActivity Report for Quarter Ended September 30, 2026 (Appendix 4C)via aggregator→ BD updateSummary on the 6-K
MESOMesoblast6-KForeign issuer report · EX-99.1 → BD updateMesoblast's Q1 FY2027 Appendix 4C arrived this morning with three simultaneous thesis-movers: the FDA greenlighted the LVAD BLA filing, the $57M receivable overhang was resolved in cash, and operating burn collapsed to $2.1M — all while the stock surged 17% pre-open.BD extracted 1 program update from this document → MESO pipeline
LXEOLexeo TherapeuticsS-3Shelf registrationLexeo filed a $300M shelf registration today — resetting and dramatically expanding its financing capacity at $3.06/share, 62% below its last formal offering price. For a stock the prior updates have flagged twice for quiet ATM sales at depressed prices, this is the third and loudest signal yet that the "cash runway into 2028" story has an asterisk that keeps getting bigger.
LCTXLineage Cell TherapeuticsReleaseLineage Provides Update on ReSonance® Program for Hearing Loss
KZIAKazia TherapeuticsReleaseKazia Therapeutics to Participate in Fireside Chat at Guggenheim 3rd Annual Healthcare Innovation Conference
KYMRKymera TherapeuticsReleaseKT-579 (IRF5) Phase 1 healthy volunteer data demonstrated deep, sustained IRF5 degradation, robust modulation of disease-relevant biomarkers and a favorable safety profile KT-579 LUMORA Phase 1b trial → BD updateSummary on the 8-K
KYMRKymera Therapeutics8-KCurrent report: results of operations · EX-99.1 → BD updateThe "high-risk moonshot" just earned its stripes: KT-579's Phase 1 data shows ≥90% IRF5 degradation in blood and skin, deep cytokine suppression across three inflammatory pathways, and clean safety — while BROADEN2's last patient has completed their final visit, setting up a year-end 2026 binary for KT-621.BD extracted 2 program updates from this document → KYMR pipeline
KYMRKymera Therapeutics10-QQuarterly report → BD updateSummary on the 8-K
KPRXKiora PharmaceuticalsReleaseKiora Pharmaceuticals In-Licenses Late-Stage, Oral Neuroprotective Calpain Inhibitor for Central Retinal Artery Occlusion (CRAO) with Planned Expansion into NAION; Asset Completed Phase 3 Clinical Tri → BD updateSummary on the 8-K
KPRXKiora Pharmaceuticals8-KCurrent report: material agreement, Reg FD disclosure · EX-99.1 → BD updateKiora dropped a bombshell this morning: it in-licensed KIO-401, an oral calpain inhibitor with completed Japanese Phase 3 data, while simultaneously killing KIO-104 — the stock's nearest-term catalyst. The market took the news badly, sending KPRX down ~25% on the day.BD extracted 5 program updates from this document → KPRX pipeline
IRDOpus GeneticsReleaseOpus Genetics Appoints Dr. Andrew Murphy as Chief Scientific Officer and Jamie Lynne Hart as Executive Director, Executive Operations → BD update
INSMInsmedReleaseInsmed Reports Third-Quarter 2026 Financial Results and Provides Business Update → BD update
INSMInsmed8-KCurrent report: results of operations · EX-99.1 EXHIBIT 99.1 → BD update
INSMInsmed10-QQuarterly report → BD update
INMBInmune BioReleaseINmune Bio Inc. to Report Third Quarter 2026 Financial Results and Provide Corporate Update on Thurs...
INMBInmune Bio8-KCurrent report: material agreement, unregistered sale of equity, Reg FD disclosure · EX-99.1 PRESS RELEASE DATED OCTOBER 28, 2026
INMBInmune Bio424B5Prospectus supplement (offering)
IMUXImmunicReleaseImmunic to Host Virtual Progressive Multiple Sclerosis R&D Day on November 5, 2026
IMRXImmuneeringReleaseImmuneering Reports Third Quarter 2026 Financial Results and Provides Business Updates → BD updateSummary on the 8-KBD extracted 1 program update from this document → IMRX pipeline
IMRXImmuneering8-KCurrent report: results of operations · EX-99.1 → BD updateImmuneering's Q3 earnings delivered a trio of thesis-movers: the Phase 2 follow-up is being extended because patients are *outliving projections*, MAPKeeper 301 enrollment is ahead of schedule with the target expanding to ~570 patients, and cash runway guidance has been formally trimmed from 2029 to Q4 2028 — the fortress balance sheet thesis just got its first official crack.BD extracted 1 program update from this document → IMRX pipeline
IMRXImmuneering10-QQuarterly report → BD updateSummary on the 8-K
IMCRImmunocoreReleaseImmunocore will present Phase 1 data for brenetafusp plus KIMMTRAK® (tebentafusp-tebn) in metastatic uveal melanoma, during a late-breaking oral session at the 2026 SITC meetingPhase 1 data for brenetafusp + KIMMTRAK in metastatic uveal melanoma — the first two-T-cell-engager combination ever tested in a solid tumor — drops at SITC on November 6–7, a catalyst not on the published calendar and one that could tell us something real about whether layering PRAME on top of gp100 adds signal.
GUTSFractyl HealthReleaseFractyl Health Announces Market Research Highlighting Substantial Patient Interest in a One-Time Procedural Approach to Post-GLP-1 Weight Maintenance
GOSSGossamer BioSCHEDULE 13D/A13D amendment
FBIOFortress BiotechSCHEDULE 13G/A13G amendment
EXELExelixisReleaseExelixis Announces Third Quarter 2026 Financial Results and Provides Corporate Update → BD updateSummary on the 8-KBD extracted 1 program update from this document → EXEL pipeline
EXELExelixis8-KCurrent report: results of operations · EX-99.1 → BD updateQ3 2026 earnings beat with CABOMETYX still printing cash, but STELLAR-304 topline has slipped to Q1 2027 — the RCC displacement leg of the Zanza Switch thesis now won't resolve until next year, alongside the March 3 PDUFA.
EXELExelixis10-QQuarterly report → BD updateSummary on the 8-K
ETONEton PharmaceuticalsReleaseEton Pharmaceuticals to Report Third Quarter 2026 Financial Results on Thursday, November 5, 2026
ENTAEnanta Pharmaceuticals8-KCurrent report: other events → BD updateThe UPC ruled Enanta's European Paxlovid patent (EP 4 051 265) invalid after the September 29 hearing — both Pfizer litigation lottery tickets are now torn up, and the last non-RSV, non-immunology optionality in the thesis is gone.
ELTXElicio TherapeuticsReleaseElicio Therapeutics to Present Phase 2 AMPLIFY-7P Results at the SITC 2026 Annual MeetingBD extracted 1 program update from this document → ELTX pipeline
ELOXEloxx PharmaceuticalsReleaseEloxx Pharmaceuticals Announces FDA Clearance of Investigational New Drug Application for Exaluren in Nonsense-Mutation ADPKD
DTILPrecision BiosciencesReleasePrecision BioSciences to Report Third Quarter 2026 Financial Results on November 3, 2026
DRTSAlpha Tau Medical6-KForeign issuer report · EX-99.1 PRESS RELEASE DATED OCTOBER 29, 2026
DFTXDefinium TherapeuticsReleaseDefinium Therapeutics to Report Third Quarter 2026 Financial Results on November 9, 2026
CTMXCytomX TherapeuticsReleaseCytomX Therapeutics to Report Third Quarter 2026 Financial Results on November 5, 2026
CRVSCorvus PharmaceuticalsReleaseCorvus Pharmaceuticals to Provide Business Update and Third Quarter 2026 Financial Results on November 5, 2026
CRVOCervoMedReleaseCervoMed Announces Publication of Two Peer-Reviewed Research Articles Supporting Neflamapimod as a Potential Treatment for Dementia with Lewy Bodies (DLB)→ BD updateSummary on the 8-K
CRVOCervoMed8-KCurrent report: Reg FD disclosure, other events · EX-99.1 EXHIBIT 99.1 → BD updateCervoMed's full Phase 2b RewinD-LB placebo-controlled data hits peer review in *Alzheimer's Research & Therapy* today — the Bad Batch thesis now has a journal citation — but the stock has cratered 30% since the October 12 nfvPPA readout, and none of today's publications bring a partner any closer.BD extracted 1 program update from this document → CRVO pipeline
CMMBChemomab TherapeuticsS-4/AS-4/A
CHRSCoherus Oncology8-KCurrent report: Reg FD disclosure, other events · EX-99.1
CCCCC4 TherapeuticsReleaseC4 Therapeutics Unveils Expansion of Discovery Platform Capabilities Utilizing Target-Centric Approach to Accelerate the Identification of Novel Molecular Glue Degraders
CADLCandel TherapeuticsReleaseCandel Therapeutics Announces Late-Breaking Abstract Accepted for Poster Presentation at the SITC 2026 Annual Meeting, Featuring Aglatimagene Besadenovec Data in Localized Prostate CancerBD extracted 1 program update from this document → CADL pipeline
BCYCBicycle TherapeuticsReleaseBicycle Therapeutics Reports Recent Business Progress and Third Quarter 2026 Financial Results → BD update
BCYCBicycle Therapeutics8-KCurrent report: results of operations · EX-99.1 EXHIBIT 99.1 → BD updateBD extracted 1 program update from this document → BCYC pipeline
BCYCBicycle Therapeutics10-QQuarterly report → BD update
BCRXBiocryst PharmaceuticalsReleaseBioCryst to Present New Data for ORLADEYO® (berotralstat) and Navenibart at the 2026 American College of Allergy, Asthma & Immunology Annual Scientific Meeting
ALTAltimmune8-KCurrent report: debt / obligation
ALLOAllogene TherapeuticsReleaseAllogene Therapeutics Announces November Investor Events Highlighting Q3 Results and Initial ALLO-329 Autoimmune Clinical Data
AKBAAkebia TherapeuticsReleaseAkebia Therapeutics to Report Third Quarter 2026 Financial Results and Discuss Recent Business Highlights
ADCTADC TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
ADCTADC TherapeuticsReleaseADC Therapeutics Announces ZYNLONTA® Updates in JapanBD extracted 1 program update from this document → ADCT pipeline
ACRVAcrivon TherapeuticsReleaseAcrivon Announces Late-Breaking Oral Plenary Presentation of Early Phase 1/2 Clinical Results in AP3-Predicted Tumors for its First-in-Class WEE1/PKMYT1 Inhibitor ACR-2316 at the 38th EORTC-NCI-AACR S → BD updateACR-2316 just produced a confirmed complete response in a heavily pretreated squamous NSCLC patient — a tumor type no WEE1 inhibitor has ever cracked — and lands a late-breaking oral plenary slot at EORTC-NCI-AACR on November 20, with PDAC expansion now added to the dose expansion program.BD extracted 2 program updates from this document → ACRV pipeline

Wednesday, October 2854

VNDAVanda PharmaceuticalsReleaseVanda Pharmaceuticals Reports Third Quarter 2026 Financial Results → BD updateSummary on the 8-K
VNDAVanda Pharmaceuticals8-KCurrent report: results of operations · EX-99.1 → BD updateQ3 2026 earnings landed after the close: revenues surged 24% to $69.8M, operating expenses fell 18% from Q2, and management raised full-year guidance to >$240M — but cash dropped to $140.5M and the $200M dilution shelf is still loaded heading into a gauntlet of Q4 catalysts.BD extracted 1 program update from this document → VNDA pipeline
VKTXViking TherapeuticsReleaseViking Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update → BD updateSummary on the 8-K
VKTXViking Therapeutics8-KCurrent report: results of operations · EX-99.1 → BD updateQ3 confirms $960M cash (better than my post-raise estimate), four Phase 3 trials now running, and language about building "commercial infrastructure" that nudges the go-it-alone sell trigger — but the Fast Follower Factory is executing on every clock it set.BD extracted 2 program updates from this document → VKTX pipeline
VIRVir BiotechnologyReleaseVir Biotechnology Announces Appointment of Suzanne Topalian to its Board of Directors
VIRVir Biotechnology8-KCurrent report: officer / director change
SLSSELLAS Life Sciences GroupReleaseSELLAS Life Sciences Reaches 80th Event in Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia → BD updateThe 80th REGAL event has arrived — the database lock, unblinding, and topline Phase 3 GPS readout are now queued for this quarter. The coin is finally in the air, and the stock is down -14.7% on the news.BD extracted 1 program update from this document → SLS pipeline
RLAYRelay TherapeuticsReleaseRelay Therapeutics to Announce Third Quarter 2026 Financial Results and Corporate Highlights on November 4, 2026
REPLReplimune GroupReleaseReplimune Reports Fiscal Second Quarter 2027 Financial Results and Provides Corporate Update → BD updateSummary on the 8-K
REPLReplimune Group8-KCurrent report: results of operations · EX-99.1 EXHIBIT 99.1 → BD updateTUDRIQEV is officially in patients — 15+ institutions have written prescriptions just weeks after the October 6 launch, payer coverage spans a majority of lives, and Replimune's cash runway is confirmed at $307.8M with no going-concern risk. The commercial war has started, and today's +23% move says the market believes it.
REPLReplimune Group10-QQuarterly report → BD updateSummary on the 8-K
RAPPRapport TherapeuticsFWPFree writing prospectus (offering terms)
RAPPRapport TherapeuticsFWPFree writing prospectus (offering terms)
RAPPRapport TherapeuticsFWPFree writing prospectus (offering terms)
RAPPRapport TherapeuticsFWPFree writing prospectus (offering terms)
QUREuniQureReleaseuniQure to Announce Third Quarter 2026 Financial Resultsvia aggregator
QTTBQ32 BioSCHEDULE 13GPassive >5% holder (13G)
QNRXQuoin PharmaceuticalsS-3Shelf registration
PYPDPolyPidReleasePolyPid Unveils Expanded Pipeline Strategy, Introducing PD01B, a New Kynatrix™ Based Product Candidate for the Treatment of Diabetic Foot InfectionsSummary on the 6-KBD extracted 1 program update from this document → PYPD pipeline
PYPDPolyPid6-KForeign issuer report · EX-99.1 PRESS RELEASE ISSUED BY POLYPID LTD. ON OCTOBER 28, 2026, TITLED "POLYPID UNVEILThirty-one days before the November 28 PDUFA, PolyPid named PD01B — a Kynatrix-based local antibiotic for diabetic foot infections — and updated its catalyst table with the first hard NTAP timing (August 2027) and a new label-expansion FDA dialogue starting Q4 2026. None of this moves the manufacturing-inspection needle, but the platform is now more than a one-product story, and the NTAP date update corrects one of the bear-case assumptions I laid out.
PRQRProQR TherapeuticsReleaseProQR to Present Clinical and Preclinical Progress from AX-0810 and AX-0811 at Upcoming Conferences
PRQRProQR Therapeutics6-KForeign issuer report · EX-99.1 EXHIBIT 99.1BD extracted 1 program update from this document → PRQR pipeline
PALIPalisade BioReleasePalisade Bio Announces First Patient Dosed in Global Phase 2b ASCENTRA-UC Study Evaluating Once-Daily Oral PALI-2108 for the Treatment of Ulcerative ColitisASCENTRA-UC has dosed its first patient — the trial I called "the entire valuation" is now enrolling — while ACG data partially addresses the β-glucuronidase variability risk and the dose discontinuity that were the two biggest structural questions I left open.
NBPNovaBridge BiosciencesReleaseNovaBridge Biosciences Appoints Chuck Silberstein as Chief Financial OfficerSummary on the 6-K
NBPNovaBridge Biosciences6-KForeign issuer report · EX-99.1NovaBridge swaps its China-heritage CFO for a Wall Street/BD veteran — the second piece of a deliberate operating-layer rebuild, timed five days before the November 2 registrational-strategy webcast where the Phase 3 funding question is finally supposed to get an answer.
MLYSMineralys TherapeuticsReleaseMineralys Therapeutics to Announce Third Quarter 2026 Financial Results and Host Conference Call on Wednesday, November 4, 2026
MLYSMineralys TherapeuticsReleaseMineralys Therapeutics Announces Publication of Phase 2 Explore-CKD Trial Results for Lorundrostat in Kidney InternationalBD extracted 1 program update from this document → MLYS pipeline
MISTMilestone Pharmaceuticals8-KCurrent report: listing notice → BD updateNasdaq fired a formal sub-$1.00 minimum bid deficiency notice on October 23, giving MIST 180 days (until April 21, 2027) to get back above $1.00 — or face delisting. The slow execution climb just acquired a hard deadline and a new structural bear argument.
LGVNLongeveronReleaseLongeveron Announces Engagement of Lucid Capital Marketsvia aggregatorLongeveron has named Lucid Capital Markets as its strategic advisor — the business-combination process the author flagged in September is now formally engaged, with a specific bank and an explicit M&A mandate, as the cash clock ticks into Q4.
LENZLENZ TherapeuticsReleaseLENZ Therapeutics Reports Third Quarter 2026 Financial Results, Announces Strategic Consumer Marketing Focused Reorganization and CEO Succession → BD updateSummary on the 8-K
LENZLENZ Therapeutics8-KCurrent report: results of operations, exit / restructuring costs, officer / director change · EX-99.1 → BD updateQ3 delivered the 50% volume jump I said was the test — 38,000+ packs on $2.6M in product sales — but LENZ simultaneously announced a 75% headcount cut, a >50% reduction in 2027 opex (targeting $70–75M), and CEO Schimmelpennink's departure, releasing everything after the close in a bundle that requires careful unpacking.
KYMRKymera TherapeuticsReleaseWATERTOWN, Mass., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicinesThe KT-579 Phase 1 healthy volunteer data — the IRF5 readout I flagged as a "near-term, dated event" in the August update — drops tomorrow morning (October 29) alongside Q3 earnings. Here's what to watch for and why it matters beyond the BROADEN2 binary.BD extracted 1 program update from this document → KYMR pipeline
KTTAPasithea TherapeuticsReleasePasithea Therapeutics to Host Virtual KOL Event on NF1 Treatment November 4, 2026
JBIOJade BiosciencesSCHEDULE 13GPassive >5% holder (13G)
IXHLIncannex HealthcareDEFA14AProxy soliciting material
IXHLIncannex HealthcareDEF 14AProxy statement
IXHLIncannex HealthcareARSAnnual report to shareholders
INMBInmune BioReleaseINmune Bio, Inc. Announces Pricing of $4.50 Million Registered Direct Offering and Concurrent Privat...→ BD updateThe dilutive raise the thesis predicted has arrived — but at $4.5M gross, it buys weeks of runway, not a clean balance sheet, and the going-concern flag is almost certain to survive intact.
INBXInhibrx BiosciencesSCHEDULE 13G/A13G amendment
GOSSGossamer Bio8-KCurrent report: shareholder vote
GLUEMonte Rosa TherapeuticsReleaseMonte Rosa Therapeutics Announces Milestone Achievement Associated with Second Phase 2 Clinical Study Initiation for VAV1-directed Molecular Glue Degrader MRT-6160 (DDY391)→ BD updateNovartis just activated its second Phase 2 for MRT-6160 (DDY391) — this time in psoriatic arthritis — and cut another check: $37.5M, non-dilutive, with more activations and milestones queued behind it.
GERNGeronReleaseGeron Corporation Provides Update on Phase 3 IMpactMF Clinical Trial of Imetelstat in Relapsed/Refractory Myelofibrosis → BD update
GERNGeron8-KCurrent report: other events · EX-99.1 → BD updateBD extracted 2 program updates from this document → GERN pipeline
GANXGain Therapeutics8-KCurrent report: officer / director change
ENTAEnanta PharmaceuticalsReleaseEnanta Pharmaceuticals Announces Planned Retirement of Longstanding Chief Executive Officer Jay R. Luly, Ph.D. After 23 Years of Company Leadership → BD updateSummary on the 8-K
ENTAEnanta Pharmaceuticals8-KCurrent report: officer / director change, Reg FD disclosure · EX-99.1 → BD updateJay Luly — the founder-era CEO who built Enanta's chemistry platform over 23 years — is retiring by February 1, 2027, right as RESOLVE heads into enrollment and EDP-978 Phase 1 nears readout; the stock dropped ~5% on the news and the successor search introduces real strategic uncertainty at the worst possible moment.
DBVTDBV TechnologiesReleaseDBV Technologies Reports Third Quarter 2026 Financial Results and Business Update → BD updateSummary on the 8-K
DBVTDBV Technologies8-KCurrent report: results of operations · EX-99.1 → BD updateDBV's Q3 10-Q drops a formal going-concern flag while the Fareva Amboise warning letter remains unresolved — but the company has now embedded a PAI target date in the BLA and pushed the toddler program to 2027, redefining the timeline and capital risk profile ahead of the filing-acceptance binary.
DBVTDBV Technologies10-QQuarterly report → BD updateSummary on the 8-K
CTNMContineum TherapeuticsSCHEDULE 13G/A13G amendment
CTNMContineum TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
CTMXCytomX TherapeuticsSCHEDULE 13G/A13G amendment
COYACoya TherapeuticsReleaseCoya Therapeutics to Present Neurofilament Light Chain (NfL) Biomarker Stratification Methodology in the ALSTARS Trial to Minimize the Impact of Heterogeneity in ALS Clinical Trials at the 2026 Annual
CMPSCOMPASS PathwaysSCHEDULE 13GPassive >5% holder (13G)
CMPSCOMPASS PathwaysReleaseCompass Pathways to Highlight Scientific Research and TRD Disease State Education Efforts at the 2026 Neuroscience Education Institute Fall Congress
CLYMClimb BioSCHEDULE 13GPassive >5% holder (13G)
CHRSCoherus OncologyReleaseCoherus Oncology Announces Compelling Tagmokitug Interim Clinical Data in Esophageal Cancer and Path to Advance Development → BD updateBD extracted 1 program update from this document → CHRS pipeline
BCTXBriaCell Therapeutics10-KAnnual report → BD updateBriaCell's FY2026 10-K confirms the Phase 3 Bria-ABC interim is still pending with no fresh 1H 2026 window, ~$20.5M in liquid assets against a ~$28.7M annual burn — roughly 8–9 months of runway from July 31 — while commercial prep signals (CRA engagement, MSK site addition, FUJIFILM manufacturing scale-up) suggest management is building for approval even as the financing clock tightens.BD extracted 1 program update from this document → BCTX pipeline
ANNXAnnexonReleaseAnnexon to Host Virtual Investor Event on November 3, 2026: Vonaprument for the Treatment of Geographic Atrophy - Highlighting Key Aspects of Phase 3 ARCHER II Trial
ADMAAdma BiologicsReleaseADMA Biologics to Report Third Quarter 2026 Financial Results on November 4, 2026
ADAGAdageneReleaseAdagene Announces Dosing of First Patient in Phase 1 Study of Muzastotug in Combination with Incyte’s INCA33890 in Patients with Microsatellite Stable Colorectal Cancer
ACTUActuate Therapeutics8-KCurrent report: material agreement, other events · EX-99.1 PRESS RELEASE DATED OCTOBER 27, 2026The offering closed October 28 at $0.355/share — $9.96M net, the smallest version of a deal that started at $41M — but the prospectus now carries the first explicit 12-month runway claim. The dilution trap executed; the going-concern cliff just moved.
ACTUActuate Therapeutics424B5Prospectus supplement (offering)Summary on the 8-K
ACETAdicet BioSCHEDULE 13G/A13G amendment
ABOSAcumen PharmaceuticalsEFFECTRegistration effective

Tuesday, October 2746

ZYMEZymeworksReleaseFaeth Appoints Adam Schayowitz, Ph.D., MBA, Head of Research and Development at Zymeworks, to Board of Directorsvia aggregator
ZURAZura BioS-3Shelf registrationSummary on the 8-K
ZURAZura BioReleaseZura Bio Reports Third Quarter 2026 Financial Results and Recent Corporate UpdatesSummary on the 8-K
ZURAZura Bio8-KCurrent report: results of operations, Reg FD disclosure · EX-99.1With TibuSHIELD data now formally due "later this quarter," Zura refreshed its balance sheet picture ($187.7M cash, $59.3M nine-month burn) and quietly filed a new $700M shelf after the close — setting up the ATM for post-data use and reminding the market the dilution toolkit is loaded.
ZURAZura Bio10-QQuarterly reportSummary on the 8-K
ZNTLZentalis PharmaceuticalsSCHEDULE 13G/A13G amendment
ZBIOZenas BioPharmaSCHEDULE 13GPassive >5% holder (13G)
XNCRXencorSCHEDULE 13G/A13G amendment
WVEWave Life SciencesSCHEDULE 13G/A13G amendment → BD updateSummary on the 8-K
WVEWave Life SciencesSCHEDULE 13GPassive >5% holder (13G)→ BD updateSummary on the 8-K
WVEWave Life SciencesReleaseWave Life Sciences Reports Third Quarter 2026 Financial Results and Provides Business Update → BD updateSummary on the 8-K
WVEWave Life Sciences8-KCurrent report: results of operations · EX-99.1 → BD updateWave's Q3 print confirmed the fortress balance sheet is holding ($431M, runway into Q3 2028), but the headline that matters most is buried: CEO Bolno's 2.9M-share sell plan was terminated on July 30 with zero shares sold — the bearish signal I flagged in July just evaporated, while the combination trial with tirzepatide and the Q4 data calendar keep the catalyst chain compounding.
WVEWave Life Sciences10-QQuarterly report → BD updateSummary on the 8-K
VYGRVoyager TherapeuticsReleaseVoyager’s Tau-Targeted Gene Therapy VY1706 and Anti-Tau Antibody VY7523 for Alzheimer’s Disease to Be Featured in Poster Presentations at CTAD 2026
VTVTvTv TherapeuticsReleasevTv Therapeutics Announces First Participant Randomized in Phase 2a Pilot Study Evaluating Cadisegliatin in Individuals with Type 1 Diabetes (T1D) Using Hybrid Closed-Loop (HCL) Insulin Delivery SysteThe Hybrid CATT1 clock just started — vTv randomized its first patient into the Phase 2a study of cadisegliatin in closed-loop pump users, tackling the payer objection I flagged as the drug's biggest commercial hurdle. Here's what the trial design tells us, and what it doesn't.
VNDAVanda PharmaceuticalsSCHEDULE 13GPassive >5% holder (13G)→ BD updateSummary on the release
VNDAVanda PharmaceuticalsReleaseVanda Pharmaceuticals Announces Positive Results from Study 3601 of NEREUS™ (tradipitant) for Prevention of GLP-1-Induced Vomiting → BD updateThe GLP-1 sidecar lottery ticket just printed a winning number: Study 3601 hit its primary endpoint (43.0% vs. 58.5% vomiting, p=0.006) and delivered an 81% relative reduction in extreme vomiting (p=0.0003) — the strongest signal in Vanda's pipeline history, and the one catalyst the entire bull case was waiting for.
VIRVir BiotechnologySCHEDULE 13G/A13G amendment
TYRATyra BiosciencesSCHEDULE 13G/A13G amendment
TGTXTg TherapeuticsSCHEDULE 13G/A13G amendment
TENXTenax TherapeuticsSCHEDULE 13G/A13G amendment
SLSSELLAS Life Sciences GroupSCHEDULE 13G/A13G amendment
RVMDRevolution MedicinesReleaseRevolution Medicines to Participate in November 2026 Investor Conferences
RAREUltragenyx PharmaceuticalReleaseUltragenyx to Host Conference Call for Third Quarter 2026 Financial Results and Corporate Update
RAPPRapport Therapeutics424B5Prospectus supplement (offering)
RAPPRapport Therapeutics424B5Prospectus supplement (offering)
PTGXProtagonist TherapeuticsSCHEDULE 13G/A13G amendment
PTGXProtagonist TherapeuticsReleaseProtagonist Therapeutics to Participate in Four Investment Bank Conferences in November 2026via aggregator
ONCYOncolytics BiotechReleaseOncolytics Biotech® Reports Strong Durability and Survival Data in Anal Cancer, Positioning Pelareorep as Potential Backbone Immunotherapy Across HPV-Driven Cancers → BD updateSummary on the 8-K
ONCYOncolytics Biotech8-KCurrent report: other events · EX-99.1 → BD updateGOBLET Cohort 4's long-awaited final durability data just landed — ~15-month median DOR, all responders alive past 12 months — but the market isn't buying it, and a buried footnote reveals the efficacy figures come from "internal calculations for this draft," not a peer-reviewed dataset.
NKTRNektar TherapeuticsReleaseNektar Therapeutics to Announce Financial Results for the Third Quarter on Thursday, November 12, 2026, After Close of U.S.-Based Financial Markets
NGNENeurogeneReleaseNeurogene Presents New Data at ESGCT Congress that Reinforce Key Differentiators of NGN-401 Gene Therapy for Rett SyndromeBD extracted 1 program update from this document → NGNE pipeline
MGTXMeiraGTxReleaseMeiraGTx Announces Four Posters at the European Society of Gene and Cell Therapy (ESGCT) 2026 Annual Congress and the Network of Excellence for ALS (NEALS) Annual Meeting
LENZLENZ TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
LEGNLegend BiotechReleaseLegend Biotech to Host Investor Conference Call on Third Quarter 2026 Results
KYMRKymera TherapeuticsSCHEDULE 13G/A13G amendment
KURAKura OncologySCHEDULE 13G/A13G amendment
KROSKeros TherapeuticsSCHEDULE 13G/A13G amendment
JBIOJade BiosciencesSCHEDULE 13GPassive >5% holder (13G)
IRDOpus GeneticsSCHEDULE 13GPassive >5% holder (13G)
IMMXImmix BiopharmaSCHEDULE 13GPassive >5% holder (13G)
HROWHarrowSCHEDULE 13G/A13G amendment
HRMYHarmony BiosciencesSCHEDULE 13G/A13G amendment
HELPHelus PharmaReleaseHelus Pharma Announces Co-Founders’ Transition from Executive Leadership as Company Advances Toward Next Stage of Development → BD updateSummary on the 6-K
HELPHelus Pharma6-KForeign issuer report · EX-99.1 EXHIBIT 99.1 → BD updateBoth Helus co-founders just stepped back from executive roles two months before the APPROACH Phase 3 readout — the move can be read as a clean CEO handoff to Halstead, or as founders quietly stepping aside ahead of a binary event.
EYPTEyePointSCHEDULE 13GPassive >5% holder (13G)
ENTXEntera BioReleaseEntera Appoints Global Research and Development Leader Dr. Juan Camilo Arjona Ferreira to Its Board of Directors
ENTXEntera Bio8-KCurrent report: officer / director change, Reg FD disclosure · EX-99.1 EXHIBIT 99.1
ENTAEnanta PharmaceuticalsSCHEDULE 13GPassive >5% holder (13G)
ELVNEnliven TherapeuticsSCHEDULE 13G/A13G amendment
DTILPrecision BiosciencesSCHEDULE 13GPassive >5% holder (13G)
DBVTDBV TechnologiesReleaseDBV Technologies to Report Third Quarter 2026 Financial Results and Business Update on October 28, 2026
COGTCogent BiosciencesReleaseCogent Biosciences to Participate in the Guggenheim Healthcare Innovation Conference
CMPSCOMPASS PathwaysReleaseCompass Pathways to Announce Third Quarter 2026 Financial Results on November 3, 2026
CLYMClimb BioSCHEDULE 13GPassive >5% holder (13G)
CLRBCellectar BiosciencesReleaseCellectar Biosciences Reports Case Study Highlighting Complete Response Lasting More Than Eight Years in Heavily Pretreated DLBCL Patient Treated with Iopofosine I 131 LEARN MORE
CGEMCullinan TherapeuticsReleaseCullinan Therapeutics Advances Velinotamig into Global Clinical Development for Autoimmune Cytopenias Following IND Clearance by the U.S. FDAVelinotamig's FDA and Australian TGA IND clearances arrived roughly a quarter ahead of the Q1 2027 calendar I'd been tracking — the global ITP/wAIHA basket trial is now enrolling, with the ACR November 8 data readout 12 days away as the next live catalyst.
CBIOCrescent BiopharmaSCHEDULE 13GPassive >5% holder (13G)
CADLCandel TherapeuticsReleaseCandel Therapeutics to Present at November Investor Conferences
CABACabaletta BioSCHEDULE 13G/A13G amendment
BEAMBeam TherapeuticsReleaseBeam Therapeutics Reports Initial Clinical Data from Phase 1/2 Trial of BEAM-301, Demonstrating Proof of Concept for Genetic Correction in Glycogen Storage Disease Type Ia (GSDIa) at ESGCT 33rd Annual → BD updateBEAM-301's ESGCT poster delivers the answers the October 13 update asked for: two 40 mg patients are now completely off cornstarch, the non-responder has a mechanistic explanation, the 60 mg cohort is enrolling, and Beam is engaging the FDA on an approval path — all on the same clean-liver-enzyme story that has anchored the platform thesis.BD extracted 1 program update from this document → BEAM pipeline
ARVNArvinasReleaseArvinas to Report Third Quarter 2026 Financial Results on November 3, 2026
ARVNArvinasReleaseArvinas Announces Return of Early Career Researcher Award to Recognize Innovation in Targeted Protein Degradation
ARTVArtiva BiotherapeuticsReleaseArtiva Biotherapeutics Announces Strategic Update and Discontinues Development of AlloNK®→ BD updateSummary on the 8-KBD extracted 1 program update from this document → ARTV pipeline
ARTVArtiva Biotherapeutics8-KCurrent report: results of operations, exit / restructuring costs · EX-99.1 → BD updateArtiva killed AlloNK this morning — durability failed, two patients died, 94% of staff are being let go, and the Phase 3 is cancelled. The bear case I named in December just got confirmed in the most brutal way possible, and the only thing left standing is $319M in cash and a strategic alternatives process.BD extracted 1 program update from this document → ARTV pipeline
ALTAltimmuneReleaseAltimmune Appoints Peter Greenleaf and Alex Howarth, Two Leading Biotech Executives, to Board of Directors to Support Its Strategic Evolution
ALTAltimmune8-KCurrent report: officer / director change, Reg FD disclosure · EX-99.1 EXHIBIT 99.1
ALLOAllogene TherapeuticsSCHEDULE 13G/A13G amendment
ADAGAdageneReleaseAdagene to Participate in the Guggenheim Securities 3rd Annual Healthcare Innovation Conference
ACTUActuate TherapeuticsReleaseACTUATE THERAPEUTICS ANNOUNCES PRICING OF $11.0 MILLION UNDERWRITTEN PUBLIC OFFERING → BD updateThe offering finally priced at $0.71/unit — smaller than every prior assumption, with warrants struck at $0.45 that are immediately in-the-money, netting the company roughly $10M to fund a runway measured in quarters, not years.
ACRSAclaris TherapeuticsReleaseAclaris Therapeutics Announces Positive Phase 1b Proof-of-Concept Primary Analysis Results for its Anti-TSLP/IL-4Rα Bispecific ATI-052 in Atopic Dermatitis (AD) and Asthma → BD updateSummary on the 8-K
ACRSAclaris TherapeuticsReleaseAclaris Therapeutics Announces Pricing of $50.0 Million Offering of Common Stock and Pre-Funded Warrants → BD updateSummary on the 8-K
ACRSAclaris Therapeutics8-KCurrent report: material agreement → BD updateATI-052's Phase 1b POC data in both atopic dermatitis (45% placebo-adjusted EASI, 78% EASI-50, durable through week 16) and asthma (59% FeNO reduction from a single dose, 200 mL FEV1 gain) landed this morning — the "prove-it moments" the thesis was built around — while a simultaneous $50M underwritten offering at $3.50/share and a strategic pivot to EoE as the Phase 2b lead indication add new wrinkles for holders.BD extracted 1 program update from this document → ACRS pipeline
ACRSAclaris Therapeutics8-KCurrent report: results of operations, Reg FD disclosure, other events · EX-99.1 → BD updateSummary on the 8-K
ACRSAclaris Therapeutics424B5Prospectus supplement (offering)→ BD updateSummary on the 8-K
ABSIAbsciSCHEDULE 13G/A13G amendment

Monday, October 2642

ZYMEZymeworksDEFA14AProxy soliciting material
ZYMEZymeworksDEF 14AProxy statement
ZYMEZymeworksARSAnnual report to shareholders
XNCRXencor8-KCurrent report: results of operations, Reg FD disclosure, other events · EX-99.1 PRESENTATION DATED OCTOBER 26, 2026 → BD updateXmAb819's ESMO oral delivered a 45.5% confirmed ORR at the proposed Phase 3 dose — decisively ahead of the 25% headline I had been tracking — with an 82% 6-month PFS estimate, median PFS not reached, and cash runway now extended into 2029; Xencor has named its RP3D, signaled an accelerated approval pathway discussion with FDA, and outlined a randomized pivotal versus tivozanib.BD extracted 2 program updates from this document → XNCR pipeline
TVTXTravere TherapeuticsReleaseTravere Therapeutics to Report Third Quarter 2026 Financial ResultsFILSPARI's randomized PROTECT biomarker data from ASN Kidney Week delivers the p-values I said to wait for: four inflammatory markers, all moving harder on sparsentan than on irbesartan in a blinded 404-patient cohort, with the IL-6 result the starkest (−45.4% vs. +8.7%). The science backs the "two-front war" mechanism at a level that chips away at the remaining bear case — and the stock hasn't priced it yet.
SRPTSarepta TherapeuticsReleaseSarepta Therapeutics to Present at Upcoming Investor Conferencesvia aggregator
SNDXSyndax PharmaceuticalsReleaseSyndax to Announce Third Quarter 2026 Financial Results and Host Conference Call and Webcast on November 2, 2026via aggregator
SLDBSolid BiosciencesReleaseSolid Biosciences Announces European Commission Orphan Designation for SGT-212 and Continued Progress in the FALCON Trial in Friedreich’s Ataxiavia aggregator
RXRXRecursion PharmaceuticalsReleaseRecursion to Host Webinar Focused on Updated REC-4881 (FAP) Data from CGA-IGC on Tuesday, November 3
ORKAOruka TherapeuticsReleaseOruka Therapeutics Announces Positive Week 16 Results for ORKA-001 from the Ongoing EVERLAST-B Trial in Moderate-to-Severe Psoriasis → BD updateSummary on the 8-K
ORKAOruka Therapeutics8-KCurrent report: Reg FD disclosure, other events · EX-99.1 PRESS RELEASE, DATED OCTOBER 26, 2026 → BD updateEVERLAST-B, the 187-patient Phase 2b dose-ranging trial, replicated EVERLAST-A's signal almost exactly — 61% PASI 100 at the 600 mg high dose vs. 0% placebo — in a larger, globally diverse cohort, locking in dose selection and clearing the runway to Phase 3 initiation in 1H 2027.BD extracted 1 program update from this document → ORKA pipeline
NVCTNuvectis PharmaReleaseNuvectis Reports Positive Data from NXP200 Phase 1b Study Demonstrating Durable Responses, Including Complete Responses, in BRAF V600-mutated Recurrent or Progressive Gliomasvia aggregator→ BD updateThe ESMO oral I promised readers would be "the first dataset in this portfolio I can inspect rather than accept secondhand" just landed — and NXP200 delivered ~40% ORR with CRs in recurrent glioma, a 17-month median OS in high-grade patients, and responses in prior BRAF-inhibitor failures. The stock is down nearly 8% anyway.BD extracted 1 program update from this document → NVCT pipeline
NRSNNeuroSense Therapeutics6-KForeign issuer report → BD updateNeuroSense has signed a collaboration to supply PrimeC through a U.S. pre-approval access pathway, targeting first revenues in H1 2027 — the first commercial arrangement since the March pharma term-sheet collapse, but one that pays the advisor in equity and carries enough "mays" and "potentials" to fill a risk-factor section.
NBPNovaBridge Biosciences6-KForeign issuer report · EX-99.1 → BD updateThe ESMO readout I've been waiting for since August finally landed — and givastomig's 16.9-month mPFS held at nearly 18 months of follow-up, directly answering the statistical fragility flag. The stock's -11.3% Monday reaction looks like a classic sell-the-news setup on data that actually strengthened the bull case.
MDNAFMedicenna TherapeuticsReleaseMedicenna Reports Potent CD122 Blockade and Extended Survival with MDNA209 in Preclinical Models of Autoimmune Disease
LGVNLongeveronReleaseLongeveron Announces Updated Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS)via aggregator→ BD updateSummary on the 8-K
LGVNLongeveron8-KCurrent report: other events · EX-99.1 PRESS RELEASE OF LONGEVERON INC., DATED OCTOBER 26, 2026 → BD updateSix weeks after ELPIS II's primary endpoint miss, a pre-specified secondary MACE endpoint has now reached statistical significance (8 SOC events vs. 1 laromestrocel, p=0.043) — and the full dataset just earned a Late-Breaking Science podium slot at the AHA. Does this reopen the regulatory door, or is it a secondary-endpoint lifeline on a sinking ship?BD extracted 1 program update from this document → LGVN pipeline
IRONDisc MedicineSCHEDULE 13D/A13D amendment
IMTXImmatics6-KForeign issuer report · EX-99.1 EXHIBIT 99.1 → BD updateIMA402's first full ESMO readout at the RP2D range delivers 32% confirmed responses and a 12.5-month median duration in PRAME-high melanoma — offering the strongest evidence yet that the off-the-shelf "Wave 3" leg can carry weight alongside anzu-cel's pending Phase 3 readout.BD extracted 3 program updates from this document → IMTX pipeline
IMRXImmuneeringReleaseImmuneering Presents Design and Methodology of Ongoing Phase 3 MAPKeeper 301 Trial at ESMO Congress 2026
IMNMImmunomeReleaseImmunome Presents Additional Clinical Data for Varegacestat in Desmoid Tumors at ESMO 2026BD extracted 1 program update from this document → IMNM pipeline
HURATuHURA BiosciencesReleaseTuHURA Biosciences Provides First Look at Data from its Open-Label Study of IFx-2.0 as an Adjunctive Therapy to Keytruda® in First Line Treatment of Patients with Deep Seated Metastatic Merkel Cell Ca → BD updateTuHURA dropped first data from its interventional-radiology IFx-2.0 study today: 3 of 3 front-line MCC patients hit confirmed partial responses (RECIST 1.1) at 6 months when combined with pembrolizumab — the first time the combination has been tested in the first-line setting and a direct preview of the Phase 3 design, if not a proof of it.BD extracted 1 program update from this document → HURA pipeline
HROWHarrowReleaseHarrow To Report Third Quarter 2026 Financial Results After Market Close on November 9, 2026
GLSIGreenwich LifeSciencesDEFA14AProxy soliciting material
GLSIGreenwich LifeSciencesDEF 14AProxy statement
GLSIGreenwich LifeSciencesARSAnnual report to shareholders
FATEFate TherapeuticsReleaseFate Therapeutics Presents Updated Preliminary Data For FT819 In Active Lupus Nephritis At American Society Of Nephrology Kidney Week 2026 → BD updateFate finally published the renal-response count the prior writeup said had gone silent — 100% CRR/PERR at Month 6 in the RECLAIM-LN bendamustine regimen — but the denominator is still only n=2, and the stock has drifted lower since the deep dive. Here's what the data actually say.BD extracted 1 program update from this document → FATE pipeline
ENTAEnanta PharmaceuticalsReleaseEnanta Pharmaceuticals Announces First Patient Dosed in the RESOLVE Phase 2b/3 Study of Zelicapavir, a Potential First-in-Disease Treatment for Respiratory Syncytial Virus (RSV)RESOLVE just dosed its first patient — the 4Q 2026 trial initiation milestone I've been tracking since June has landed on schedule, moving the 2027 replication binary from calendar commitment to active enrollment.
ELDNEledon PharmaceuticalsReleaseEledon Pharmaceuticals Presents Phase 2 BESTOW Trial Data Showing Sustained Improvements in Quality of Life and Symptom Burden with Tegoprubart Compared to Tacrolimus at American Society of Nephrology
EIKNEikon TherapeuticsReleaseEikon Therapeutics Presents Updated EIK1001 Data from TeLuRide-005 at the European Society for Medical Oncology Congress → BD updateSummary on the 8-K
EIKNEikon Therapeutics8-KCurrent report: Reg FD disclosure, other events · EX-99.1 → BD updateToday's full TeLuRide-005 NSCLC readout at ESMO delivers what I called a genuine two-sided catalyst: the squamous cohort posts a respectable 12.9-month median DOR, but non-squamous durability resolves below KEYNOTE-189's benchmark at 11.2 months — and the stock is down 23.7% as the market renders its verdict.BD extracted 1 program update from this document → EIKN pipeline
CYDYCytoDynReleaseCytoDyn Presents Updated Leronlimab Data in Metastatic Colorectal Cancer at ESMO Congress 2026 → BD updateESMO delivered the ctDNA story again — but the primary endpoint (ORR by RECIST) was conspicuously absent from the poster. The stock slid 9.2% on Monday, and the silence around confirmed responses may be louder than the data that was presented.
CLYMClimb Bio8-KCurrent report: Reg FD disclosure, other events · EX-99.1 → BD updateThe long-awaited PrisMN Phase 2 data landed at ASN over the weekend, and the market's -13.5% reaction today is less about a clinical failure than a dose-complexity reveal: budoprutug works immunologically at 200 mg, but proteinuric patients clear it ≥2× faster than healthy volunteers, meaning the real efficacy story lives at 600–1000 mg doses with clinical remission data pushed to 2027.BD extracted 2 program updates from this document → CLYM pipeline
CHRSCoherus OncologyReleaseCoherus Oncology to Report Third Quarter 2026 Financial Results on November 9, 2026
CGENCompugenReleaseCompugen to Release Third Quarter 2026 Results on Monday, November 9, 2026
AUTLAutolus TherapeuticsReleaseAUTOLUS THERAPEUTICS TO REPORT THIRD QUARTER 2026 FINANCIAL RESULTS AND HOST CONFERENCE CALL ON NOVEMBER 10, 2026
APVOAptevo TherapeuticsReleaseAptevo Reports Mipletamig Combination Therapy Enabled 21% of Frontline AML Patients to Advance to Potentially Curative Stem Cell TransplantSummary on the 8-K
APVOAptevo Therapeutics8-KCurrent report: other events · EX-99.1Mipletamig's transplant bridge rate just jumped to 21% (10/47 evaluable patients) vs. 0.7% in VIALE-A's ven/aza arm — the strongest clinically legible signal the drug has produced, arriving into a stock that has lost another 12% since the September data drop and still sits 63% below the warrant strike that funds the company.BD extracted 1 program update from this document → APVO pipeline
ANIXAnixa BiosciencesReleaseOCT 26, 2026 8:30 AM EDT Anixa Biosciences Announces Completion of Treatment of Fifth Cohort in its Ovarian Cancer CAR-T Clinical Trial↗ It has completed dosing of the fifth cohort in its ongoing PhasCohort 5 dosing is complete and cohort 6 — a 10x dose increase to 1×10⁸ cells/kg — is next after a 30-day safety check, but the survivor count quietly lost a patient since July, and the CEO is still benchmarking against "weeks" when the literature says months.BD extracted 1 program update from this document → ANIX pipeline
AKBAAkebia TherapeuticsReleaseU.S. Renal Care Presents Analysis of VOICE Trial Demonstrating Favorable Safety Outcomes for Patients Treated with Vadadustat Versus an ESA During a Late-Breaking Session at American Society of Nephro → BD updateThe full VOICE dataset landed at ASN Kidney Week with new safety data — fewer serious adverse events and dramatically better hemoglobin control versus ESAs — giving Vafseo's sales force the peer-reviewed ammunition they need for post-TDAPA conversations, even as the structural risks I named in October remain unchanged.BD extracted 1 program update from this document → AKBA pipeline
ACTUActuate TherapeuticsEFFECTRegistration effective
ABOSAcumen PharmaceuticalsS-3Shelf registration → BD updateSummary on the 8-K
ABOSAcumen PharmaceuticalsReleaseAcumen Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Highlights → BD updateSummary on the 8-K
ABOSAcumen Pharmaceuticals8-KCurrent report: results of operations, Reg FD disclosure · EX-99.1 → BD updateALTITUDE-AD topline data lands in November 2026 — the binary event is now weeks away, not quarters — but with only $78.6M in cash, a persistent going-concern flag, and a freshly filed $500M shelf registration, the financing overhang hasn't gone away.
ABOSAcumen Pharmaceuticals10-QQuarterly report → BD updateSummary on the 8-K

Sunday, October 254

XNCRXencorReleaseXencor Presents Phase 1 Dose Selection Data for XmAb819, a Potential First-in-Class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Patients With Advanced Clear Cell Renal Cell Carcinoma and → BD updateSummary on the 8-K of Oct 26, 2026BD extracted 1 program update from this document → XNCR pipeline
SMMTSummit TherapeuticsReleaseIvonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer in HARMONi-GI1 S → BD updateThe HARMONi-GI1 blank I flagged in August finally got filled at ESMO 2026's Presidential Symposium — OS HR 0.75, p=0.0031, PFS HR 0.61, ORR 53.8% — and Summit simultaneously announced a Western registration-enabling BTC trial via ECOG-ACRIN, even as the stock continues bleeding ahead of the November 14 PDUFA.BD extracted 1 program update from this document → SMMT pipeline
ORKAOruka TherapeuticsReleaseOruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-B Trial on October 26, 2026 → BD updateSummary on the 8-K of Oct 26, 2026
NBPNovaBridge BiosciencesReleaseNovaBridge Biosciences Reports Mature Phase 1b Data at ESMO 2026 Positioning Givastomig for Registrational Development → BD updateSummary on the 6-K of Oct 26, 2026

Saturday, October 244

ZYMEZymeworksReleaseZymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191 at ESMO Congress 2026via aggregator→ BD updateThe randomized Part 2a dose-optimization data I've been waiting for just landed at ESMO: ZW191 hit 64.5% confirmed ORR in high-grade serous PROC at 6.4 mg/kg with a 100% disease control rate, median duration of response not reached at 7 months, and a dramatically cleaner safety profile than the higher dose — and the FRα-negative activity that makes this drug different from Elahere held up in the randomized cohort.
IMTXImmaticsReleaseImmatics Presents Clinical Activity of IMA402 PRAME Bispecific and IMA203CD8 PRAME Cell Therapy across Advanced Solid Tumors in Two Oral Presentations at 2026 ESMO Annual Meeting → BD updateSummary on the 6-K of Oct 26, 2026BD extracted 2 program updates from this document → IMTX pipeline
CMPXCompass TherapeuticsReleaseCompass Therapeutics Announces Publication of Phase 2/3 COMPANION-002 Results for Tovecimig in the Journal of Clinical Oncology and Oral Presentation at ESMO 2026 → BD updateBD extracted 1 program update from this document → CMPX pipeline
CLYMClimb BioReleaseClimb Bio Presents Initial PrisMN Phase 2 Data from Budoprutug in pMN at an Oral Session at ASN Kidney Week 2026 → BD updateSummary on the 8-K of Oct 26, 2026

Friday, October 2333

ZYMEZymeworksReleaseZymeworks Enters into an Exclusive Global License and Collaboration Agreement with Roche for ZW209, a Trispecific T cell Engager Targeting DLL3via aggregator→ BD updateSummary on the 8-K
ZYMEZymeworks8-KCurrent report: material agreement, Reg FD disclosure · EX-99.1 → BD updateZymeworks just signed a global Roche partnership for ZW209 — the DLL3 trispecific T-cell engager I called a placeholder — for $55M upfront, $40M at Phase 1b, and up to $718M in milestones. The R&D-to-royalty engine just printed its first wholly-owned deal.BD extracted 2 program updates from this document → ZYME pipeline
ZNTLZentalis PharmaceuticalsReleaseZentalis Pharmaceuticals Announces Meaningful Median Overall Survival Data in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer from DENALI Part 1b to be Presented at the ESMO Congress 2026
TVTXTravere TherapeuticsReleaseTravere Presents New Biomarker Data at ASN Kidney Week Suggesting FILSPARI® (sparsentan) May Modify Underlying Disease Pathophysiology in IgA NephropathyBD extracted 1 program update from this document → TVTX pipeline
TNGXTango TherapeuticsReleaseTango Presents Promising Results from Phase 1/2 Study of Vopimetostat and Daraxonrasib in Pancreatic Cancer and Provides Updates to Development Strategy → BD updateSummary on the 8-K
TNGXTango Therapeutics8-KCurrent report: Reg FD disclosure, other events · EX-99.1 → BD updateToday's ESMO update confirmed the June 92% ORR thesis with a larger patient pool and longer follow-up — 82% ORR, 88% nine-month PFS rate in 22 evaluable PDAC patients — yet TNGX fell 16.4% during the session, creating one of the thesis's most analytically interesting disconnects since the original data print.BD extracted 1 program update from this document → TNGX pipeline
TGTXTg TherapeuticsReleaseTG Therapeutics Announces Phase 1 Data Evaluating Azer-cel in Progressive Multiple Sclerosis in a Late-Breaking Oral Presentation at MSToronto2026 → BD updateAzer-cel's Phase 1 data in progressive MS just landed at ACTRIMS-ECTRIMS: n=26, clean safety across six dose levels, and 89% EDSS stable/improved at Day 90 in a population that had already failed high-efficacy therapies including anti-CD20 — the "free call option" is starting to look like it might cost something.BD extracted 1 program update from this document → TGTX pipeline
SMMTSummit TherapeuticsReleaseSummit Therapeutics and Lunit Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology Development
RVMDRevolution MedicinesReleaseRevolution Medicines Presents Overall Survival Data for RASONQUE™ (daraxonrasib) Across Subgroups in Previously Treated Metastatic Pancreatic Cancer at ESMO 2026RASONQUE's OS benefit held across every RAS genotype subgroup at ESMO — including patients with no detected RAS mutation — delivering the granular validation that the label's biomarker-agnostic breadth needed to be believed commercially.BD extracted 1 program update from this document → RVMD pipeline
RCUSArcus Biosciences8-KCurrent report: other events → BD updateThe Arcus offering priced Tuesday night at $17.50/share and closed today with the greenshoe exercised in full — 16.4M shares sold, ~$269.7M in net proceeds, and the institutional bid answered at the offer price.
PCSAProcessa PharmaceuticalsEFFECTRegistration effective
ORICOric Pharmaceuticals8-KCurrent report: Reg FD disclosure, other events · EX-99.1
NBPNovaBridge Biosciences6-KForeign issuer report · EX-99.1Ragistomig dose-optimization data landed at ESMO this morning — two days before the givastomig Phase 1b readout that is the entire thesis catalyst. Here's what the secondary-asset data means and what to watch Saturday.BD extracted 1 program update from this document → NBP pipeline
KYTXKyverna TherapeuticsReleaseKyverna Therapeutics Highlights Promising Updated Clinical Data with Miv-cel in Progressive Multiple Sclerosis at MS Toronto 2026BD extracted 1 program update from this document → KYTX pipeline
KTTAPasithea TherapeuticsReleasePasithea Therapeutics Announces Positive PAS-004 Clinical Data from Phase 1 Advanced Cancer Study Presented at ESMO Congress 2026PAS-004's ESMO Congress poster extends the chronic-tolerability story to 500+ days with a Cmax/Cmin below 1.5 — the macrocycle's core pitch, rendered in the most compelling human data yet — while the stock paradoxically sold off 9% on the session.BD extracted 1 program update from this document → KTTA pipeline
IONSIonis PharmaceuticalsReleaseIonis partner Roche announces new Phase 3 data showing sefaxersen significantly reduced proteinuria in people with IgA nephropathy (IgAN)→ BD updateSummary on the 8-K
IONSIonis Pharmaceuticals8-KCurrent report: Reg FD disclosure, other events · EX-99.1 EXHIBIT 99.1 → BD updateSefaxersen's IMAgINATION data finally has a number attached — 43.1% proteinuria reduction vs. placebo (p<0.0001) — and it beats the iptacopan benchmark I said to watch for. The stock shrugged anyway, because the question gating this thesis still isn't sefaxersen's.BD extracted 1 program update from this document → IONS pipeline
IMTXImmatics6-KForeign issuer report · EX-99.1 EXHIBIT 99.1 → BD updateImmatics dropped the ESMO 2026 IMA203CD8 Phase 1 dataset this morning — 51% ORR across four tumor types and 60% ORR in gynecologic cancers at higher doses — and the stock fell anyway, which is the story worth unpacking.BD extracted 2 program updates from this document → IMTX pipeline
IDYAIDEAYA BiosciencesReleaseIDE849 (SHR-4849) DLL3 TOP1 ADC Updated Phase 1 Results at ESMO 2026 Demonstrates Promising Anti-Tumor Activity and Preliminary Overall Survival Results in Relapsed Small Cell Lung Cancer and Neuroend → BD updateIDE849's Hengrui Phase 1 at ESMO delivers the first OS data — 17.4-month median in second-line SCLC and a 65.4% confirmed response rate in brain-met patients — numbers that compare favorably to tarlatamab's randomized 13.6-month OS benchmark, while IDEAYA's own Western trial flashes an early safety split between the two candidate Phase 3 doses.BD extracted 1 program update from this document → IDYA pipeline
ELTXElicio TherapeuticsReleaseElicio Therapeutics Presents Late-Breaking Phase 2 AMPLIFY-7P Results at ESMO Congress 2026 and Announces Simultaneous Publication in Nature Medicine → BD updateAMPLIFY-7P lands at ESMO and in Nature Medicine with pre-specified ctDNA subgroup data that reframes the June miss: HR 0.51 in the ctDNA-negative majority (n=93) and a multivariable-adjusted ITT HR of 0.47 — but the stock sits 39% below August levels, cash remains critical, and "subject to funding" still qualifies every next step.BD extracted 1 program update from this document → ELTX pipeline
EIKNEikon TherapeuticsReleaseEikon Therapeutics Presents Data from PARP1-Selective and WRN Helicase Programs at the European Society for Medical Oncology Congress → BD updateSummary on the 8-KBD extracted 1 program update from this document → EIKN pipeline
EIKNEikon Therapeutics8-KCurrent report: Reg FD disclosure, other events · EX-99.1 → BD updateEikon's ESMO data landed today — EIK1005 posted its first patient efficacy signal (one PR in a MSI-H/dMMR patient on combo, six stable diseases on monotherapy), EIK1004 showed a strikingly clean heme profile (Grade ≥3 anemia/neutropenia each at just 1.5%), and the stock still dropped ~12% during the session, telling you exactly what the market thought of the pipeline read versus the still-absent TeLuRide-006 melanoma interim.BD extracted 2 program updates from this document → EIKN pipeline
CLYMClimb BioReleaseClimb Bio and Mabworks Announce CLYM116/MIL116 Data Demonstrating Deep, Durable APRIL Suppression and ~70% Gd-IgA1 Reduction at ASN Kidney Week 2026Summary on the 8-K
CLYMClimb Bio8-KCurrent report: Reg FD disclosure, other events · EX-99.1CLYM116's sweeper mechanism just got its most rigorous validation yet — dual-study, 88-subject dataset at ASN confirms ~33-day half-life (3.5x sibeprenlimab) and ≥90% free APRIL suppression through 12 weeks, while the stock sits 30% below the September data high.BD extracted 1 program update from this document → CLYM pipeline
CATXPerspective TherapeuticsReleasePerspective’s [212Pb]Bamzireotide Navoxetan (VMT-α-NET) Demonstrates Encouraging Safety, Durable Disease Control, and Robust Tumor Response Across Multiple Dose Cohorts in Phase 1/2a Trial in Advanced → BD updateSummary on the 8-K
CATXPerspective Therapeutics8-KCurrent report: other events · EX-99.1 → BD updateThe ESMO oral delivered a dose-response signal — 50% ORR at 6.0 mCi vs. 33% at 5.0 mCi — and 72% PFS at 18 months, but two new Grade 3 renal events (2.9%) broke the "zero serious renal complications" streak and appear to have driven a -28.8% session drop.BD extracted 1 program update from this document → CATX pipeline
BCTXBriaCell TherapeuticsReleaseBriaCell Announces ESMO 2026 Poster Highlighting Circulating Immune Biomarker Associated with Clinical Outcomes in Metastatic Breast Cancervia aggregatorBD extracted 1 program update from this document → BCTX pipeline
ATHEAlterity Therapeutics6-KForeign issuer report · EX-99.1 EXHIBIT 99.1
ATHEAlterity Therapeutics6-KForeign issuer report · EX-99.1 EXHIBIT 99.1
ATHEAlterity Therapeutics6-KForeign issuer report · EX-99.1 EXHIBIT 99.1
ARDXArdelyxReleaseArdelyx Presents Real-World Data at ASN Kidney Week 2026 Showing Serum Phosphate Reductions Following XPHOZAH® (tenapanor) Initiation With or Without Phosphate Binders
APVOAptevo Therapeutics8-KCurrent report: material agreement, holder rights modified
AKBAAkebia Therapeutics8-KCurrent report: listing notice
ACETAdicet BioSCHEDULE 13GPassive >5% holder (13G)
AARDAardvark Therapeutics8-KCurrent report: other events · EX-99.1

Thursday, October 2236

XERSXeris BiopharmaReleaseXeris Biopharma to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026
VSTMVerastemReleaseVerastem Oncology to Report Third Quarter 2026 Financial Results on November 5, 2026
VRCAVerrica PharmaceuticalsReleaseVerrica Pharmaceuticals Announces Achievement of Milestones Unlocking Access to the Full $27.5 Million of Non-Dilutive Growth Capital Under Credit Facility → BD updateThe redacted milestone gate that kept the $15M delayed draw locked — and kept VRCA on a watch list — just cleared. The full $27.5M facility is now available, funding both Phase 3 wart readouts and removing the central financing uncertainty the bear case was built on.
VORVor BiopharmaReleaseTelitacicept Demonstrates Durable Preservation of Kidney Function Through Two Years in Phase 3 TELIGAN Trial in IgA Nephropathy → BD updateTELIGAN's two-year final analysis just delivered what the May NEJM interim promised: hard kidney-function preservation with an eGFR slope near zero (-0.6 vs -5.7 mL/min/1.73m²/year, p<0.001) and an 89% relative risk reduction in clinically meaningful eGFR decline — presented in the plenary session at ASN Kidney Week, while the stock sits 24.5% below the September enrollment-completion update.
VERAVera TherapeuticsReleaseVera Therapeutics Announces Positive ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgA Nephropathy Presented at ASN Kidney Week 2026 and Published in the New England Journal of MedThe ORIGIN 3 full dataset just landed in the New England Journal of Medicine — nephrology's highest court — and VERA is down 6.9% on the day. The science keeps winning; the tape keeps not caring.BD extracted 1 program update from this document → VERA pipeline
STOKStoke TherapeuticsReleaseStoke Therapeutics to Host Webcast and Conference Call to Discuss Third Quarter 2026 Business and Financial Updates
SRPTSarepta TherapeuticsReleaseSarepta Therapeutics to Announce Third Quarter 2026 Financial Results
SMMTSummit TherapeuticsReleaseIvonescimab Data Sets across Multiple Tumor Types to Be Featured at ESMO 2026HARMONi-GI1's OS hazard ratio lands at ESMO tomorrow — the topline we've been waiting on since August — while a new U.S.-based ECOG-ACRIN biliary trial directly addresses the FDA's geography problem, and 10 ivonescimab presentations across 8 tumor types hit Madrid this week, 23 days before the November 14 PDUFA.
SGMTSagimet BiosciencesReleaseSagimet Biosciences Announces First Patient Dosed in AURORA Phase 3 U.S. Clinical Trial of Denifanstat for Moderate to Severe Acne → BD updateSummary on the 8-K
SGMTSagimet Biosciences8-KCurrent report: Reg FD disclosure · EX-99.1 → BD updateThe first patient has been dosed in AURORA — Sagimet's US registrational Phase 3 for denifanstat in moderate-to-severe acne — and the company has quietly pulled forward the topline readout to 2H 2027, a year sooner than prior guidance suggested, with cash now guided through mid-2029 including NDA submission.BD extracted 1 program update from this document → SGMT pipeline
SCYXScynexisReleaseSCYNEXIS Completes Phase 1 Study of Intravenous SCY-247, a Novel, Triterpenoid Antifungal in Development for Treatment and Prevention of Invasive Fungal DiseasesThe IV SCY-247 Phase 1 that I flagged as nearly slipping in the September update just cleared cleanly — 50 mg QD hits the murine-model efficacy target, no serious adverse events, and Phase 2 is now slated for 2027 with both oral and IV formulations fully Phase 1-complete under the BARDA umbrella.BD extracted 1 program update from this document → SCYX pipeline
SABSSAB Biotherapeutics25-NSEDelisting noticeA tranche of SABS warrants expired today, shrinking the dilution wall I've flagged in every update — and the stock's +13.4% move this week may be the market pricing that in.
REPLReplimune GroupReleaseReplimune to Report the Fiscal Second Quarter 2027 Financial Results and Provide Corporate Update on October 28, 2026
RCUSArcus BiosciencesReleaseArcus Biosciences Announces Pricing of $250 Million Public Offering of Common Stockvia aggregator
RCUSArcus Biosciences424B5Prospectus supplement (offering)
PCSAProcessa PharmaceuticalsDEF 14AProxy statement
OCSOculis HoldingReleaseOculis Reports New Phase 2 ACUITY Biomarker Data Further Supporting Privosegtor’s Neuroprotective Potential in Optic NeuritisOculis dropped new blood-biomarker data from ACUITY at MSToronto 2026 showing Privosegtor suppressed NfL and GFAP — objective markers of nerve destruction and brain-cell inflammation — adding a third convergent layer of evidence to the structural and functional signals already on the table, while the stock has quietly bled another 37% since August.BD extracted 1 program update from this document → OCS pipeline
OCGNOcugenReleaseOcugen to Provide Business Update and Third Quarter 2026 Financial Results on November 4
MLYSMineralys TherapeuticsReleaseMineralys Therapeutics Presents New Lorundrostat Data in Participants with Hypertension and Chronic Kidney Disease at ASN Kidney Week 2026BD extracted 1 program update from this document → MLYS pipeline
MDNAFMedicenna TherapeuticsReleaseMedicenna to Present Preclinical Data on Its CD122 Superantagonist MDNA209 at The Promises of Treg and Interleukin-2 Therapies Conference
LENZLENZ TherapeuticsReleaseLENZ Therapeutics to Report Third Quarter 2026 Financial Results on October 29, 2026
KYMRKymera TherapeuticsReleaseWATERTOWN, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines
IRONDisc Medicine8-KCurrent report: material agreement, results of operations, other events · EX-99.1
IONSIonis PharmaceuticalsReleaseIonis ranked #1 on Science’s Top Employers list
IBRXImmunityBioReleaseJefferies Global Healthcare Conference
GUTSFractyl HealthReleaseFractyl Health Sharpens Focus on Revita Following Positive Pivotal Results, Advancing Toward Planned FDA De Novo Submission in Post-GLP-1 Weight Maintenance → BD updateSummary on the 8-K
GUTSFractyl Health8-KCurrent report: exit / restructuring costs, officer / director change, other events · EX-99.1 → BD updateFractyl kills Rejuva internally, cuts 45% of staff, and loses its co-founder — but the burn drops to ~$8M/quarter and runway extends to Q2 2027, buying time for the De Novo filing and the 12-month pivotal readout that could still attract a strategic buyer.BD extracted 2 program updates from this document → GUTS pipeline
ELOXEloxx Pharmaceuticals8-KCurrent report: officer / director change, other events
ELOXEloxx Pharmaceuticals424B3Prospectus (resale / update)
DRTSAlpha Tau Medical6-KForeign issuer report · EX-99.1 PRESS RELEASE DATED OCTOBER 22, 2026
CTNMContineum TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
CGTXCognition TherapeuticsReleaseCognition Therapeutics Announces Alignment with FDA on Pivotal Phase 3 Trial of Zervimesine (CT1812) in Dementia with Lewy Bodies → BD updateSummary on the 8-K
CGTXCognition Therapeutics8-KCurrent report: other events · EX-99.1 EXHIBIT 99.1 → BD updateThe FDA alignment on Phase 3 design is the milestone I've been pointing at since September — NPI-2 (hallucinations + delusions) is the locked primary endpoint, ADCS-ADL the key secondary, 100 mg / 9-month / randomized design confirmed. The stock's -6.2% session move despite the news demands explanation.
CADLCandel TherapeuticsReleaseCandel Therapeutics Appoints Maria Ostrovsky as General Counsel
ACETAdicet BioReleaseAdicet Bio to Participate in Upcoming Investor Conferences
ABOSAcumen PharmaceuticalsReleaseAcumen Pharmaceuticals to Present Preliminary Baseline Characteristics and Data on Care Experiences and Participation in Phase 2 ALTITUDE-AD Trial at the 19th Annual Clinical Trials on Alzheimer’s Dis
AARDAardvark Therapeutics8-KCurrent report: other events · EX-99.1

Wednesday, October 2143

VYGRVoyager TherapeuticsReleaseVoyager Announces CEO Succession Plan, Appoints Robin Swartz President → BD update
VYGRVoyager Therapeutics8-KCurrent report: officer / director change → BD update
VNDAVanda PharmaceuticalsReleaseVanda Pharmaceuticals to Announce Third Quarter 2026 Financial Results on October 28, 2026
VKTXViking TherapeuticsReleaseViking Therapeutics to Report Financial Results for Third Quarter 2026 on October 28, 2026
VIRVir BiotechnologyReleaseVir Biotechnology to Host Conference Call for Third Quarter 2026 Financial Results
UNCYUnicycive TherapeuticsReleaseUnicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate New Drug Application Resubmission and PDUFA Date of March 25, 2027 → BD updateThe FDA has accepted the OLC resubmission and set a March 25, 2027 PDUFA — the exact trip-wire I flagged on September 29 — but UNCY is still trading below every warrant strike, and the TDAPA clock has ticked three more weeks closer to expiration.
TTRXTurn TherapeuticsReleaseU.S. Bancorp | BTIG to Host Turn Therapeutics for Virtual Fireside Chat
TLXTelix Pharmaceuticals6-KForeign issuer report · EX-99.1TLX dropped 10.1% today after its Q3 2026 update confirmed the franchise plateau the prior writeup warned about — Precision Medicine revenue flat at $201M for the second consecutive quarter, dose volumes up just 1%, Zircaix still not resubmitted, and the ProstACT Global US IND amendment still being drafted rather than under FDA review.BD extracted 1 program update from this document → TLX pipeline
TLSATiziana Life SciencesReleaseTiziana Management Team to Attend the 10th Joint ACTRIMS-ECTRIMS Meeting in Toronto
TLSATiziana Life Sciences6-KForeign issuer report · EX-99.1 TIZIANA LIFE SCIENCES LTD PRESS RELEASE, DATED OCTOBER 21, 2026
TGTXTg TherapeuticsReleaseTG Therapeutics Highlights New Clinical Data Across Multiple Sclerosis Portfolio at MSToronto2026
STROSutro BiopharmaReleaseSutro Biopharma Announces First Patient Dosed in Phase 1 Trial of STRO-006, a Next-Generation ITGB6-Targeting ADC, in Advanced Solid Tumorsvia aggregatorSTRO-006 just dosed its first patient — Sutro's second ADC in the clinic in under a year, right on the catalyst timeline I published in August, even as the stock has been cut in half since that update.BD extracted 1 program update from this document → STRO pipeline
SMMTSummit TherapeuticsReleaseSummit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II / III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancer
SCYXScynexisReleaseSCYNEXIS to Feature SCY-247 in a Pipeline Presentation at IDWeek
RYTMRhythm PharmaceuticalsReleaseRhythm Pharmaceuticals to Report Third Quarter 2026 Financial Results on Tuesday, November 3, 2026
RVMDRevolution MedicinesReleaseRevolution Medicines to Report Financial Results for Third Quarter 2026 After Market Close on November 4, 2026
RCUSArcus BiosciencesReleaseArcus Biosciences Announces Commencement of Public Offering of Common Stock → BD update
RCUSArcus BiosciencesReleaseArcus Biosciences Announces Pricing of $250 Million Public Offering of Common St...→ BD update
RCUSArcus Biosciences8-KCurrent report: results of operations → BD update
RCUSArcus Biosciences424B5Prospectus supplement (offering)→ BD update
PYPDPolyPidReleasePolyPid to Present D-PLEX₁₀₀ Microbiology Data at IDWeek 2026 → BD updateFive weeks before the November 28 PDUFA, PolyPid drops the microbiology data I said was missing — pooled across 2,185 patients, it shows lower bacterial burden in breakthrough SSIs and no evidence of resistance selection, directly answering the antimicrobial stewardship objection that was the biggest adoption-tax risk nobody was modeling.BD extracted 1 program update from this document → PYPD pipeline
LENZLENZ TherapeuticsSCHEDULE 13G/A13G amendment
KYTXKyverna TherapeuticsReleaseKyverna Therapeutics Presents Full One-Year Registrational Data Set Demonstrating Sustained Clinical Benefit of Miv-cel in Stiff Person Syndrome at MS TorontoThe full KYSA-8 one-year poster at MS Toronto answers every question the September 24 topline left open — secondaries held across the board, the 6-minute walk deepened to 119 meters, and IEC-HS stays at zero. KYTX is down 16.5% since September 1 with the data getting steadily better.BD extracted 1 program update from this document → KYTX pipeline
JBIOJade BiosciencesReleaseOCTOBER 21, 2026 Jade Biosciences to Highlight Advancement of JADE101 Development Program at American Society of Nephrology (ASN) Kidney Week 2026 → BD updateEVERGREEN, the JADE101 registrational Phase 3, just got pulled forward to Q4 2026 — a full quarter ahead of schedule — while the stock still sits within striking distance of the June deal-price floor.
IVVDInvivydReleaseInvivyd Presents VMS063, a Potential Best-in-Class Monoclonal Antibody Candidate for the Treatment and Prevention of Measles, at IDWeek 2026
IRONDisc MedicineReleaseDisc Medicine Announces Pricing of $450 Million Upsized Public Offering of Common Stockvia aggregator
IRONDisc Medicine424B5Prospectus supplement (offering)
IRDOpus GeneticsReleaseOpus Genetics Announces FDA Clearance of IND Application for OPGx-RDH12 Gene Therapy for Inherited Childhood Blindness → BD updateSummary on the 8-K
IRDOpus Genetics8-KCurrent report: officer / director change → BD updateOpus's third gene therapy just cleared the FDA's IND hurdle and will dose its first patient this quarter — but the same day, the Chief Scientific and Development Officer quietly walked out the door.
IONSIonis Pharmaceuticals8-KCurrent report: Reg FD disclosure, other events · EX-99.1 EXHIBIT 99.1 → BD updateHIBSAGO (bepirovirsen) won FDA approval after the close on October 20 — six days ahead of the PDUFA — with a 19% functional cure rate against less than 1% on standard of care, but a Boxed Warning and a tighter-than-expected label narrow the addressable pool and cap Ionis's royalty upside in ways the headline doesn't show.BD extracted 1 program update from this document → IONS pipeline
INMBInmune BioReleaseINmune Bio Establishes Global Commercialization Framework for Ebstrocel™ Through Strategic Agreeme...→ BD updateSummary on the 8-K
INMBInmune BioReleaseINmune Bio Advances Ebstrocel™ Toward Potential UK Approval in Mid-2027 → BD updateSummary on the 8-K
INMBInmune Bio8-KCurrent report: Reg FD disclosure, other events · EX-99.1 PRESS RELEASE DATED OCTOBER 21, 2026 → BD updateINmune Bio submitted its final pre-MAA package to the MHRA on October 20 and signed a commercialization deal with Uniphar — the lottery ticket now has a submission on file, a February 2027 full MAA target, a mid-2027 UK approval window, and a named-patient access framework operating before any approval lands.BD extracted 1 program update from this document → INMB pipeline
IMVTImmunovantReleaseImmunovant to Report Financial Results for the Second Fiscal Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026
IMUXImmunicReleaseImmunic Presents New Clinical, Biomarker, and Preclinical Data for Vidofludimus Calcium in Four Poster Presentations at MSToronto2026 - the 10th Joint ACTRIMS-ECTRIMS MeetingBD extracted 1 program update from this document → IMUX pipeline
IBRXImmunityBioReleaseImmunityBio Announces Database Lock for Registrational Trial of Locally Delivered, Chemotherapy-Free ANKTIVA® Plus BCG in BCG-Naïve Non-Muscle Invasive Bladder CancerThe database lock on QUILT-2.005 is complete — the final analysis of the BCG-naïve first-line bladder cancer trial is now underway, with topline data expected in November and an sBLA filing on track for Q4 2026. The biggest remaining catalyst in the IBRX story is now weeks away.BD extracted 1 program update from this document → IBRX pipeline
HELPHelus PharmaReleaseHelus Pharma Highlights Clinical Program Advancements at Investor Presentation Held on October 21, 2026
HELPHelus Pharma6-KForeign issuer report · EX-99.1 EXHIBIT 99.1
GERNGeronReleaseGeron Plans to Announce Third Quarter 2026 Financial Results on November 4, 2026
BCRXBiocryst PharmaceuticalsReleaseBioCryst Announces U.S. FDA Approval of ORLADEYO® 150 mg Oral Pellets for Adults and Adolescents with HAESummary on the release
BCRXBiocryst PharmaceuticalsReleaseBioCryst to Report Third Quarter 2026 Financial Results on November 4The FDA just expanded ORLADEYO's pellet formulation to adults and adolescents who can't or won't swallow a capsule — a small but real label win that shores up ORLADEYO's "first and only oral HAE prophylactic for ages 2+" positioning heading into two competitor PDUFA dates in 2027.
ATHEAlterity Therapeutics6-KForeign issuer report · EX-99.1 EXHIBIT 99.1Alterity filed two AGM-related documents today that, read together, are the clearest signal yet of a dual-track M&A/financing process: a restructured CEO contract with full change-of-control acceleration, and a shareholder vote to unlock 25% placement capacity earmarked for Phase 3.
ATHEAlterity Therapeutics6-KForeign issuer report · EX-99.1 EXHIBIT 99.1Summary on the 6-K
ACHVAchieve Life SciencesReleaseAchieve Life Sciences Presents 52-Week Cytisinicline Results for Smoking and Vaping Cessation at CHEST 2026BD extracted 1 program update from this document → ACHV pipeline

Tuesday, October 2031

WVEWave Life SciencesReleaseWave Life Sciences Third Quarter 2026 Financial Results Scheduled for October 27, 2026
VRDNViridian TherapeuticsReleaseViridian Therapeutics to Report Third Quarter 2026 Financial Results on November 4, 2026
VERAVera TherapeuticsReleaseVera Therapeutics to Host ASN Kidney Week Investor Webcast and Third Quarter 2026 Financial Results Conference WebcastBD extracted 1 program update from this document → VERA pipeline
TLXTelix PharmaceuticalsReleaseTelix Reports Third Quarter 2026 Financial Performancevia aggregatorBD extracted 3 program updates from this document → TLX pipeline
SLDBSolid BiosciencesReleaseSolid Biosciences to Present Research Across Gene Therapy Development, Delivery and Manufacturing at ESGCT 2026via aggregator
RVMDRevolution MedicinesReleaseRevolution Medicines Begins Treating Patients in Phase 3 RASolve 308 Trial Evaluating Zoldonrasib in Combination with Pembrolizumab and Chemotherapy as First-Line Treatment for Patients with Metastati
RCUSArcus BiosciencesReleaseArcus Presents New Data from ARC-20 that Demonstrate the Opportunity for Casdati...→ BD updateBD extracted 1 program update from this document → RCUS pipeline
RCUSArcus Biosciences8-KCurrent report: other events → BD update
RAREUltragenyx PharmaceuticalSCHEDULE 13GPassive >5% holder (13G)
RAPPRapport Therapeutics8-KCurrent report: Reg FD disclosure, other events · EX-99.1
QNRXQuoin PharmaceuticalsReleaseQuoin Pharmaceuticals Announces Publication of Peer-Reviewed Paper on QRX003 for Netherton Syndrome in Dermatology and Therapy
QNRXQuoin Pharmaceuticals8-KCurrent report: Reg FD disclosure, other events · EX-99.1 EXHIBIT 99.1BD extracted 1 program update from this document → QNRX pipeline
PTGXProtagonist TherapeuticsReleaseA Phase 3 Win and a 130% Takeover Premium Lit Up Rare Blood-Disease Stocks on Monday → BD updateMerck KGaA's $1.3B acquisition of Silence Therapeutics at a 130% premium validates the hepcidin-axis thesis PTGX is built on — and simultaneously hands MIMRYLO's most dangerous weekly-dosing competitor a balance sheet that can run a global Phase 3. The bull and bear cases both just got louder.BD extracted 2 program updates from this document → PTGX pipeline
PALIPalisade BioReleasePalisade Bio Presents Rapid Endoscopic Improvement and New Translational Evidence for PALI-2108 in Inflammatory Bowel Disease at UEG Week 2026via aggregatorBD extracted 1 program update from this document → PALI pipeline
ONCYOncolytics BiotechReleaseOncolytics Biotech® to Present REO 033 Trial in Progress Abstract at ESMO Showcasing Pelareorep’s Potential in Colorectal Cancer
ONCYOncolytics Biotech8-KCurrent report: other events · EX-99.1
OCSOculis HoldingReleaseOculis to Present Late-Breaking Phase 2 ACUITY Biomarker Analyses of Privosegtor in Optic Neuritis at the 10th Joint ACTRIMS-ECTRIMS MeetingBD extracted 1 program update from this document → OCS pipeline
NKTRNektar TherapeuticsS-8Employee plan registration
NGNENeurogeneReleaseNeurogene Announces Upcoming Presentations Highlighting Key Differentiators of NGN-401 for Rett Syndrome at the ESGCT 33rd Annual Congress
NBPNovaBridge BiosciencesReleaseVisara Secures Exclusive Option for Potential Acquisition of YOL104-2 for Ocular Surface Squamous Neoplasia
MBRXMoleculin BiotechReleaseMoleculin Releases Next CEO Corner Segment Highlighting Recent Progress in Annamycin MIRACLE Trial
MBRXMoleculin Biotech8-KCurrent report: holder rights modified, charter / bylaws / fiscal year, other events · EX-99.1 EXHIBIT 99.1
KODKodiak SciencesS-3ASRAutomatic shelf registration → BD updateKodiak filed a $350M ATM shelf after today's close — the raise I've been flagging since May is no longer a prediction, it's a distribution agreement with J.P. Morgan already signed. The mechanism matters: dilution will drip through the tape, not land in a single priced block.
IRONDisc MedicineReleaseWATERTOWN, Mass., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization o
IRONDisc Medicine424B5Prospectus supplement (offering)
IONSIonis PharmaceuticalsReleaseIonis partner GSK announces Hibsago (bepirovirsen) approved in the U.S. for the treatment of chronic hepatitis B (CHB)BD extracted 1 program update from this document → IONS pipeline
INSMInsmedReleaseInsmed Appoints Two New Directors to Its BoardSummary on the 8-K
INSMInsmed8-KCurrent report: officer / director change, Reg FD disclosure · EX-99.1 EXHIBIT 99.1Insmed added two board members today that are worth reading carefully: a former Sanofi/Novartis CEO with deep AstraZeneca roots joins the same week as a CFO-track finance executive with Gilead/Amgen pedigree — and both land nine days before the Q3 print that will either confirm or crack the BRINSUPRI persistence thesis.
HRMYHarmony BiosciencesReleaseHarmony Biosciences to Report Third Quarter 2026 Financial Results on November 4, 2026
ELOXEloxx PharmaceuticalsReleaseEloxx Pharmaceuticals Finalizes 52-Week Phase 2 EXPRESS Study Design in Nonsense-Mutation ADPKD and Appoints T.R. Srinivas, M.D., Chief Medical Officer → BD updateEloxx finalized the EXPRESS Phase 2 design in nonsense-mutation ADPKD — 60 patients, 52 weeks, htTKV primary — with FDA pre-IND feedback flagging htTKV as a potential accelerated-approval surrogate and a Breakthrough Therapy Designation pathway, while simultaneously appointing a Novartis nephrology CMO with direct ADPKD credentials.
CLNNClene8-KCurrent report: material agreementThe NIH just renewed Clene's ALS expanded-access grant for another $7.2M through August 2027 — non-dilutive oxygen that quietly extends the runway past the cash wall the September insider raise barely papered over.
ARDXArdelyxReleaseArdelyx to Report Third Quarter 2026 Financial Results on November 3, 2026
ACRVAcrivon TherapeuticsReleaseAcrivon Advances ACR-7280, an Optimized, AP3-Enabled, Potential First-in-Class, Oral CDK11 Inhibitor Toward IND Filing in First Half of 2027The AP3 engine just named its third candidate — ACR-7280, a potential first-in-class oral CDK11 inhibitor showing complete tumor regression in AML models with synergy alongside venetoclax and menin inhibitors — turning the "free option" pipeline slot into a named, data-backed asset in a new oncology franchise.

Monday, October 1945

ZYMEZymeworksReleaseZymeworks Appoints Suzanne Monahan as Senior Vice President, Commercial and General Manager, Theravance Biopharmavia aggregator
XNCRXencorReleaseXencor to Host Webcast to Discuss Results From the Phase 1 Study of XmAb819 in Advanced Clear Cell Renal Cell CarcinomaBD extracted 1 program update from this document → XNCR pipeline
WVEWave Life SciencesReleaseWave Life Sciences to Host Virtual Research Day on Wednesday, November 4, 2026
TTRXTurn TherapeuticsDEF 14AProxy statement
TTRXTurn TherapeuticsARSAnnual report to shareholders
SMMTSummit TherapeuticsReleaseSummit Therapeutics Announces Opening of Global Phase II Study of Ivonescimab-Based Regimens in Advanced Clear Cell Renal Cell CarcinomaBD extracted 1 program update from this document → SMMT pipeline
SMMTSummit TherapeuticsDEF 14AProxy statement
RAREUltragenyx Pharmaceutical8-KCurrent report: other events
OCSOculis HoldingReleaseOculis Completes Randomization in PREDICT-1 Registrational Trial of Licaminlimab for TNFR1-Mediated Dry Eye DiseasePREDICT-1 is fully enrolled — 176 patients, 2/3 TNFR1-positive — with topline data due around year-end 2026, while OCS has quietly bled ~43% since the August update, resetting the risk/reward math heading into the first binary event.
NRXPNRX PharmaceuticalsReleaseNRx Pharmaceuticals (Nasdaq:NRXP) Announces Completion of Manufacturing Process Validation and Two-Year Stability of Preservative-Free KetamineWith 22 days until the November 10 GDUFA goal date, NRx just confirmed three GMP process-validation lots manufactured, two-year stability data in hand, and commercially releasable KETAFREE supply on the shelf — the manufacturing leg of the bear case is now retired.
NRSNNeuroSense TherapeuticsReleaseNeuroSense Files U.S. Patent Application for Traumatic Brain Injury
NRSNNeuroSense Therapeutics6-KForeign issuer report · EX-99.1 PRESS RELEASE DATED OCTOBER 19, 2026
MRKRMarker TherapeuticsReleaseMARKER THERAPEUTICS AWARDED $2.6 MILLION FDA ORPHAN PRODUCTS DEVELOPMENT GRANT TO ADVANCE MT-601 IN PANCREATIC CANCER → BD updateSummary on the 8-K
MRKRMarker Therapeutics8-KCurrent report: other events · EX-99.1 EXHIBIT 99.1 → BD updateMarker just won a $2.6M FDA Orphan Products grant for MT-601 in pancreatic cancer — the sixth federal/state agency to back the MAR-T platform — but the fine print quietly pushes the PANACEA trial initiation from 1H 2026 to Q1 2027, and the stock is up +15.4% on news that changes nothing about the dilution architecture.
MLYSMineralys TherapeuticsReleaseMineralys Therapeutics Expands its Board of Directors with the Appointments of Kristine Peterson and Lonnel Coatsvia aggregator
MLYSMineralys Therapeutics8-KCurrent report: officer / director change
MISTMilestone PharmaceuticalsReleaseMilestone Pharmaceuticals Announces Clinical Data Presentations at Upcoming Cardiology Conferences
LXEOLexeo TherapeuticsReleaseLexeo Therapeutics to Host Educational Event Focused on Clinical Endpoints and Outcome Measures in PKP2-ACMcompany site may be offline after the acquisition
KYTXKyverna TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
IRONDisc MedicineReleaseWATERTOWN, Mass., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization o → BD updateSummary on the 8-K
IRONDisc MedicineReleasePositive APOLLO trial topline results demonstrated statistically significant and clinically meaningful benefit across all study endpoints Successfully met co-primary endpoints of reduction in protopor → BD updateSummary on the 8-K
IRONDisc Medicine8-KCurrent report: Reg FD disclosure, other events · EX-99.1 → BD updateAPOLLO delivered: bitopertin gained +12.2 hours of pain-free sunlight per month (p=0.0010) and cut phototoxic reactions by 71% (p<0.0001) — the exact endpoints the thesis said would set the company's value — while Disc simultaneously launched a $350M equity raise to fund the NDA resubmission and launch ramp.BD extracted 1 program update from this document → IRON pipeline
INSMInsmedReleaseInsmed Launches BRINSUPRI® Tablets 25 mg (brensocatib hydrate) for the Treatment of Non-Cystic Fibrosis Bronchiectasis in Japan
IMUXImmunicReleaseImmunic Appoints Jaa Roberson as Chief People Officer
IDYAIDEAYA BiosciencesReleaseIDEAYA Biosciences and Servier Announce Data From Three Clinical Trials at ESMO 2026 Supporting the Potential of Darovasertib to Become a Foundational New Therapy for Patients Across the Treatment Jou → BD updateAhead of Saturday's ESMO poster session, IDEAYA dropped the full data package: OptimUM-01 shows a 27.1-month median OS in treatment-naïve HLA-A*02:01-positive patients and a 35.7% ORR after prior tebentafusp — the first evidence darovasertib sequences cleanly through Kimmtrak — while OptimUM-09 holds its 57% eye preservation rate with 86.3% of patients metastasis-free at 15 months.BD extracted 1 program update from this document → IDYA pipeline
GPCRStructure TherapeuticsReleaseStructure Therapeutics Announces Multiple Upcoming Presentations at ObesityWeek® 2026
EYPTEyePointReleaseEyePoint Announces Topline Results from LUCIA, the Second Pivotal Phase 3 Clinical Trial of DURAVYU™ in Wet AMD → BD updateSummary on the 8-K
EYPTEyePointReleaseEyePoint Announces Strategic Prioritization → BD updateSummary on the 8-K
EYPTEyePoint8-KCurrent report: results of operations, exit / restructuring costs, other events · EX-99.1 → BD updateLUCIA confirmed what LUGANO started: two identical Phase 3 trials, two missed primary endpoints, and now a 53% workforce reduction and early AMD trial termination that leaves EYPT a drastically smaller company betting everything on a DME readout 14 months away with $118M in cash.BD extracted 2 program updates from this document → EYPT pipeline
EYPTEyePoint8-KCurrent report: other events · EX-99.1 → BD updateSummary on the 8-K
ELOXEloxx PharmaceuticalsReleaseEloxx Pharmaceuticals Appoints Biopharmaceutical Industry Veteran Geno Germano to its Board of Directors
DRTSAlpha Tau Medical6-KForeign issuer report · EX-99.1 PRESS RELEASE DATED OCTOBER 19, 2026 → BD updateFDA just doubled REGAIN from 10 to 20 patients and added endpoints pointing toward a market submission — and new GBM data drops at the world's largest neuro-oncology conference on November 13.
CYDYCytoDynReleaseCytoDyn Appoints Robert E. Hoffman as Chief Executive Officer → BD update
CYDYCytoDynDEFA14AProxy soliciting material
CYDYCytoDyn8-KCurrent report: officer / director change, Reg FD disclosure · EX-99.1 → BD update
CMMBChemomab TherapeuticsS-4/AS-4/ASummary on the 6-K
CMMBChemomab Therapeutics6-KForeign issuer reportAmendment No. 2 halves the combined company's share count to 5 million and resets the ADS conversion ratio — every CMMB holder's math just changed — while the S-4/A confirms in registered form the same Scipher wreckage I flagged in September and adds a shareholder meeting vote that will determine whether CVR holders get to keep their contingent rights.
CLNNCleneReleaseClene Announces New Drug Application Submission to FDA for CNM-Au8 for the Treatment of ALS → BD updateSummary on the 8-K
CLNNClene8-KCurrent report: other events · EX-99.1 EXHIBIT 99.1 → BD updateThe CNM-Au8 NDA is officially submitted to the FDA under the Subpart H accelerated approval pathway — the drawing date on the lottery ticket just became real, and the ~$22M milestone tranches are now in play.BD extracted 1 program update from this document → CLNN pipeline
CGEMCullinan TherapeuticsReleaseZipalertinib Demonstrates Clinically Meaningful Intracranial Antitumor Activity in Patients with NSCLC with EGFR Exon 20 Insertion or Uncommon EGFR Mutations and Active CNS MetastasesThe prospective REZILIENT2 CNS cohort delivers a 30.2% intracranial ORR in 43 evaluable patients with active brain metastases — the first dedicated iORR dataset for zipalertinib and a commercial argument that strengthens the ATM Machine floor ahead of the February 2027 PDUFA and rolling frontline NDA.BD extracted 1 program update from this document → CGEM pipeline
BLTEBelite BioReleaseBelite Bio Announces Uplisting to the Nasdaq Global Select Market
BLTEBelite Bio6-KForeign issuer report · EX-99.1 EXHIBIT 99.1
ATHEAlterity Therapeutics6-KForeign issuer report · EX-99.1 EXHIBIT 99.1
ANABAnaptysBioReleaseJemperli (dostarlimab) Approved in the U.S. as First and Only Immunotherapy for Adults with MSI-H/dMMR Locally Advanced Rectal Cancer → BD updateJemperli just got FDA-approved for MSI-H/dMMR locally advanced rectal cancer — ahead of its February 2027 PDUFA date — with zero recurrences among responders at over two years of follow-up, locking in the label expansion that underpins GSK's >$2.7B peak sales guidance and the >$390M annualized royalty math I've been tracking all year.BD extracted 2 program updates from this document → ANAB pipeline
ALTAltimmuneReleaseAltimmune to Present New Data on Pemvidutide in Serious Liver Diseases at AASLD The Liver Meeting® 2026BD extracted 1 program update from this document → ALT pipeline
ACTUActuate TherapeuticsS-1/ARegistration statement (amended)→ BD updateThe offering that was chasing the stock down has been restructured a second time: units with warrants replace the straight equity deal, the assumed price resets to $0.50/share, and the post-offering diluted count shrinks — but the warrant overhang balloons. Here's what actually changed and what it means for the equity.
ABOSAcumen PharmaceuticalsReleaseAcumen Pharmaceuticals to Report Third Quarter Financial Results on October 26, 2026

Sunday, October 184

ZNTLZentalis PharmaceuticalsReleaseZentalis Pharmaceuticals Announces First Overall Survival Data for Azenosertib from DENALI Part 1b Published in ESMO Congress 2026 Abstract → BD updateDENALI Part 1b posts the first-ever OS data for azenosertib: 15.8 months median in Cyclin E1-positive PROC — a 2.1x separation from Cyclin E1-negative patients, presented at ESMO 2026 Oct 23. The single biggest gap in the prior bear case just got partially addressed.BD extracted 1 program update from this document → ZNTL pipeline
SYRESpyre TherapeuticsReleaseSpyre Therapeutics Announces Clinical and Preclinical Data Presentations at United European Gastroenterology Week (UEGW) 2026
IRONDisc MedicineReleaseWATERTOWN, Mass., Oct. 18, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel → BD updateSummary on the 8-K of Oct 19, 2026BD extracted 1 program update from this document → IRON pipeline
EIKNEikon TherapeuticsReleaseEikon Therapeutics Announces Availability of Seven Abstracts for Presentation at the European Society for Medical Oncology CongressBD extracted 5 program updates from this document → EIKN pipeline

Friday, October 1620

ZYMEZymeworksPRE 14APRE 14A
TNGXTango TherapeuticsReleaseTango Therapeutics to Present Updated Vopimetostat + RAS(ON) Combination Data at European Society For Medical Oncology (ESMO) Congress 2026BD extracted 1 program update from this document → TNGX pipeline
TLSATiziana Life SciencesReleaseTiziana Doses Last Patient in Phase 2 Trial of Intranasal Foralumab for Mild Alzheimer’s Disease → BD updateSummary on the 6-K
TLSATiziana Life Sciences6-KForeign issuer report · EX-99.1 TIZIANA LIFE SCIENCES LTD INTERIMS, DATED OCTOBER 16, 2026 → BD updateTiziana's first balance sheet since the auditor's going-concern warning confirms the crisis: shareholders' equity turned negative (-$2.747M), H1 2026 cash burn hit $7.4M operating outflow, and the company has $3.9M in cash today against $13.1M in current liabilities — with INFORM-MS topline and a near-certain dilution event both imminent.BD extracted 2 program updates from this document → TLSA pipeline
TLSATiziana Life Sciences6-KForeign issuer report · EX-99.1 TIZIANA LIFE SCIENCES LTD PRESS RELEASE, DATED OCTOBER 16, 2026 → BD updateSummary on the 6-K
QUREuniQureSCHEDULE 13G/A13G amendment
PRLDPrelude TherapeuticsReleasePrelude Therapeutics to Participate in the Chardan Healthcare Conference
OMEROmerosReleaseOmeros Corporation Receives CHMP Negative Opinion Following Re-Examination of European Marketing Authorization Application for Narsoplimab in TA-TMA → BD updateThe CHMP has issued a second negative opinion on narsoplimab's European MAA following re-examination — definitively closing the European approval pathway under the current data package, with a procedurally controversial process that withheld Omeros's own patient-level data from the expert panel it convened.BD extracted 1 program update from this document → OMER pipeline
OLMAOlema PharmaceuticalsSCHEDULE 13D/A13D amendment
NRXPNRX Pharmaceuticals8-KCurrent report: other events
NGENNervGen Pharma6-K/AForeign issuer report (amended) · EX-99.1 EXHIBIT 99.1 → BD updateThe restatement that I flagged with a governance asterisk in September just got its full accounting — two named material weaknesses, a specific remediation roadmap, and confirmation that the books are now clean and cash is untouched. The stock has bled another 8% since RESTORE first-patient-dosed, and the audit picture deserves a clear-eyed update.
NGENNervGen Pharma40-F/A40-F/A → BD updateSummary on the 6-K/A
MESOMesoblast6-KForeign issuer report · EX-99.1
MBRXMoleculin BiotechReleaseMoleculin Announces Reverse Stock Split → BD updateSummary on the 8-K
MBRXMoleculin Biotech8-KCurrent report: Reg FD disclosure · EX-99.1 EXHIBIT 99.1 → BD updateMoleculin announced a 1-for-20 reverse stock split effective October 20 — the company's second in fourteen months — completing the ratchet-reset-split loop I warned about and confirming the equity's structural deterioration even as Annamycin's chemistry remains intact.
MAZEMaze Therapeutics8-KCurrent report: material agreement, unregistered sale of equity
IRDOpus GeneticsReleaseOpus Genetics Announces FDA Approval of Phentolamine Ophthalmic Solution 0.75% for the Treatment of PresbyopiaThe FDA approved phentolamine 0.75% for presbyopia on its expected PDUFA date — the thesis called it "a royalty event, not an equity re-rating," and the market agreed, with IRD down 5.2% on the day. The milestone payment is real but the gene-therapy bull case is unchanged.BD extracted 1 program update from this document → IRD pipeline
IONSIonis PharmaceuticalsReleaseTRYNGOLZA® (olezarsen) recommended for approval in the EU by CHMP for severe hypertriglyceridemia (sHTG)The CHMP has recommended TRYNGOLZA for EU approval in sHTG — ahead of schedule, adding ~2 million European patients to the addressable market — just ten days before the bepirovirsen PDUFA and the Q3 earnings print that will make or break the thesis.BD extracted 1 program update from this document → IONS pipeline
IBRXImmunityBioReleaseImmunityBio Reports Phase 3 Data Showing 84% Cystectomy Avoidance at Three Years and Complete Responses Beyond 53 Months with ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC With CIS, With or Without PapiBD extracted 1 program update from this document → IBRX pipeline
HURATuHURA Biosciences8-KCurrent report: debt / obligation
GUTSFractyl HealthReleaseFractyl Health's Revita Meets Six-Month Co-Primary Endpoint in Ongoing REMAIN-1 Pivotal Study, With Highly Statistically Significant Reduction in Weight Regain After GLP-1 Discontinuation → BD updateSummary on the 8-K
GUTSFractyl Health8-KCurrent report: Reg FD disclosure, other events · EX-99.1 → BD updateThe REMAIN-1 Pivotal readout (n=308) hit p=0.0023 — but the stock cratered 63% on the day. This is the thesis-defining data drop, and the market's reaction makes the post essential reading.BD extracted 1 program update from this document → GUTS pipeline
ERASErasca8-KCurrent report: officer / director change

Thursday, October 1534

ZYMEZymeworksReleaseZymeworks Announces Participation in Upcoming Investor Conferences and Date of Third Quarter 2026 Financial Resultsvia aggregator
XERSXeris BiopharmaReleaseXeris Biopharma Reinforces Leadership in Endocrinology With Data Disclosures Spanning Commercial Portfolio and Pipeline at Multiple Scientific MeetingsBD extracted 2 program updates from this document → XERS pipeline
TENXTenax TherapeuticsSCHEDULE 13G/A13G amendment
TARAProtara TherapeuticsReleaseProtara Therapeutics Completes Enrollment of the Phase 2b Open-Label Dose Confirmation Phase of the THRIVE-3 Registrational Trial of IV Choline Chloride in Patients on Parenteral SupportTHRIVE-3's 24-patient Phase 2b dose-confirmation cohort is fully enrolled, keeping the 4Q 2026 interim readout on schedule — the lowest-risk catalyst in a portfolio that just lost one of its three registrational paths.
SPRBSpruce BiosciencesReleaseSpruce Biosciences to Participate in the Craig-Hallum Biotech Catalyst Conference
SNDXSyndax PharmaceuticalsReleaseSyndax’s Revuforj® (revumenib) Named to TIME’s Best Inventions of 2026 Listvia aggregator
RXRXRecursion PharmaceuticalsReleaseRecursion Announces Pricing of $200 Million Underwritten Offering of Class A Common Stock → BD updateSummary on the 8-K
RXRXRecursion PharmaceuticalsReleaseRecursion Announces $200 Million Oversubscribed Follow-On Offering, Clinical Data Updates, and Partnership Milestone → BD updateSummary on the 8-KBD extracted 2 program updates from this document → RXRX pipeline
RXRXRecursion PharmaceuticalsReleaseRecursion Announces Sanofi Options Potential First-in-Class Immunology Development Candidate from Their Collaboration → BD updateSummary on the 8-K
RXRXRecursion Pharmaceuticals8-KCurrent report: material agreement, results of operations, Reg FD disclosure · EX-99.1 → BD updateRecursion delivered today on three fronts at once: expanded TUPELO data in FAP showing deep upper GI responses the prior writeup flagged as the hardest endpoint to crack, first REC-1245 clinical efficacy in solid tumors validating the platform thesis, and a $200M dilutive offering at $3.25 that buys runway to 2029 and funds the registrational trial the FDA path question has been pointing toward.BD extracted 2 program updates from this document → RXRX pipeline
RXRXRecursion Pharmaceuticals424B5Prospectus supplement (offering)→ BD updateSummary on the 8-K
RXRXRecursion Pharmaceuticals424B5Prospectus supplement (offering)→ BD updateSummary on the 8-K
RVMDRevolution MedicinesReleaseRevolution Medicines’ RASONQUE™ (daraxonrasib) Receives Positive CHMP Opinion Recommending Marketing Authorization in European Union for Metastatic Pancreatic Cancer → BD updateThe EMA's CHMP recommended EU marketing authorization for RASONQUE today under an expedited Cancer Medicines Pathfinder review — a second major regulatory body endorsing the RASolute 302 data package and opening the door to ~147,000 European PDAC patients. The thesis-relevant question is whether this changes the worldwide peak-sales math enough to move the Watch List needle before November's revenue print.BD extracted 1 program update from this document → RVMD pipeline
RCKTRocket PharmaceuticalsReleaseRocket Pharmaceuticals to Participate in Chardan’s 10th Annual Healthcare Conference
PYPDPolyPidReleasePolyPid to Host Virtual Investor Day on Wednesday, October 28, 2026BD extracted 1 program update from this document → PYPD pipeline
OLMAOlema Pharmaceuticals8-KCurrent report: officer / director change
OCGNOcugen8-KCurrent report: Reg FD disclosure · EX-99.1 EXHIBIT 99.1 → BD updateThe Roots MENA deal closed as expected — but the October 26 authorized-share vote has been pushed to December 22, just nine days before the CEO letter-agreement cash penalty deadline, while OCGN bleeds below $1.00 and into Nasdaq deficiency territory. The governance hole just got much deeper.
OCGNOcugen8-KCurrent report: material agreement, Reg FD disclosure, other events · EX-99.1 EXHIBIT 99.1 → BD updateSummary on the 8-K
NRXPNRX PharmaceuticalsReleaseNRx Pharmaceuticals Announces Receipt of FDA Labeling Review Letter for Preservative-Free KetamineFDA's labeling review for KETAFREE came back "MINOR" across the board with 26 days to the November 10 GDUFA goal date — the last substantive review hurdle before approval is now cleared, and commercial-scale manufacturing validation runs are underway.BD extracted 1 program update from this document → NRXP pipeline
MESOMesoblast6-KForeign issuer report · EX-99.1
MBRXMoleculin BiotechS-8Employee plan registration
LEGNLegend BiotechReleaseLegend Biotech Announces U.S. FDA Clearance of IND Application for LB2501, an Investigational CD19/CD20 In Vivo CAR-T TherapySummary on the 6-K
LEGNLegend Biotech6-KForeign issuer report · EX-99.1 PRESS RELEASELegend's FDA IND clearance for LB2501 checks off a named FY2026 catalyst and makes it the first dual-targeting in vivo CAR-T to clear US regulatory entry — a milestone that matters most as M&A signal, not clinical signal, with $350M–$7B in comparable deals as the reference frame.
IRDOpus GeneticsReleaseOpus Genetics Presents Positive Clinical Data from OPGx-BEST1 and OPGx-LCA5 Gene Therapy Programs at Retina in Rio 2026 → BD updateSummary on the 8-K
IRDOpus Genetics8-KCurrent report: Reg FD disclosure · EX-99.1 EXHIBIT 99.1 → BD updateThe Retina in Rio presentations delivered the granular structure-function data I told readers to watch for after September 9 — EZ-to-RPE thickness moved in all three evaluable BEST1 participants, pediatric LCA5 patients showed cone sensitivity reaching normal ranges, and Cohort 2 now has 11 participants. Meanwhile the stock has drifted -29% from the post-readout high to $4.05, creating a fresh entry question.BD extracted 2 program updates from this document → IRD pipeline
INSMInsmedReleaseInsmed Features the Global Phase 3 PALM Clinical Development Program Evaluating Treprostinil Palmitil Inhalation Powder (TPIP) at CHEST 2026
IMCRImmunocoreReleaseImmunocore announces first patient dosed in the Phase 1 trial of IMC-S118AI – its first tissue-specific autoimmune candidate – for patients with type 1 diabetesThe first tissue-tethered PD-1 agonist to enter the clinic just dosed its first patient — a named catalyst from the deep dive that arrives as institutional sellers dominate the headlines, and quietly confirms the ImmTAAI platform is more than a slide deck.BD extracted 1 program update from this document → IMCR pipeline
HELPHelus PharmaReleaseHelus Pharma Appoints Dr. Suresh Durgam to Board of Directors
HELPHelus Pharma6-KForeign issuer report · EX-99.1
EXELExelixisReleaseExelixis to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026
EIKNEikon TherapeuticsReleaseEikon Therapeutics Submits IND for Novel Androgen Receptor Antagonist EIK1006 in Prostate CancerBD extracted 1 program update from this document → EIKN pipeline
CYDYCytoDynReleaseCytoDyn to Host Investor Webcast
CLRBCellectar BiosciencesReleaseCellectar Biosciences Presents Compelling Efficacy Data from Phase 2b CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Relapsed/Refractory to BTK Inhibitor Therapy at the International WorksBD extracted 1 program update from this document → CLRB pipeline
CBIOCrescent BiopharmaReleaseCrescent Biopharma Announces Clinical Pipeline Momentum, including Enrolling Patients in Standard of Care Chemotherapy Combination Cohorts of Global Phase 1/2 ASCEND Trial of CR-001, a PD-1 x VEGF Bis → BD updateSummary on the 8-K
CBIOCrescent Biopharma8-KCurrent report: other events → BD updateASCEND dose escalation is complete with 125+ patients dosed and the Q1 2027 monotherapy readout now has a defined scope: ORR from a 1L NSCLC cohort of up to 12 patients plus PK/PD/safety from the full dataset — and for the first time, management is explicitly guiding Phase 3 initiation in early 2028, signaling conviction that the data will support it.
ADMAAdma BiologicsReleaseADMA Biologics Announces Peer-Reviewed Publication Highlighting New Data From Its Optimized, Proprietary IVIG Manufacturing Process

Wednesday, October 1448

XERSXeris Biopharma8-KCurrent report: other events
WVEWave Life SciencesDEF 14AProxy statement
WVEWave Life SciencesARSAnnual report to shareholders
VSTMVerastemReleaseVerastem Oncology Announces Planned Chief Executive Officer Transition and Succession Plan → BD updateSummary on the 8-K
VSTMVerastemReleaseVS-7375 Demonstrates Robust Anti-Tumor Activity Across Advanced KRAS G12D-Mutant Cancers, Highlighted by 50% Confirmed ORR in 2L Pancreatic Ductal Adenocarcinoma and Two Complete Responses in 2L+ Dise → BD updateSummary on the 8-K
VSTMVerastemReleaseVerastem Oncology Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants → BD updateSummary on the 8-K
VSTMVerastem8-KCurrent report: other events → BD updateVerastem's first multi-tumor VS-7375 data update delivered the confirmed US RECIST responses the thesis demanded — 41% cORR in 2L+ PDAC including complete responses, 43% cORR in 2L+ NSCLC — while a $250M equity offering and FDA-aligned Phase 3 design together clear the two named gates that kept VSTM on the Watch List.BD extracted 1 program update from this document → VSTM pipeline
VSTMVerastem8-KCurrent report: results of operations, officer / director change, Reg FD disclosure · EX-99.1 EXHIBIT 99.1 → BD updateSummary on the 8-K
VSTMVerastem424B5Prospectus supplement (offering)→ BD updateSummary on the 8-K
VSTMVerastem424B5Prospectus supplement (offering)→ BD updateSummary on the 8-K
VNDAVanda PharmaceuticalsReleaseVanda Pharmaceuticals Provides Update on VQW-765 Clinical Development Program → BD updateVQW-765 just washed out in Phase III (p=0.89) — the social anxiety asset is on hold — while a previously uncovered HETLIOZ® win in delayed sleep-wake phase disorder quietly adds a new sNDA shot to an eroding franchise.BD extracted 1 program update from this document → VNDA pipeline
VKTXViking TherapeuticsReleaseViking Therapeutics Announces Initiation of VK2735 Oral Phase 3 Clinical Program in Patients with Obesity → BD updateThe oral VK2735 Phase 3 program (SUNRISE-1 and SUNRISE-2) just launched — the milestone I've been tracking since December — but the stock is down 31% from the September raise price. The science delivered; the market isn't celebrating.BD extracted 1 program update from this document → VKTX pipeline
VIRVir BiotechnologyReleaseVir Biotechnology Enters Multi-Program Collaboration and License Agreement with Gilead Sciences to Discover and Develop Novel PRO-XTEN® Dual-masked T-cell Engagers for Solid Tumors → BD updateSummary on the 8-K
VIRVir Biotechnology8-KCurrent report: unregistered sale of equity, other events · EX-99.1 → BD updateGilead — the same company whose CHD drug competes with tobevibart + elebsiran — just paid $65M cash plus a $25M equity stake at a 30% premium to co-develop three new PRO-XTEN masked T-cell engagers for solid tumors, the second major validation of the platform in eight months. The stock fell anyway.
STROSutro BiopharmaRelease17th Annual World ADC Conference – Presentations
SRPTSarepta TherapeuticsReleaseSarepta Therapeutics Presents New Preclinical Data Demonstrating Robust Knockdown of Pathogenic DMPK RNA in the Nucleus with SRP-1003 in DM1 at 2026 Oligonucleotide Therapeutics Society Annual MeetingBD extracted 1 program update from this document → SRPT pipeline
SABSSAB BiotherapeuticsReleaseSAB BIO to Participate in Chardan 10th Annual Healthcare Conference
RAREUltragenyx PharmaceuticalReleaseUltragenyx Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $203 Million → BD updateSummary on the 8-K
RAREUltragenyx Pharmaceutical8-KCurrent report: material agreement → BD updateUltragenyx just sold its second Priority Review Voucher in one week — the FAYUVI PRV — for $203M gross, roughly double my ~$100M model. Two vouchers, $413M combined, and the Dilution Gap that dominated this year's coverage is now closed with real cash rather than modeled cash.
QNRXQuoin PharmaceuticalsReleaseQuoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Peeling Skin Syndrome
QNRXQuoin Pharmaceuticals8-KCurrent report: Reg FD disclosure, other events · EX-99.1 EXHIBIT 99.1BD extracted 1 program update from this document → QNRX pipeline
ONCYOncolytics BiotechReleaseOncolytics Biotech® Provides Update on GOBLET Study Clinical Data and Final PanCAN Grant Payment
ONCYOncolytics Biotech8-KCurrent report: other events · EX-99.1BD extracted 1 program update from this document → ONCY pipeline
OCGNOcugenReleaseOcugen and Roots Pharmaceutical Complete License Agreement for OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North AfricaThe definitive Roots MENA license for OCU400 just closed — the partnership playbook held right at the 90-day wire, delivering a commercial validation tick while the cap table still awaits its October 26 vote.
LQDALiquidia8-KCurrent report: material agreement, agreement terminated, Reg FD disclosure · EX-99.1 EXHIBIT 99.1 → BD updateThe full settlement 8-K reveals that HCR's minimum cash covenant quietly tripled from $15M to $45M — tightening the post-payment cash cushion the October 13 update modeled — while the market's +26.6% session reaction prices in a clean resolution that the fine print complicates at the margin.
LGVNLongeveron8-KCurrent report: officer / director changeLGVN's Chief Medical Officer resigned effective today — four weeks after ELPIS II failed and during an active strategic review. With no clinical program left to run, the CMO exit reads less like a personnel change and more like a confirmation that the drug development chapter is closing.
IVVDInvivydReleaseInvivyd and the SPEAR Study Group Announce Initiation of “FLINTLOCK” Phase 2 Study of VYD2311, a Monoclonal Antibody for the Potential Treatment of Long COVID or Post-Vaccination SyndromeBD extracted 1 program update from this document → IVVD pipeline
IPSCCentury TherapeuticsReleaseCentury Therapeutics to Attend 2026 Jefferies Global Healthcare Conference in London
INSMInsmedReleaseInsmed to Present New Data Across Its Respiratory Portfolio at CHEST 2026 and IDWeek 2026BD extracted 2 program updates from this document → INSM pipeline
INMBInmune BioReleaseINmune Bio Inc. and Quantum Computing Inc. Partner to Apply Quantum Optimization and AI to Advance A...
IBRXImmunityBioReleaseFDA Expands ANKTIVA® Approval for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer to Cover Both Papillary and CIS Disease → BD updateSummary on the 8-K
IBRXImmunityBio8-KCurrent report: Reg FD disclosure · EX-99.1 → BD updateThe FDA just granted the papillary-only label expansion for ANKTIVA — the regulatory milestone I've been tracking since the May 2025 Refuse to File — arriving three months ahead of the January 6, 2027 PDUFA date and formally opening the ~85% of BCG-unresponsive NMIBC patients who present with papillary disease to on-label treatment.
ETONEton PharmaceuticalsReleaseEton Pharmaceuticals and Aquestive Therapeutics Announce Exclusive U.S. Licensing Agreement for LIBERVANT® (diazepam) Buccal Film → BD updateSummary on the 8-K
ETONEton Pharmaceuticals8-KCurrent report: material agreement, acquisition / disposition · EX-99.1 EXHIBIT 99.1 PRESS RELEASE RELATING TO LIBERVANT LICENSING AGREEEMENT → BD updateEton paid $10M upfront to license LIBERVANT (diazepam buccal film) for the U.S. seizure rescue market — a $450M+ opportunity that pushes the boring machine into neurology for the first time, with an April 2027 launch target contingent on final FDA approval.
ENTXEntera BioDEF 14AProxy statement
ELVNEnliven Therapeutics8-KCurrent report: officer / director change, Reg FD disclosure · EX-99.1
CYDYCytoDyn10-QQuarterly report → BD update
CRVOCervoMed8-KCurrent report: Reg FD disclosure
COYACoya TherapeuticsReleaseCoya to Initiate Open-Label Extension of Phase 2/3 ALSTARS Trial of COYA 302 in ALSvia aggregator
COYACoya Therapeutics8-KCurrent report: other events
CMPSCOMPASS PathwaysReleaseCompass Pathways Joins Forces with Leading Mental Health Organizations to Mark First-Ever U.S. Treatment-Resistant Depression (TRD) Awareness Day
CHRSCoherus OncologyReleaseCoherus Oncology to Host Webcast to Disclose Interim Tagmokitug Clinical Data on October 28, 2026Coherus just set October 28 as the date for interim tagmokitug clinical data across its solid tumor program — a 90-minute KOL webcast that raises the signal-to-noise stakes on the CCR8 program I've been tracking since the deep dive.
CAPRCapricor TherapeuticsSCHEDULE 13G/A13G amendmentMillennium Management (Israel Englander's firm) disclosed 1,669,083 shares (2.9%) as of September 30 — a fourth specialist name on the register six weeks before the November 22 PDUFA, as CAPR sits 15% below the October 5 close.
BMEABiomea Fusion8-KCurrent report: Reg FD disclosure, other events · EX-99.1 → BD updateThe market delivered its verdict on the BMF-650 data overnight — BMEA cratered 33.8% in Tuesday's session, a drop the October 13 post flagged as still pending. The full slide deck adds new detail: a human peak-to-trough ratio of 1.7, a competitive GI tolerability chart that looks favorable, and explicit next-steps language pointing to partnership/licensing rather than independent Phase 2 — confirming the thesis shift from "buyout bait" to "licensing asset."BD extracted 1 program update from this document → BMEA pipeline
BLTEBelite BioReleaseBelite Bio Announces Multi-Market Submission of Marketing Authorization Applications Via the Access Consortium Pathway for Tinlarebant for the Treatment of Stargardt Disease Type 1
APVOAptevo TherapeuticsReleaseAptevo to Showcase Multispecific Platform at SITC 2026 Annual Meeting
APVOAptevo Therapeutics8-KCurrent report: other events · EX-99.1
AKBAAkebia Therapeutics8-KCurrent report: officer / director change → BD updateAkebia's Chief Commercial Officer just resigned — effective November 6, 2026 — seven weeks before the TDAPA reimbursement cliff that management's own guidance says will cause Vafseo revenues to "decrease significantly" in 2027. The timing couldn't be worse, and the stock's 45.6% slide since the August update has already been pricing in bad news.
ADAGAdageneReleaseAdagene to Participate in H.C. Wainwright 4th Annual Immune Cell Engager Virtual Conference
ACTUActuate TherapeuticsS-1/ARegistration statement (amended)→ BD updateThe offering that was supposed to save Actuate just got bigger and cheaper: the S-1/A upsizes to 65M shares at $0.64, down from 50M shares at $0.82, pushing the post-deal share count toward 89M and the stock to new lows near $0.43.

Tuesday, October 1337

ZBIOZenas BioPharma8-KCurrent report: Reg FD disclosure · EX-99.1 EXHIBIT 99.1New INDIGO open-label extension data show obexelimab's flare protection holding at 93% probability through 12 months, and a vaccine sub-study delivers the first human proof that the drug's "pausability" feature actually works — six of seven patients mounted influenza immunity during a ~35-day treatment-free window with zero flares.BD extracted 1 program update from this document → ZBIO pipeline
WVEWave Life SciencesReleaseWave Life Sciences to Present at Chardan’s 10th Annual Healthcare Conference
TENXTenax TherapeuticsSCHEDULE 13G/A13G amendment
SABSSAB BiotherapeuticsReleaseSAB BIO Receives FDA Fast Track Designation for SAB-142 in Stage 3 Type 1 Diabetes → BD updateSummary on the 8-KBD extracted 1 program update from this document → SABS pipeline
SABSSAB Biotherapeutics8-KCurrent report: other events · EX-99.1 → BD updateThe FDA granted Fast Track designation to SAB-142 this morning — a formal regulatory signal that advances the accelerated-approval angle I flagged in the deep dive, yet SABS closed down 5.3% on the day. The designation doesn't move the science, but it does move the regulatory clock and opens rolling review; the market's non-reaction tells you exactly what the overhang is doing to this stock.BD extracted 1 program update from this document → SABS pipeline
RYTMRhythm PharmaceuticalsSCHEDULE 13GPassive >5% holder (13G)
RYTMRhythm PharmaceuticalsReleaseRhythm Pharmaceuticals Announces Commercial Launch of IMCIVREE® (setmelanotide) in Japan for Patients with Acquired Hypothalamic Obesity
RVMDRevolution Medicines8-KCurrent report: debt / obligation, other events → BD updateThe $250M mandatory Royalty Pharma term loan closed October 8 as predicted — but RVMD then passed on an optional additional $250M in royalty financing it could have claimed by October 10, a quiet signal that management is confident enough in early RASONQUE revenue to forgo the capital rather than layer more royalty burden onto the asset.
PRLDPrelude TherapeuticsReleasePrelude Announces Clinical Trial Collaboration and Supply Agreement with Lilly to Evaluate KAT6A Selective Degrader PRT13722 in Combination with Verzenio® and Inluriyo® in Patients with HR+/HER2- BreaLilly has agreed to supply abemaciclib (Verzenio) and imlunestrant (Inluriyo) for combination cohorts in Prelude's PRT13722 Phase 1 — the exact first-line combo thesis the prior writeup called the central bull case, now backed by the world's leading CDK4/6 franchise holder.
PHIOPhio PharmaceuticalsReleasePhio Pharmaceuticals Announces Successful Completion of First Commercial-Scale cGMP Batch of PH-762 Drug Substance
PHIOPhio Pharmaceuticals8-KCurrent report: other events · EX-99.1 EXHIBIT 99.1BD extracted 1 program update from this document → PHIO pipeline
OTLKOutlook TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
ONCYOncolytics Biotech8-KCurrent report: other events · EX-99.1
NTLAIntellia TherapeuticsReleaseIntellia Therapeutics Appoints Jing L. Marantz, M.D., Ph.D., as Chief Medical OfficerIntellia has appointed Jing L. Marantz — the CMO who shepherded Scholar Rock's first-approved SMA drug through simultaneous FDA/EMA submissions — as its new Chief Medical Officer, effective October 26, exactly five months before the March 10, 2027 PDUFA date for lonvo-z.
NRSNNeuroSense TherapeuticsReleaseNeuroSense Secures Nasdaq Hearing Date as PrimeC Approaches Key Regulatory and Funding Milestones
NRSNNeuroSense Therapeutics6-KForeign issuer report · EX-99.1 PRESS RELEASE DATED OCTOBER 13, 2026BD extracted 1 program update from this document → NRSN pipeline
NRIXNurix Therapeutics8-KCurrent report: results of operations · EX-99.1BD extracted 1 program update from this document → NRIX pipeline
NRIXNurix Therapeutics10-QQuarterly reportBD extracted 1 program update from this document → NRIX pipeline
NBPNovaBridge BiosciencesReleaseVisara Expands Ophthalmology Pipeline with Exclusive License for Investigational Nerve Growth Factor Therapy for Neurotrophic KeratitisBD extracted 2 program updates from this document → NBP pipeline
NBPNovaBridge Biosciences6-KForeign issuer report · EX-99.1BD extracted 1 program update from this document → NBP pipeline
MESOMesoblast6-KForeign issuer report · EX-99.1
LXEOLexeo TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
LQDALiquidiaReleaseLiquidia Announces Global Settlement Resolving All Pending Litigation with United Therapeutics, Ensuring Continued Commercialization of YUTREPIA in PAH → BD updateLiquidia and United Therapeutics have settled all six lawsuits — PAH sales are safe, the January trade-secret trial is gone, and the litigation queue that kept LQDA on the watch list has been cleared in a single stroke. The price: $380.7M in net cash payments, roughly one quarter's revenues, against a balance sheet that just printed $396.1M in cash at quarter-end.BD extracted 1 program update from this document → LQDA pipeline
LEGNLegend Biotech6-KForeign issuer reportCARVYKTI printed ~$710M in Q3 net trade sales — a sequential record that re-accelerates the growth narrative two months before anito-cel's PDUFA, and the first quarter with Ingrid Zhang's signature on the filing.
LBRXLB PharmaceuticalsSCHEDULE 13G/A13G amendment
KURAKura OncologyReleaseCaspian Therapeutics and Kura Oncology Outline KO-7246 Development Strategy in DiabetesBD extracted 1 program update from this document → KURA pipeline
IRDOpus GeneticsReleaseOpus Genetics to Present at the Chardan Annual Healthcare Conference
INBXInhibrx BiosciencesReleaseInhibrx Announces Participation in Upcoming Scientific ConferencesBD extracted 2 program updates from this document → INBX pipeline
HURATuHURA BiosciencesReleaseTuHURA Biosciences Receives New U.S. Patent Broadening Coverage for its VISTA Inhibitor, TBS-2025
HRMYHarmony Biosciences8-KCurrent report: officer / director change, Reg FD disclosure · EX-99.1
GUTSFractyl HealthSCHEDULE 13GPassive >5% holder (13G)
ENTXEntera BioReleaseEntera Presents Markedly Enhanced Anabolic Effects of EB613 (First-in-Class Oral PTH(1-34) Tablet) in Postmenopausal Women with Osteoporosis at High Risk of Fracture and Showcases Phase 3 Design at ASBD extracted 1 program update from this document → ENTX pipeline
ENTAEnanta PharmaceuticalsReleaseEnanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at IDWeek™ 2026BD extracted 1 program update from this document → ENTA pipeline
CRVOCervoMed8-KCurrent report: Reg FD disclosure, other events · EX-99.1 EXHIBIT 99.1BD extracted 1 program update from this document → CRVO pipeline
CLNNCleneSCHEDULE 13G/A13G amendment
CGTXCognition TherapeuticsReleaseCognition Therapeutics Announces Issuance of Composition of Matter Patent, Extending Protection for Zervimesine (CT1812) Through 2045
CGONCG OncologyReleaseCG Oncology Appoints Proven Biopharmaceutical Commercial Leader Isabel Kalofonos as Chief Commercial Officer → BD updateCG Oncology has filled the Chief Commercial Officer vacancy with Isabel Kalofonos — a two-time CCO with successful launches at Crinetics (PALSONIFY) and ImmunoGen (ELAHERE) — closing the launch-readiness footnote the author flagged as the #2 watch item since May.
BMEABiomea FusionReleaseBiomea Fusion Announces Phase 1 Results for BMF-650, its Investigational Next-Generation Oral Small Molecule GLP-1 Receptor Agonist → BD updateBMF-650's Phase 1 data is in: clean tolerability, a one-step titration path to 400 mg, but outpatient weight loss of 1.5–3.2% that trails the oral GLP-1 field benchmark — and the company is now explicitly shopping the asset for a partnership rather than developing it alone.BD extracted 1 program update from this document → BMEA pipeline
BEAMBeam TherapeuticsReleaseBeam Therapeutics to Present Initial Data from Phase 1/2 Trial of BEAM-301 in Glycogen Storage Disease Type Ia (GSDIa) at the ESGCT 33rd Annual Congress → BD updateBEAM-301's first-in-human data in GSDIa delivers a genuine functional proof of concept — 40 mg patients achieved ≥15 hours of controlled fasting from a 2.5-hour baseline, with ~80-92% starch reductions — and the LNP safety profile held, extending the platform de-risking story that Barcelona started in September.BD extracted 1 program update from this document → BEAM pipeline
ANIXAnixa BiosciencesReleaseOCT 13, 2026 8:40 AM EDT Anixa Biosciences' Ovarian Cancer CAR-T Therapy Inventor to Deliver Keynote at Ovarian Cancer Midwest Focus Conference↗ Jose Conejo-Garcia, MD, PhD, inventor of Anixa's CAR-T
AGMBAgomab TherapeuticsReleaseAgomab Announces First Patient Dosed in Global NOV-ERA Phase 2b Study of Ontunisertib in Fibrostenosing Crohn’s DiseaseSummary on the 6-K
AGMBAgomab Therapeutics6-KForeign issuer report · EX-99.1 EXHIBIT 99.1NOV-ERA is officially enrolling: the first patient has been dosed in the 320-patient, three-arm, FDA-aligned Phase 2b of ontunisertib in fibrostenosing Crohn's disease — the exact milestone the October 1 update told readers to watch for, and the starting gun on the clock to the Week-24 passability readout.
ADCTADC Therapeutics8-KCurrent report: material agreement, results of operations, unregistered sale of equity · EX-99.1 EXHIBIT 99.1
ABSIAbsciReleaseAbsci to Report Business Updates and Third Quarter 2026 Financial and Operating Results on November 12, 2026via aggregator

Monday, October 1214

ZBIOZenas BioPharmaReleaseZenas BioPharma Announces the Presentation of New Obexelimab Data in IgG4-Related Disease at the 6th International Symposium on IgG4-Related DiseaseBD extracted 1 program update from this document → ZBIO pipeline
TGTXTg TherapeuticsReleaseTG Therapeutics Announces Publication of Five-Year Comparative Analysis of BRIUMVI Versus Ocrelizumab and Ofatumumab in Relapsing Multiple Sclerosis
STROSutro BiopharmaReleaseSutro Biopharma Announces Participation at the 17th Annual World ADC Conferencevia aggregator
SNDXSyndax PharmaceuticalsReleaseSyndax Announces Topline Results from MAXPIRe Phase 2 Trial of Axatilimab in Idiopathic Pulmonary Fibrosisvia aggregator→ BD updateBD extracted 2 program updates from this document → SNDX pipeline
PALIPalisade BioReleasePalisade Bio Presents New Clinical, Pharmacokinetic, Pharmacodynamic and Mechanistic Data Strengthening the Phase 2 Rationale for PALI-2108 in Ulcerative Colitis and Crohn’s Disease at ACG 2026via aggregatorBD extracted 1 program update from this document → PALI pipeline
ONCYOncolytics BiotechReleaseOncolytics Biotech® Secures Patent Protection to Late 2040s and Provides Intellectual Property Portfolio Update
NRIXNurix TherapeuticsReleaseNurix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update → BD updateNurix's Q3 print confirms $1.1B in actual cash (runway to H2 2029), quietly kills zelebrudomide, and advances NX-1607 into four solid-tumor expansion cohorts — the portfolio is sharpening its focus around bexobrutideg while the wildcard starts to show its hand.BD extracted 3 program updates from this document → NRIX pipeline
NGENNervGen PharmaReleaseNervGen Announces First Participant Dosed in RESTORE, a Phase 3 Registrational Study Evaluating NVG-291 in Chronic Spinal Cord Injuryvia aggregator→ BD updateRESTORE just dosed its first patient — the milestone I ranked #1 on my watch list has printed, and the 18-month countdown to the binary readout in 1H 2028 officially starts today.
HRMYHarmony BiosciencesReleaseHarmony Biosciences Announces Planned CEO Transition to Support Next Phase of Growth → BD updateJeffrey Dayno is out as CEO at year-end, replaced by COO Peter Anastasiou — announced today, ten days before the October 22 oral argument that the prior writeup called "the single most consequential date in the story." The stock fell 5.1% on the news, and the pattern of executive turnover at Harmony is now two-for-two in six months.
GERNGeronReleaseGeron Corporation Announces Oral Presentations Highlighting Imetelstat at International Hematology Congresses in Europe and Asia
FATEFate TherapeuticsReleaseFate Therapeutics Appoints Jamie Harrell As Senior Vice President, Market Development & Commercial Operations To Lead The Commercialization Of CAR T-Cell Therapies
CRVOCervoMedReleaseCervoMed Presents Initial Results of Phase 2a Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Showing Positive Effects on a Key Neurodegeneration Biomarker in Late-Brea → BD updateThe nfvPPA biomarker data the thesis has been waiting for landed today — NfL dropped where natural history says it should rise, but the n is small, the design is open-label, and the stock is down 22% on the session. Here's what the data actually means for the partner pitch.BD extracted 1 program update from this document → CRVO pipeline
BMEABiomea FusionReleaseBiomea Fusion to Announce Phase I Results for BMF-650, Its Next-Generation Oral Small-Molecule GLP-1 Receptor AgonistThe BMF-650 Phase I GLP-131 results drop tomorrow after the close — the catalyst the pulled September offering was waiting for, and the last clean financing window before the cash gets tight.
ARDXArdelyxReleaseArdelyx Presents Real-World Data at ACG 2026 Showing Reduced Healthcare Resource Utilization Following IBSRELA® Initiation in Adults with IBS-C

Saturday, October 101

VTVTvTv TherapeuticsReleasevTv Therapeutics Announces Oral Presentation at Breakthrough T1D Clinical and Research Congress 2026

Friday, October 915

XFORX4 PharmaceuticalsReleaseX4 Pharmaceuticals to Host Virtual Investor Day on Thursday, October 29, 2026, Featuring Key Opinion Leaders
VNDAVanda PharmaceuticalsSCHEDULE 13G/A13G amendment
TENXTenax TherapeuticsSCHEDULE 13G/A13G amendment
SYRESpyre TherapeuticsSCHEDULE 13D/A13D amendment
SGMTSagimet BiosciencesReleaseSagimet To Present Positive Full 52-Week Results from License Partner Ascletis' Phase 3 Open-Label Extension Clinical Trial of Denifanstat in Acne and Mechanistic Data at the 2026 Fall Clinical DermatBD extracted 1 program update from this document → SGMT pipeline
QTTBQ32 BioSCHEDULE 13GPassive >5% holder (13G)
PCVXVaxcyteReleaseVaxcyte Announces Closing of $1.15 Billion Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes, Including Full Exercise of Underwriters’ Options to Purchase Additional S
PCVXVaxcyte8-KCurrent report: material agreement, debt / obligation, other events
PCSAProcessa PharmaceuticalsS-3Shelf registration
PCSAProcessa PharmaceuticalsPRE 14APRE 14A
PCSAProcessa PharmaceuticalsPRE 14APRE 14A
OTLKOutlook TherapeuticsReleaseOutlook Therapeutics Names Greg DiPasquale Chief Commercial OfficerGreg DiPasquale — who launched BEOVU, ran national Eylea sales, and has been inside Outlook since December 2025 — is named CCO as the U.S. launch window opens, giving the commercial bear case its most direct answer yet.
NVCTNuvectis PharmaReleaseNuvectis Pharma to Participate in the Maxim Growth Summit 2026via aggregator
MISTMilestone PharmaceuticalsReleaseMilestone Pharmaceuticals Announces First European Study Participant Enrolled in ReVeRA-301 Phase 3 Clinical Trial
MBRXMoleculin Biotech8-KCurrent report: officer / director change, shareholder vote
GHRSGH Research6-KForeign issuer report
ELTXElicio TherapeuticsDEF 14AProxy statement
CRVOCervoMed8-KCurrent report: Reg FD disclosure
ATHEAlterity TherapeuticsReleaseAlterity Therapeutics to Present at the Canaccord Genuity Drug and Device Conferencevia aggregator
ATHEAlterity Therapeutics6-KForeign issuer report · EX-99.1 EXHIBIT 99.1

Thursday, October 828

XFORX4 PharmaceuticalsReleaseX4 Pharmaceuticals Secures Up to $150 Million Senior Debt Facility with K2 HealthVenturesvia aggregator
XFORX4 Pharmaceuticals8-KCurrent report: material agreement, agreement terminated, debt / obligation · EX-99.1
VTVTvTv TherapeuticsSCHEDULE 13G/A13G amendment → BD updateMillennium Management quietly grew its VTVT stake from 5.0% to 8.7% — adding 144,244 shares through the ATM scare, the enrollment delay, and the dead-money drift — and the market hasn't priced it yet.
VIRVir BiotechnologyReleaseVir Biotechnology Announces PSMA-targeted PRO-XTEN® Dual-masked T-cell Engager VIR-5500 Received FDA Fast Track Designation for the Treatment of Prostate CancerSummary on the 8-K
VIRVir Biotechnology8-KCurrent report: other events · EX-99.1The FDA has granted Fast Track designation to VIR-5500, Vir's PRO-XTEN dual-masked PSMA T-cell engager, for late-line mCRPC — a regulatory stamp that accelerates the path to the 2027 pivotal Phase 3 and formally validates the unmet need case Astellas already paid $335M to bet on.
TGTXTg TherapeuticsReleaseTG Therapeutics Announces Schedule of Data Presentations at MSToronto2026
TENXTenax Therapeutics8-KCurrent report: other events · EX-99.1BD extracted 1 program update from this document → TENX pipeline
SPRBSpruce BiosciencesReleaseSpruce Biosciences Announces Presentation of MPS IIIB Natural History Data at the 55th Child Neurology Society Annual Meeting
SIONSionna TherapeuticsReleaseSionna Therapeutics to Present Data at the 2026 North American Cystic Fibrosis ConferenceBD extracted 1 program update from this document → SION pipeline
PCVXVaxcyte424B5Prospectus supplement (offering)The $1B+ dual offering that launched alongside the OPUS-1 clean readout has now priced: equity at $64.00/share and converts at a ~$89.60 conversion price, confirming the capital structure reset I said was coming — and explaining why the stock has given back ~12% from its October 5 pop.
PCVXVaxcyte424B5Prospectus supplement (offering)Summary on the 424B5
NBPNovaBridge BiosciencesReleaseNovaBridge Biosciences Announces Expanded Givastomig Safety and Efficacy Data to be Presented at the European Society for Medical Oncology 2026
LXEOLexeo TherapeuticsReleaseLexeo Therapeutics to Participate in the Chardan Healthcare Conferencecompany site may be offline after the acquisition
IBRXImmunityBioReleaseImmunityBio to Participate in the Piper Sandler Virtual Oncology Symposium
HELPHelus PharmaReleaseHelus Pharma to Host Investor Presentation on October 21, 2026
HELPHelus Pharma6-KForeign issuer report · EX-99.1
GOSSGossamer BioSCHEDULE 13D/A13D amendment
GANXGain TherapeuticsReleaseGain Therapeutics to Attend the 2026 Maxim Growth Summit
EWTXEdgewise TherapeuticsReleaseEdgewise Therapeutics Doses First Patient in Phase 2 EQUINOX-HFpEF Trial of EDG-15400EDG-15400 just dosed its first Phase 2 patient in EQUINOX-HFpEF — a randomized, placebo-controlled trial — and the Phase 1 human data the company went silent on for six months will be presented at HFSA this weekend.
ENTXEntera BioReleaseEntera Bio Announces Additional Presentation of EB613 Phase 3 Study Design at the ASBMR 2026 Annual MeetingBD extracted 1 program update from this document → ENTX pipeline
DTILPrecision BiosciencesReleasePrecision BioSciences Announces Late-Breaking Oral Presentation for PBGENE-HBV at AASLD The Liver Meeting 2026PBGENE-HBV just earned a late-breaking oral slot at AASLD 2026 (November 8, Denver) — the abstract title signals durable pgRNA loss across both HBeAg+ and HBeAg- patients, a key expansion of the May EASL dataset that lands four weeks after GSK's bepirovirsen PDUFA and directly ahead of the year-end ELIMINATE-B update I've been flagging as the thesis-defining catalyst.
CYDYCytoDynReleaseCytoDyn to Present Updated Data from Phase 2 CLOVER Clinical Study at ESMO Congress 2026BD extracted 1 program update from this document → CYDY pipeline
CUECue BiopharmaSCHEDULE 13G/A13G amendment
CGEMCullinan TherapeuticsReleaseCullinan Therapeutics Announces First Patient Dosed in Planned Registrational Phase 2 Study of CLN-049 in Relapsed/Refractory Acute Myeloid LeukemiaThe AML Hammer just enrolled its first patient in the pivotal Phase 2 — closing the open question I flagged in the October 2 update and formally activating Cullinan's third clinical engine alongside an exploratory TP53-mutated cohort that could be the differentiator.BD extracted 1 program update from this document → CGEM pipeline
CATXPerspective TherapeuticsReleasePerspective Therapeutics Granted Fast Track Designation for [212Pb]PSV359 for the Treatment of Adult Patients with Locally Advanced Unresectable and/or Metastatic FAP-Positive Solitary Fibrous Tumors → BD updateSummary on the 8-K
CATXPerspective Therapeutics8-KCurrent report: other events · EX-99.1 → BD updateThe FDA granted Fast Track Designation for PSV359 — the wholly-owned FAP-α program — specifically in FAP-positive solitary fibrous tumors, a rare cancer with no approved targeted therapies. The stock gained +10.2% on the day, and with the ESMO oral on VMT-α-NET just 15 days away, this adds another regulatory receipt to a pipeline that keeps compounding.
AGMBAgomab TherapeuticsReleaseAgomab to Present STENOVA Open-Label Extension Data of Ontunisertib at UEG Week 2026 and Host Scientific Symposium on Fibro-Inflammation
ADCTADC TherapeuticsReleaseADC Therapeutics Announces Comprehensive Strategic Financial Restructuring Marking Key Capital Structure Improvements → BD updateADCT just executed a three-part balance sheet overhaul — $86.6M PIPE, term loan cut to $50M with the liquidity covenant eliminated, and the HCR change-of-control payment removed entirely — buying itself runway into 2029 and stripping away the distress-discount logic. The regulatory binary on LOTIS-7 and the 3L+ label is unchanged, but the balance sheet trap I described in August just got materially defused.
ACTUActuate TherapeuticsFWPFree writing prospectus (offering terms)
AARDAardvark Therapeutics8-KCurrent report: officer / director change, other events · EX-99.1